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ABSTRACT 
The objective of this work was to determine the effect of the inflammatory response 
during Mannheimia haemolytica pneumonia on expression of selected antimicrobial peptides 
in the ruminant lung. The first study determined the presence of anionic peptide (AP) in the 
bronchoalveolar lavage fluid (BALF) of neonatal calves during acute inflammation. Anionic 
peptide was present at a similar concentration in all infected and uninfected calves and was 
three times higher in neonates than in adult cattle; however, BALF from neonates had little or 
no anti-M haemolytica activity in vitro, compared with adult cattle. As neutrophils have an 
important role in pulmonary tissue damage associated with M. haemolytica infection, the 
effect of a selectin inhibitor. TBC1269, used on a group of infected calves, was determined. 
TBC1269 decreased the amount of pulmonary tissue injury in infected calves; however, it 
had no effect on BALF AP concentration or antimicrobial activity. The second study used 
the same calves to examine the presence in the lung during acute inflammation of an 
inducible P-defensin. tracheal antimicrobial peptide (TAP). In addition, two molecules vital 
to neutrophil infiltration, interleukin (IL)-8 and intercellular adhesion molecule (ICAM)-l 
were examined. Messenger ribonucleic acid (mRNA) expression of TAP and ICAM-1 was 
found to be rapidly upregulated; however, there was variation between individual animals 
that could result in suboptimal innate immunity at birth. In addition, it was found that 
TBC1269 did not significantly alter TAP expression. Also, within individuals, there was 
positive correlation between mRNA expression of TAP and IL-8. suggesting common pro­
inflammatory stimuli for upregulation. In the final study, a suspected inducible ovine P-
defensin, sheep P-defensin-1 (SBD-1), was examined during acute, subacute and chronic 
inflammation. Surprisingly, it was found that there was no difference in SBD-1 mRNA 
expression in infected and uninfected sheep, nor did this expression change over time after 
infection. These results suggest that SBD-1 expression is constitutive in lung and is not 
altered during acute, subacute or chronic inflammation. The above studies demonstrate that 
antimicrobial peptide expression is a dynamic process in the ruminant lung during M 
viii  
haemolytica pneumonia and can be markedly affected by the degree of pulmonary 
inflammation. 
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Mannheimia haemolytica pneumonia is serious in both neonatal and adult cattle and 
sheep, resulting in significant mortality and economic losses. During stress, bacteria increase 
in number (Frank, 1983; Frank. 1996) and induce an acute inflammatory response in the 
lungs characterized by dense infiltrates of neutrophils into alveolar spaces and tissue damage 
(Whiteley, 1990; Whiteley, 1991; Ackermann, 1996). Neutrophil products released in the 
respiratory airways can damage the epithelia (Slocombe, 1985; Breider, 1988; Breider, 1991: 
Weiss, 1991; Maheswaran, 1993), detrimentally impacting the efficiency of the pulmonary 
innate immune mechanisms. 
Antimicrobial peptides (AMP) are a relatively recently recognized component of the 
innate immune defense system, a system that functions to protect mucosal and skin surfaces 
from microbial colonization (Steiner, 1981; Selsted, 1984; Selsted, 1985). Antimicrobial 
peptides are produced by diverse species, including animals and plants. In mammals, AMP 
are produced by both epithelial cells and blood phagocytes, and are either produced 
constitutively or upon induction by bacteria and inflammatory substances. The first 
discovered epithelial-derived AMP, tracheal antimicrobial peptide (TAP), was identified in 
the tracheal mucosa of cattle (Diamond, 1991). Tracheal antimicrobial peptide has a (3 sheet 
structure and is termed a p-defensin. Since then, several other mammalian P-defensins have 
been discovered in several different species. These include two in cattle (TAP and lingual 
antimicrobial peptide (LAP)), two in sheep (sheep p-defensin (SBD)-l and -2) and three in 
humans (human p-defensin (HBD)-l. -2, and -3) (Diamond, 1991; Bensch, 1995; 
Schonwetter, 1995; Harder. 1997; Huttner, 1998; Jia, 2001). Most (TAP. LAP, SBD-1. 
HBD-1, HBD-2 and HBD-3) are expressed, among other places, by the epithelia of the 
respiratory tract. Anionic peptide (AP) is another important AMP produced in lung that 
differs from P-defensins biochemically. Anionic peptide is anionic, small and composed of 
seven aspartate residues, whereas p-defensins are cationic, larger and composed of 
approximately 45 various amino acid residues and have multiple cysteine disulfide bridges 
(Brogden, 1996). 
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Although work in vitro and some studies in vivo have demonstrated that expression of 
some p-defensins is increased by pro-inflammatory substances, the extent of expression of 
TAP, SBD-1 and AP in the ruminant respiratory tract during acute M. haemolytica 
pneumonia has not been determined. Also, it is unknown if the patterns of in vivo expression 
of ruminant P-defensins in the lung change during the progression to chronic inflammation. 
Human P-defensins have been shown to have altered expression patterns in some acute and 
chronic pulmonary diseases (Hiratsuka, 1998; Singh, 1998). However, few, if any. studies in 
humans or ruminants have followed through the chronic phase the expression patterns of a P-
defensin that is induced during acute pneumonia. 
Although M haemolytica is a known inducer of one bovine p-defensin, LAP 
(Stolzenberg, 1997). this AMP is expressed at only small levels in the respiratory tract in 
comparison to TAP, and the expression of P-defensins and AP by neonates has not been 
determined. Innate immunity is particularly important in neonates and juveniles, as an intact 
innate immune system is particularly vital at these ages to prevent and/or reduce microbial 
infection. Finally, because excessive neutrophil infiltration may destroy respiratory epithelial 
cells vital to AMP expression, reduction of neutrophil infiltration and neutrophil-mediated 
tissue damage during M. haemolytica pneumonia through inhibition of the leukocyte 
adhesion molecules, the selectins, might have an effect on AMP expression. 
The objective of this work was to determine the effect of the inflammatory response 
during M haemolytica pneumonia on expression of selected antimicrobial peptides in the 
ruminant lung. 
Dissertation Organization 
This dissertation is organized to include six chapters composed of a general introduction, 
a literature review, three manuscripts suitable for publication and general conclusions, 
respectively. The references have been included at the end of each chapter. The manuscripts 
correspond to three separate experiments. The first manuscript was recently published in the 
American Journal of Veterinary Research, the second is prepared for submission to the 
American Journal of Respiratory and Critical Care Medicine, and the third is prepared for 
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submission to Infection and Immunity. In all manuscripts, the first author is the PhD 
Candidate, Jessica M. Caverly, and the Major Professor, Mark R. Ackermann, is co-author. 
In the first experiment, the presence and concentration of AP in bronchoalveolar lavage 
fluid (BALF) and the anti-M haemolytica activity of BALF containing AP from neonatal 
calves in health and during acute inflammation caused by M haemolytica pneumonia was 
determined, and compared to BALF AP concentration and anti-M haemolytica activity from 
healthy adult cattle. The effect of a selectin inhibitor on BALF neutrophil percentage and 
degeneration and BALF protein as a measure of tissue damage during acute inflammation in 
neonatal calves, as well as its effect on BALF AP concentration and anti-M haemolytica 
activity, was determined. The second experiment used the same calves to examine the 
presence and level of messenger ribonucleic acid (mRNA) expression of the inducible (3-
defensin, TAP, in neonatal lung in health and during acute inflammation and attenuation of 
the inflammation with a selectin inhibitor. In addition, the mRNA expression of two 
molecules vital to neutrophil infiltration, interleukin (IL)-8 and intercellular adhesion 
molecule (ICAM)-l were examined. In the final study, the level of mRNA expression of a 
suspected inducible ovine P-defensin, sheep P-defensin-1 (SBD-1), was examined in health 
and during acute, subacute and chronic inflammation caused by M haemolytica pneumonia 
in juvenile sheep. The results obtained from the above three experiments demonstrate that 
AMP expression is a dynamic process in the ruminant lung during Mannheimia haemolytica 
pneumonia and can be markedly affected by the degree of pulmonary inflammation. 
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CHAPTER 2. LITERATURE REVIEW 
Mannheimia haemolytica 
Mannheimia haemolytica pneumonia 
Mannheimia haemolytica is an important respiratory pathogen of domestic and wild 
ruminants that colonizes the tonsils and pharyngeal portion of the respiratory tract of cattle 
(Shoo, 1990; Frank, 1992). During transport, viral infection or other stresses, bacteria 
increase in number (Frank, 1983; Frank, 1996) and induce an acute inflammatory response in 
the lungs characterized by dense infiltrates of neutrophils into alveolar spaces and tissue 
damage (Whiteley, 1990; Whiteley. 1991; Ackermann, 1996). Mannheimia haemolytica 
pneumonia is particularly serious in neonatal and juvenile cattle and sheep, resulting in 
significant mortality and economic losses, although it can also cause pneumonia in adult 
animals. Release of substances such as elastase, myeloperoxidase and oxidative free radicals 
from neutrophils has been associated with tissue damage (Harlan, 1987; Henson, 1987; 
Varani, 1994) and plays a role in the pathogenesis of pneumonia attributable to M. 
haemolytica (Breider. 1991; Maheswaran, 1993). Additional evidence of the importance of 
neutrophils in M. haemolytica-induced pneumonia was indicated in the reduction of tissue 
damage and vascular leakage of protein by depletion of neutrophils (Slocombe, 1985; 
Breider, 1988; Abe, 1990; Weiss, 1991). Neutrophil-mediated damage to the respiratory 
tract removes the protective barrier provided by endothelial cells and the mucosal epithelium 
(Slocombe, 1985; Breider. 1988; Breider. 1991; Weiss. 1991; Maheswaran. 1993). allowing 
access of bacteria and inflammatory mediators to the exposed capillaries and reducing 
gaseous exchange. 
Adhesion molecules 
Neutrophil infiltration is mediated by adhesion molecules. Selectin adhesion molecules 
mediate the first, relatively unstable, "tethering" step of neutrophil adherence to the 
vasculature by binding sialyl Lewis* and related oligosaccharide receptors. There are three 
types of selectins: L-selectin, which is present on neutrophils and other leukocytes and binds 
ligands on endothelial cells (Spertini, 1991) and E- and P-selectin, which are expressed 
7 
primarily by endothelial cells and bind ligands on neutrophils (Pilewski, 1993; Bevilacqua, 
1994; Frenette, 1996). This initial selectin/ligand binding initiates expression of Pz-integrins 
on the surface of neutrophils (Simon, 1995), which mediate a more stable adherence to 
endothelial intracellular adhesion molecule (ICAM)-l in preparation for movement through 
the endothelium and into the tissues. In bovine lungs, ICAM-1 is expressed by endothelial 
cells, epithelial cells, neutrophils and alveolar macrophages during M haemolytica 
pneumonia (Radi, 1999). Expression of ICAM-1 is increased by tumor necrosis factor 
(TNF)-a, interleukin (IL)-1, interferon (INF)-y and endotoxin (Rothlein, 1988; Wawryk, 
1991; Lassalle, 1993; Bevilacqua, 1994). 
Interleukin-8 
One of the most potent neutrophil chemoattractants is the chemokine IL-8 (Baggiolini, 
1994). Interleukin-8 is produced by endothelial cells, epithelial cells, activated macrophages 
and neutrophils, and causes activation and chemotaxis of neutrophils into sites of secretion 
(Baggiolini, 1994). Interleukin-8 production is induced by other cytokines, IL-1 and TNF-a 
being the most potent (Kunkel, 1995). Neutrophils not only produce IL-8 and other 
neutrophil chemoattractants such as leukotriene B4 (Sibille, 1993), but they also release 
elastase, which induces IL-8 synthesis in human bronchial epithelial cells in vitro 
(Nakamura, 1992; Bédard, 1993). Also, a-defensins released by stimulated neutrophils have 
been shown to stimulate IL-8 synthesis by human airway epithelial cells (van Wetering, 
1997a). 
Selectin inhibition 
Inhibition of the initial selectin-mediated tethering of neutrophils to endothelium may 
play a role in reduction of neutrophil infiltration into the lungs during acute M. haemolytica-
induced pneumonia. TBC1269 is a nonoligosaccharide selectin antagonist which provides 
competitive inhibition of sialyl Lewis* binding, in vitro, to selectins (Kogan. 1997; Palma-
Vargas, 1997; Kogan, 1998; Abraham, 1999; Radi, 2001). This mimetic has been used in 
vivo in an ovine model of asthma (Abraham, 1999) and in clinical studies for use in the 
treatment of human allergic asthma. Use of this mimetic during bovine M haemolytica 
pneumonia reduces the number of neutrophils infiltrated into the lungs (Radi, submitted). 
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This may reduce neutrophil-mediated pulmonary damage and maintain the epithelial barrier 
and it's associated defenses, including mucociliary clearance and production of antimicrobial 
peptide (AMP). 
Antimicrobial Peptides 
Introduction 
Microorganisms are present in all aspects of the environment of vertebrates, invertebrates 
and plants; yet normally, the epithelial surfaces of these eukaryotes remain free of pathogenic 
microbial colonization. This is due, in part, to AMP. Antimicrobial peptides are an 
important part of the innate defense system of higher eukaryotes, and function as a chemical 
shield preventing the infection of epithelia by microorganisms (Nissen-Meyer, 1997. 
Gudmundsson, 1999; Hecht, 1999). 
Antimicrobial peptides were recognized in the early to middle 1980s (Steiner, 1981; 
Selsted, 1984; Selsted, 1985) and as a group are usually cationic, are structurally diverse and 
are found in epithelial cells, phagocytes and other cell types. Today, more than 500 AMP 
sequences are known, and additional new AMP are commonly reported (Tossi. 2000). They 
have characteristics that make them an excellent first line of defense as they are synthesized 
rapidly (theoretically more than 100 times faster than IgM (Nissen-Meyer, 1997)) and are 
able to diffuse through solution quicker than proteins and immune cells (Nissen-Meyer, 
1997). Antimicrobial peptides have been isolated from all phyla examined, including plants, 
invertebrates and species lacking clonal immune mechanisms. They are divided into several 
different groups based on their structural characteristics. Please see Table I. 
Plants 
Plants do not have an adaptive immune system comparable to that found in animals; but 
they do share components of the innate immune system, including surface expression of 
AMP. Some plant AMP are constitutively expressed; whereas others can be induced upon 
exposure to microbial signals (Schroder. 1999). Thionines are one family of inducible AMP 
found mainly on the surface of flowers and leaves (Schroder, 1999). They are 45-47 amino 
acids long, cysteine-rich, contain three or four disulfide bonds, and are toxic to gram-positive 
9 
Table 1: Structural classification of and organisms within which the non-synthetic 
antimicrobial peptides represented in this manuscript are found. It is 
important to note that these structures can change depending on whether the 
peptide is in an aqueous or membrane-bound state (Epand, 1999). 
Structural Group Peptide Organisms 
linear peptides which form cecropins insects, mammals 
amphipathic and andropin insects 
hydrophobic a-helices moricin insects 
dermaseptins frogs 
magainin frogs 
bombinins frogs 
LL37 (cathelicidin) mammals 
CIS (cathelicidin) mammals 
PMAP-36 and -37 (cathelicidins) mammals 
SC5 (cathelicidin) mammals 
BMAP-27 and -28 (cathelicidins) mammals 
CRAMP (cathelicidin) mammals 
pardaxin fish 
melittin insects 
PGLa frogs 
pleurocidin fish 
peptides with disulfide bonds, thionines plants 
often forming P-sheet and/or defensins plants, insects, mammals, birds 
cyclic structures hevein-type and knottin-type plants 
peptides 
thanatin insects 
brevinins-1 frogs 
cyclic dodecapeptide (cathelicidin) mammals 
protegrins (cathelicidin) mammals 
tachyplesins horseshoe crabs 
peptides with unique amino acid apidaecins (proline) insects 
compositions abaecin (proline) insects 
drosocin (proline) insects 
PR-39 (cathelicidin, proline) mammals 
prophenin (cathelicidin, proline) mammals 
bactenecins (cathelicidin, proline) mammals 
indolicidin (cathelicidin. mammals 
tryptophan) mammals 
tritrpticin (cathelicidin, tryptophan) mammals 
anionic peptide (aspartates) 
cyclic peptides with thio-ether nisin bacteria 
groups in the ring 
macrocyclic knotted peptides circulin A and B plants 
larger proteins whose lysozyme birds, viruses 
antimicrobial activity can be lactoferrin (lactoferricin) mammals 
traced to a cationic peptide ribosomal proteins bacteria 
histone proteins amphibians, fish 
bactericidal/permeabi I ity-inc reasing mammals 
protein (BPl) 
unclassified ranaiexin frogs 
bombinin H frogs 
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and -negative bacteria, fungi, yeast and various mammalian cell types (Broekaert, 1997). 
Plants also produce defensins, whose structural and functional properties resemble insect and 
animal defensins (Broekaert, 1995). They are present in seeds and vegetative tissues, are 
expressed constitutively and on induction, are cysteine-rich (similar to mammals) and show a 
broad-spectrum of activity, particularly against fungi (Terras, 1993; Broekaert, 1995; 
Broekaert, 1997). Two other cysteine-rich AMP (hevein-type and knottin-type) have been 
found in plants (Chagolla-Lopez, 1994), some members of which are produced in seeds 
(Schroder, 1999). 
Insects 
Insects express several different families of AMP, displaying varying degrees of activity, 
inducibility and numbers of cysteine bridges. Many have antimicrobial activity at 
micromoler concentrations (Hultmark, 1994; Boman, 1995; Hoffman, 1995), and for many, a 
regulatory gene cassette similar in structure to the mammalian IL-l/inhibitor protein I-
icB/nuclear transcription factor KB (IL-1/I-KB/NF-KB) system controls inducibility 
(Lemaitre, 1996). Cecropins are one family of AMP produced by hemolymph cells and other 
cells of insects, including moths and butterflies (order Lepidoptera) and flies (order Diptera) 
(Hoffman, 1995; Schroder. 1999); however, a cecropin-like peptide, cecropin PI. has been 
isolated from the small intestine of pigs (Lee, 1989), so cecropins may be widespread in the 
animal kingdom. Cecropins are synthesized as preproproteins, which must undergo further 
processing before becoming biologically active (Gudmundsson, 1991). They are principally 
active against gram-negative bacteria, but can also kill gram-positive bacteria and fungi, and 
function by membrane permeabilization enabled by amphipathic a-helix formation (Nissen-
Meyer, 1997, Millier. 1999). A chemically synthesized all-D cecropin, cecropin A. had the 
same antimicrobial activity as the natural all-L cecropin A (Wade, 1990), pointing towards a 
non-receptor mediated mode of action, in this instance. Andropin (from the ejaculatory duct 
of the Drosophila fly) (Hultmark. 1994) and moricin (from hemolymph of the silkworm 
Bombyx mori) (Hara, 1995) also have cationic amphiphilic a-helix N-terminal regions. 
Insects also express defensins (Lambert, 1989). Insect defensins are 38-43 amino acids 
long, have 3 cysteine bridges that stabilize a P-sheet structure, and are cationic (White, 
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1995), resembling both mammalian and plant defensins. However, contrary to mammalian 
defensins, insect and plant defensins have an additional a-helix motif (White, 1995). In 
addition, insect defensins do not act within phagocytes, but are instead secreted into the 
hemolymph of infected insects (Nissen- Meyer, 1997). Insect defensins are primarily active 
against gram-positive bacteria (Hoffman, 1995). Some are expressed constitutively and 
others are induced, and they are widespread amongst insect species (Hoffman. 1995). One 
insect defensin, drosomycin. contains four cysteine bridges and has specific activity against 
fungi (Fehlbaum, 1994). 
A third group of insect AMP are rich in proline. These include the apidaecins and 
abaecin in honeybees, and drosocin in Drosophila flies (Casteels, 1989; Casteels, 1990; 
Bulet, 1993). They are primarily active against gram-negative bacteria, although they have 
some efficacy against gram-positive bacteria (Nissen-Meyer, 1997). The D-enantiomer of 
apidaecin is not active, indicating potential interaction with a chiral cellular component 
(Casteel, 1994). 
A final newly identified AMP in insects is thanatin, which does not belong to any of the 
groups above, and in fact the sequence resembles frog skin AMP of the brevinin-1 family 
(Fehlbaum, 1996). 
Frogs 
Perhaps the organism that deserves the most glory in the discovery of AMP is the frog. 
The importance of antimicrobial peptides to host protection was discovered quite by accident 
roughly 15 years ago, when it was noticed that frogs (Xenopus laevis) with wounds only 
rarely developed skin infections while in water dense with bacteria (Zasloff, 1987). Frog 
skin has been used medicinally for centuries in South American countries. Initially, 
magainins were isolated from frog skin, but have also been found in the stomach (Moore, 
1991). Since then, many different AMP have been discovered in frogs of different species, 
including dermaseptins (in Phyllomedusa sp. (Mor, 1994)), and bombinins (in Bombina sp. 
(Gibson, 1991 ; Simmaco. 1991)). Magainins. dermaseptins. bombinins, and many other 
AMP from frogs, are linear, about 21-34 amino acids long, form amphiphilic a-helices and 
have broad-spectrum antimicrobial activity at micromoler concentrations against gram-
positive and -negative bacteria, fungi and protozoa (Zasloff. 1987; Soravia, 1988; Jacob, 
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1994). Magainins are synthesized as preproproteins, which must undergo further processing 
before becoming biologically active (Zasloff, 1987; Terry, 1988). Similarly to the cecropins, 
a chemically synthesized all-D magainin, magainin 2. has the same antimicrobial activity as 
the natural all-L magainin 2 (Wade, 1990), pointing towards a non-receptor mediated mode 
of action, in this instance. 
However, other AMP isolated from frog skin do not form amphiphilic a-helices, thus 
their mode of action may be different than the previously mentioned ones. These include the 
brevinins-1, ranalexin and bombinin H (Nissen-Meyer, 1997). Interestingly, bombinins H 
have been found to contain naturally occurring D-amino acids (Mignogna, 1993) (which, 
previous to this, had only been demonstrated in nature in opioid peptides isolated from South 
American frogs (Erspamer, 1989)). D-isomers are not essential for antimicrobial activity, but 
may increase the biostability of these substances (Mignogna. 1993). Vertebrate skin has the 
same embryological origin as brain, and several frog skin peptides have been found to have 
counterparts in the mammalian gastrointestinal tract and brain (Erspamer. 1973). In addition. 
AMP from several different frog species have been found to have signal sequences similar to 
opioid precursor peptides from frog skin (Richter. 1987). The meaning of this is unknown, 
but has prompted experimentation with AMP as potential neuromodulators. 
Comparative structure of mammalian antimicrobial peptides 
Defensins 
Defensins, which are AMP belonging to the structural group that contains disulfide 
bridges, are some of the most well characterized AMP in mammals. The defensins have a (3-
hairpin stabilized by three disulfide bonds (although plant and insect defensins, as opposed to 
mammalian defensins, contain an additional a-helical motif) (Schroder, 1999). They are 29-
40 amino acids long, 3 to 4 kDa, cationic (arginine is the predominant cationic residue in 
defensins), amphipathic peptides that contain six cysteine residues arranged in three disulfide 
bonds (Diamond. 2000a). They exhibit strong microbicidal activity against bacteria, fungi, 
mycobacteria and viruses (Diamond. 2000a). Besides a role in protecting the host against 
infection, defensins are suspected to have roles in other aspects of immunity, including innate 
and acquired immunity, as well as various other functions, such as wound repair. Defensins 
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can be further characterized structurally into two classes: a- and P- defensins. They differ 
based on number of amino acids (29-35 for a-defensins and 38-42 for P-defensins), location, 
sulfhydrol linkage of the cysteines, and in consensus sequences unique to either one or the 
other, although members of both subfamilies share similar molecular conformations (Nissen-
Meyer, 1997). Defensins are synthesized as preproproteins of approximately 95 amino acids, 
with a typical 19 amino acid signal sequence at the N-terminus followed by a 40 to 45 amino 
acids prosequence (Lehrer, 1993; Ganz, 1994; Martin, 1995; Selsted, 1995). The signal 
sequence targets the preproprotein to the endoplasmic reticulum, whereas the function of the 
prosequence is unknown (Nissen-Meyer, 1997). It may prevent premature membrane 
permeabilizing activity, assist in proper folding, or aid in targeting to the proper cellular 
organelle (Nissen-Meyer, 1997). 
In addition, there is a third class of defensins, the 6-defensins. Currently, there is only 
one member, rhesus 0-defesnin-l (RTD-1) (Tang. 1999). It is a macrocyclic. tridisulfide, 18 
amino acid AMP fund in neutrophils and monocytes (Tang, 1999). It is so named due to its 
resemblance to the Greek letter, as it is formed by the head-to-tail ligation of two a-defensin-
related nonapeptides (Tang, 1999). Rhesus 0-defensin-l is microbicidal for gram-positive 
and -negative bacteria and fungi at low micromolar concentrations (Tang, 1999). This 
peptide most closely resembles circular peptides in plants, circulin A and B (Tang, 1999). 
These later peptides are reported to have anti-HIV activity (Gustafson, 1994). To date, no 
human 6-defensin has been found. 
a-defensins. In the protection of epithelial surfaces of the higher vertebrates from 
pathogenic microbes, multiple cell types are important to the innate immunity provided by 
AMP. Antimicrobial peptides are produced not only directly by epithelial cells, but animals 
also employ cell-mediated immunity through production of AMP by blood phagocytes, 
particularly neutrophils. Neutrophils have available many methods of killing ingested 
microbes, including AMP, which mediate killing following phagolysosomal fusion. In 
humans, these AMP include a-defensins, which were first described in 1985 (Ganz, 1985), 
and presently have 6 members, four of which are found in neutrophils (HNP-1, -2, -3 and -4) 
and two of which are found in Paneth cells in the small intestinal crypts and the epithelial 
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cells of the female genital tract (HD5 and HD6) (Jones, 1992; Lehrer, 1993; Martin, 1995; 
Quayle, 1998; Schroder, 1999). (Interestingly, HD5 is variably expressed in the 
endometrium correlating with the phase of the menstrual cycle (Quayle, 1998).) Intestinal a-
defensins are thought to have a role in constraint of intestinal bacteria (Nissen-Meyer, 1997). 
Myeloid a-defensins have also been found in rabbits, rats, guinea pigs and monkeys (Lehrer. 
1993; Selsted, 1995; Tang, 1999). 
Mammalian a-defensins are cysteine-rich, and each differs in its antimicrobial spectrum 
(including gram-negative and -positive bacteria, fungi, viruses and mycobacteria) and 
potency (depending on its net positive charge). In humans, myeloid a-defensins are 
produced in the bone marrow during neutrophil maturation in very large amounts (5-10 
mg/kg body weight/day) (Schroder, 1999). They are stored in the azurophilic granules as 
prepropeptides (Schroder. 1999) and are not inducible. The microbicidal concentration for 
a-defensins ranges from 1 to 100 ng/ml and is optimal in low ionic strength media in the 
absence of serum; therefore, they are thought to exert their effect mainly in the 
phagolysosome (Lehrer, 1993). Human patients with specific granule deficiency lack 
neutrophil defensins. and are prone to frequent and severe bacterial infections, despite a 
generally normal oxidative burst (Root, 1972; Boxer, 1982; Gallin. 1982; Ambruso. 1984; 
Ganz. 1988). There is evidence that some human myeloid a-defensins cross the blood-brain 
barrier when released from activated neutrophils (Schluesener, 1995). 
a-defensins accumulate in the airway secretions during several inflammatory diseases of 
humans, including cystic fibrosis (Soong, 1997). In patients with diffuse panbronchiolitis. a-
defensin levels are increased in correlation with levels of IL-8 (Ashitani. 1998). Partly this 
increase is likely due to the neutrophil attractive properties of IL-8, but may also be due to a-
defensin induction of IL-8 synthesis by epithelial cells (van Wetering, 1999). Neutrophil a-
defensins have been shown to chemoattract monocytes (Territo, 1989) and T-cells (Chertov, 
1996). In fact, depletion of neutrophils in mice has resulted in inhibition of subsequent 
chronic inflammatory reactions, which may in part be due to prevention of a-defensin-
mediated chemoattraction of monocytes and T cells (Taub, 1996). As well, a-defensins 
stimulate the production of the neutrophil chemoattractants leukotriene B4 and IL-8 by 
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alveolar macrophages (Paone, 1999). In addition, a-defensins have been shown to induce 
INF-y, IL-6 and IL-10 release by T-cells (Lillard, 1999). Finally, it has been suggested that at 
low concentrations (3-30 ng/ml), a-defensins potentiate TNF-a release by stimulated 
monocytes, whereas at higher concentrations (> l|ig/ml), they inhibit TNF-a production 
(Misuno, 1992). Thus, a-defensins within phagocytes play not only a role in microbial 
killing, but a signaling role as well. Based on these findings, it is becoming increasingly 
clear that AMP are not simply important in innate defense, but have a role in linking the 
innate and adaptive immune systems. 
a-defensins may also be implicated in directly causing some amount of airway epithelial 
damage. As neutrophils are becoming increasingly recognized as important in the 
pathogenesis of human asthma, the role of a-defensins in this disease becomes increasingly 
important to examine. In vitro studies demonstrate that a-defensins, in concentrations likely 
to occur in vivo, cause lysis of airway epithelial cells (van Wetering, 1997b). In addition, 
levels of glutathione have been shown to be decreased in airway epithelial cells in the 
presence of a-defensins. possibly making these cells more susceptible to oxidative injury 
(van Wetering, 1998b). Also, due to their cationic nature, they bind anionic serum proteins 
such as a 1-proteinase inhibitor (al-PI), preventing al-PI from binding and inactivating 
neutrophil elastase (Panyutich, 1995). It should be noted, however, that the binding of a-
defensins to anionic substances may function in vivo to restrict them from having access to 
host cells and causing lysis (Panyutich. 1995). as well as reducing their ability to lyse 
microorganisms (van Wetering, 1999) and induce chemokine synthesis (van Wetering, 
1997b). Also, levels of another elastase inhibitor, secretory leukocyte protease inhibitor 
(SLPI), are increased in the airway in the presence of a-defensins (van Wetering, 1998a), and 
a-defensins in high concentrations have been shown to increase the resistance of epithelial 
cells to neutrophil elastase- or cathepsin G-induced detachment (van Wetering, 1997b). a-
defensins have also been shown to increase airway hyperresponsiveness, by increasing 
histamine release by human mast cells (van Overveld, 1995), and enhancing tracheal 
responsiveness to histamine in isolated guinea pig tracheas (van Gessel, 1999). The mast cell 
has been suggested to regulate the innate immune response through the production of 
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cytokines (Galli, 1999), and a-defensins may play a role in coordinating this response, again 
implying that they are not only important in microbial killing, but in mediating the immune 
inflammatory response itself. 
In addition to the pro-inflammatory effects of a-defensins. they have anti-inflammatory 
effects, also. They have been shown to inhibit fibrinolysis (Higazi, 1995), inhibit natural 
killer (NK) cells in vitro (Ouellette, 1999) and to bind to Clq, thus preventing activation of 
the classical complement pathway (van den Berg, 1998). In vitro. in low, nontoxic 
concentrations, a-defensins promote epithelial cell proliferation, potentially promoting 
wound repair in vivo (Murphy, 1993). Paradoxically, it has been found that a-defensins 
promote binding of Haemophilus influenzae to cultured airway epithelial cells (Gorter, 
1998). Theoretically, this could promote killing of the bacteria by exposure to high 
concentrations of cell-derived AMP. such as the P-defensins. as well as other cell-derived 
substances with antibacterial activity, such as SLPI (Hiemstra, 1996; van Wetering. 1999). 
Similarly, Paneth cell a-defensins have been found, in vitro, to stimulate chloride secretion 
in intestinal epithelial cells, potentially working to flush the gut and help distribute a-
defensins and other crypt secretions to the villous surface in vivo (Lencer. 1997). 
A recombinant form of the human non-myeloid a-defensin, HD5. is active against 
several species of bacteria and Candida albicans, even after partial proteolysis, which 
indicates its ability to function within the intestinal environment (Porter, 1997). 
Constitutively expressed intestinal a-defensins with broad-spectrum antimicrobial activity 
are also found in the Paneth cells of mice and are called cryptdins (Ouellette. 1989; Ouellette. 
1996; Ouellette, 1997). Mouse cryptdin precursors are posttranslationally processed and 
activated by a metal loproteinase expressed abundantly in the Paneth cells of the small bowel, 
matrilysin (MMP-7) (Wilson, 1999). Paneth cell deficiency seems to induce crypt 
intermediate cells to produce and secret Paneth cell a-defensins (Garabedian, 1997). 
Additionally, T cell activation appears to induce the crypt epithelium to modify its genetic 
programs to produce more Paneth cell a-defensins (Ouellette, 1999). Which leads to the 
suggestion that identification of changes of the level of expression of intestinal a-defensins 
may be used as a marker of gastrointestinal disease (Ouellette, 1999). 
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Human Paneth cell a-defensins map in proximity to the myeloid a-defensins and P-
defensins on chromosome 8 (Ouellette, 1999). Mouse Paneth cell a-defensins map to a 
similar locus on chromosome 8 (Ouellette, 1999). Levels of both a-defensin messenger 
ribonucleic acid (mRNA) and peptide appear to be similar in human and mouse Paneth cells, 
although mice have many more isoforms (Ouellette, 1999). Cryptdins have also been 
isolated from Leydig and Sertoli cells of the mouse testes (Grandjean, 1997). Similarly, a 
distinct non-myeloid a-defensin has been isolated from rabbit kidney (Bateman, 1996; Wu, 
1998). Although a-defensins have been studied for a longer time than P-defensins and are 
somewhat better characterized, their functions in vivo are still not entirely understood and in 
vitro studies often represent abilities that seemingly counteract each other. However, as 
more in vivo studies are performed on a-defensins. these contradictions may become 
explained. 
p-defensins. In contrast to rodents and humans, bovine neutrophils do not contain a-
defensins, but instead produce p-defensins. Thirteen different kinds of P-defensins have 
been discovered in bovine neutrophils (Selsted, 1993). Alveolar macrophages (Ryan, 1998) 
and a variety of epithelial cells, including cells in the respiratory (Diamond, 1991 ; Diamond, 
1993) and the gastrointestinal mucosa (Schonwetter, 1995; Tarver. 1998), also express P-
defensins in cattle. In addition, P-defensins have been identified in humans (Bensch. 1995; 
Zhao, 1996; Harder, 1997a), chimpanzees (Duits. 2000), rhesus monkeys (Bals. 2001). mice 
(Huttner. 1997; Morrison, 1998; Bals, 1998b; Bals, 1999a; Morrison, 1999), rats (Jia, 1999) 
sheep (Huttner, 1998a; Huttner, 1998b), goats (Zhao, 1999), pigs (Zhang, 1998), chickens 
and turkeys (Harwig, 1994; Evans, 1994). An AMP with structural characteristics similar to 
P-defensins, Binlb, has been discovered recently in a specific region of the rat epididymis 
(Li, 2001). Binlb shares structural similarity to isoforms of epididymis-specific genes from 
humans and chimpanzees (Li. 2001). Furthermore, this substance is developmental^ 
expressed, being expressed most highly during sexual maturity, leading to postulation that 
not only is it important in preventing ascending genital infections, but also may have a role in 
sperm maturation (Li, 2001). 
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Perhaps most important to the protection of mammalian surfaces from infection by 
microbes is the epithelial production of P-defensins. Tracheal antimicrobial peptide (TAP) 
was the first epithelial-derived peptide found in mammals (Diamond, 1991). Tracheal 
antimicrobial peptide was initially isolated from bovine tracheal mucosa. The TAP gene is 
expressed at high levels in the ciliated airway epithelium (Diamond, 1993). It is distinct 
from the neutrophil-derived P-defensins in size, charge and cysteine placement. The 
prepropeptide contains 64 amino acids, and in vitro, TAP is microbicidal at very low minimal 
inhibitory concentrations (MIC) against a variety of bacteria and at least one fungus, some of 
which colonize the bovine respiratory mucosa (Diamond, 1991). Tracheal antimicrobial 
peptide mRNA expression has been detected in columnar epithelial cells of the trachea and 
bronchi in adult animals by in situ hybridization (Diamond, 1993). Tracheal antimicrobial 
peptide expression is tissue-specific, and it is not detected in fetal tissues (Diamond, 1993). 
Expression in neonates has not been determined. 
In addition, TAP expression is inducible. Heat-killed Pseudomoncis aeruginosa and its 
lipopolysaccharide (LPS) induce TAP mRNA expression in cultured bovine epithelial cells 
(Diamond, 1996), presumably through binding of the LPS to CD-14 on epithelial cells 
(Diamond, 1996). In fact, interference with the binding activity of CD-14 with specific 
monoclonal antibodies inhibited the LPS-mediated upregulation of the TAP gene (Diamond. 
1996). Similar results were seen with the LPS upregulation of the human P-defensin (HBD)-
2 gene, a proposed human TAP homolog, in human airway epithelial cells (Diamond, 
2000a). In the bovine cells, but not in the human cells, this LPS-mediated upregulation was 
seen in the absence of serum. This indicates that LPS-binding protein, a protein that binds 
LPS and enhances the efficiency of LPS signaling, was not needed for TAP LPS-mediated 
upregulation, although the presence of serum did potentate the upregulation (Diamond. 
1996). Mouse p-defensin (MBD)-2 is also upregulated in response to LPS (Morrison, 1999). 
Sheep P-defensin (SBD)-l, an ovine P-defensin present in airway epithelium (Huttner, 
1998b), may have similar inductive properties, but this has not been assessed. 
Toll-like receptors are suspected to work in concert with CD 14 in responding to LPS and 
upregulating the expression of the HBD-2 gene in humans (Diamond. 2000a). Cultured 
bovine airway epithelial cells express toll-like receptor-3 (Diamond, 2000a), and possibly 
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other homologs, which may serve a similar, suspected function in cattle as the receptors do in 
humans. In addition to LPS, several other infectious and inflammatory agents will 
upregulate the expression of TAP, including phorbol 12-myristate 13-acetate (Diamond. 
1996), TNF-a (Russell, 1996). IL-lp, muramyl dipeptide, lipoteichoic acid (Diamond. 
2000b) and INF-y (Diamond, 2000a). Isoleucine and its analogs have also been shown to 
induce the expression of epithelial P-defensins through activation of the nuclear factor (NF)-
KB family of trans-activating factors (Fehlbaum, 2000). This essential amino acid is not 
produced by the host, so may have emerged as a trigger for epithelial P-defensin induction by 
virtue of being a likely marker of bacterial infection, either by bacterial secretion or by 
degradation of host cells (Fehlbaum. 2000). 
The promoter region of TAP contains NF-KB motifs (Diamond, 1993) as well as binding 
sites for NF IL-6 (Diamond. 2000a), transcription factors which mediate the induction of 
genes involved in the immune and inflammatory responses, often synergistically (Akira. 
1990; Betts, 1993; Matsusaka, 1993; Kopp, 1995; Tanaka, 1995). Nuclear factor-icB 
consensus binding sites have also been found in the promoter of the HBD-2 gene (Liu. 1998). 
Members of the NF-KB family are also involved in the induction of AMP in insects (Ip, 
1993; Boman, 1995; Lemaitre, 1996). Experiments with cultured bovine tracheal epithelial 
cells have demonstrated the necessity of both NF-KB and NF IL-6 for expression and 
upregulation of the TAP gene in response to LPS (Diamond. 2000b). Immunohistochemical 
studies have shown translocation of NF-KB in human airway epithelial cells after incubation 
with LPS or IL-ip (Diamond. 2000a). These studies indicate aspects of a conserved signal 
transduction pathway for AMP upregulation among varied species, both insect and 
mammalian. Numerous signaling pathways are suspected between LPS binding to CD-14 
and NF-KB activation, including a number of kinase cascades (Diamond, 2000a). In 
addition, activation by TNF may occur through a distinct pathway, which may differ from the 
LPS-induced pathway early in the cascade (Delude, 1998). 
Interestingly, several natural and synthetic AMP have been shown to bind LPS (Piers. 
1994; Hirata, 1995; Scott, 1999). In vitro studies have shown that various naturally 
occurring AMP. as well as synthetic analogs, can block the ability of LPS to stimulate the 
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production of TNF-a, IL-6 and other inflammatory mediators (Hirata, 1994; VanderMeer, 
1995; Gough, 1996; Brackett, 1997; Ganz, 1998; Kirikae, 1998; Scott, 1999). In addition, 
AMP have been shown to reduce mortality associated with endotoxemia in mice, in which a 
portion of the endotoxic effects are suspected be due to TNF-a release by activated 
macrophages (Kirikae, 1998). AMP from several different structural groups have been 
shown to prevent the in vitro binding of LPS to LPS-binding protein, which correlated with 
their ability to prevent TNF-a production by a macrophage cell line (Scott, 2000). The a-
defensin and P-defensin representatives in this study, 10 fig/ml each of HNP-1 and HBD-2. 
respectively, blocked only a modest amount (40%) of LPS-induced TNF-a release (Scott. 
2000). These results point to the potential use of AMP in anti-endotoxin treatment. Also, it 
suggests that AMP produced by LPS-induction may serve, in turn, to limit further 
inflammatory mediator production (including their own) by preventing further LPS induction 
of these substances. 
An additional bovine P-defensin. lingual antimicrobial peptide (LAP) was first isolated 
from bovine tongue (Schonwetter, 1995), and mRNA expression has been detected in 
bronchi, trachea, conjunctiva, colon, rectum and urinary tract (Schonwetter. 1995). LAP has 
structural homology to TAP and a similar spectrum of activity, but differs from TAP in its 
potency against many microbes (Schonwetter. 1995). Similarly to TAP. LAP is also induced 
by killed bacteria, LPS, and TNF-a in cultured bovine epithelial cells (Russell. 1996). A NF-
KB binding region is expected within the genetic sequence of LAP, but has not yet been 
found. Lingual antimicrobial peptide has been demonstrated to be induced by M 
haemolytica in the lung and Mycobacterium paratuberculosis in the ileum (Stolzenberg, 
1997). 
Another epithelial P-defensin, enteric P-defensin (EBD), is expressed by the bovine distal 
small intestine and colon crypts, and is induced by infection with Cryptosporidium parvum 
(Tarver, 1998). p-defensins of note in other species include a porcine P-defensin that has 
been recently discovered which could have important implications for the 
xenotransplantation of porcine organs and tissues in humans (Zhang, 1998). Also, in mice, 
induced expression of MBD-3 has been seen not only in tracheal epithelium, but also in the 
intestinal tract in response to intratracheal instillation of P. aeruginosa (Bals, 1999a). 
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(Similar system-wide induction of HBD-2 has been seen in human patients with bacterial 
pneumonia (Hiratsuka, 1998) and induction of the cathelicidin, LL37, in human patients with 
sarcoidosis (Agerberth, 1999).) 
Human P-defensin-1 was discovered in 1995 (Bensch, 1995). This 36 amino acid long 
peptide was originally isolated from the hemofiltrate of patients with end-stage kidney 
disease (Bensch, 1995). Since then, multiple forms have been found in human urine ranging 
in size from 36 to 47 amino acids with differing antimicrobial activities (Valore, 1998). The 
original isolate has not been found to have antimicrobial activity; however, a chemically 
synthesized form has activity against gram-negative bacteria (Goldman, 1997). This form 
contains three disulfide bridges (Goldman, 1997). Using reverse transcriptase (RT)-
polymerase chain reaction (PGR), HBD-1 was found to be expressed at high levels in the 
kidney, pancreas and salivary gland, at moderate levels in the prostate, placenta and trachea, 
and at low levels in the thymus, testis and small intestine (Zhao, 1996). It was not found at 
all in the leukocytes, spleen and skeletal muscle (Zhao. 1996). Other studies have reported 
mRNA expression in the female reproductive tract (Valore. 1998). and throughout the 
conducting airways of the lung in alveolar epithelial cells and submucosal glands (Singh, 
1998), in addition to cultured mammary gland epithelial cells (Zhao, 1996). As well, HBD-1 
has been demonstrated in human breast tissue and milk, perhaps augmenting neonatal host 
defenses (Jia, 2001a). Also, it has been found in gingival epithelial cells and is presumed to 
have a function in protecting the highly exposed oral mucosa from invading organisms 
(Weinberg, 1998). Similarly, HBD-1 is theorized to play a role in the maintenance of healthy 
skin, but this theory had not yet been substantiated. In studies using epithelial cells of the 
small and large intestine, it is produced constitutively (Hecht, 1999). 
Human P-defensin-1 has been mapped to a chromosomal region in close proximity to the 
gene for the human neutrophil a-defensin, HNP-l, leading to the assumption that a-
defensins and P-defensins arose from a common defensin progenitor (Liu, 1997). In addition, 
the mouse homolog of HBD-1, MBD-1, maps to a similar location in the mouse chromosome 
(Huttner, 1997). Besides the airways, MBD-1 is expressed in mouse kidney (Huttner, 1997; 
Morrison, 1998), a tissue that expresses high levels of HBD-1 in humans. Human P-
defensin-1 is probably not a homolog of TAP or LAP as it is not inducible, nor does its 
promoter region contain NF-KB binding regions (Liu, 1997), although the HBD-1 gene does 
contain NF IL-6 and INF-y consensus sites, suggesting possible influences on HBD-1 
expression by inflammatory mediators (Valore, 1996; Liu, 1996). The chimpanzee also 
expresses a possible HBD-l homolog in airway and skin, termed chimpanzee p-defensin-1 
(cBDl) (Duits, 2000). 
A second human P-defensin, HBD-2, was isolated from the skin of patients with psoriasis 
in 1997 (Harder, 1997a). Similar to the organ distribution of TAP, mRNA expression of 
HBD-2 has been found in human foreskin, lung and trachea, but not kidney, salivary gland, 
uterus or liver (Harder, 1997a). It has also been localized to epithelial cells of the small and 
large intestine (Hecht. 1999). It is 41 amino acids long, has high activity against gram-
negative bacteria, less activity against gram-positive bacteria, and kills C. albicans very 
effectively (Harder. 1997a). The antimicrobial activity of HBD-1 and HBD-2 ranges from 
0.1 to 50 ng/ml. although HBD-2 is 10 times more potent than HBD-l (van Wetering, 1999). 
Also, there is antimicrobial synergy between HBD-2, lysozyme and lactoferrin (Bals. 1998c). 
The sequence of HBD-2 has more homology to TAP than to HBD-1 (Harder. 1997a). In 
addition, HBD-2 is induced by heat-inactivated P. aeruginosa and TNF-a (Harder. 1997a). 
as well as P. aeruginosa LPS (Diamond, 2000a) and IL-ip (Singh, 1998). which is similar to 
TAP and in contrast to HBD-1. These qualities make HBD-2, rather than HBD-1. the more 
likely homolog to TAP. Also, heat-inactivated Staphylococcus aureus and C. albicans 
induce HBD-2, pointing to additional means of gene regulation than those used by TAP. 
which is not induced by these organisms (Harder. 1997a). In addition, increased HBD-2 
protein levels have been found in the plasma of patients with bacterial pneumonia (Hiratsuka, 
1998) and in the bronchoalveolar lavage fluid (BALF) of patients with cystic fibrosis and 
inflammatory lung diseases (Singh, 1998). However. HBD-1, but not HBD-2. is found in 
BALF from healthy volunteers, implying that it is important in host defense in the absence of 
inflammation (Singh, 1998). 
Human p-defensin-2 maps to the same chromosomal region as the other human a-
defensins and P-defensins, leading to the theory that genetic disruption of this area may lead 
to abnormalities in the expression of one or more AMP and result in unexplained, recurrent 
infections of epithelia (Harder, 1997b). Both HBD-1 and -2 have been shown to be 
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chemotactic for immature dendritic cells and memory T cells, indicating a potential role P-
defensins may play linking the innate and adaptive immune responses (Yang, 1999), similar 
to that seen with the a-defensins. 
A third human P-defensin, HBD-3, has been recently discovered via PGR analysis and 
RT-PCR analysis to be expressed in adult heart, skeletal muscle, placenta and fetal thymus, 
as well as skin, esophagus, gingival keratinocytes and trachea (Jia, 2001b). In fetal lung 
expiants and gingival keratinocytes, mRNA expression was induced by IL-ip (Jia, 2001b). 
An additional possible splice variant of this gene (HE2pl) was detected by RT-PCR in 
gingival keratinocytes and bronchial epithelium (Jia, 2001b). Human p-defesinin-3 has also 
been found in lesional psoriatic scales (Harder. 2001). Skin, tonsils and airway epithelial 
cells were discovered to be major tissue expression sites, and HBD-3 was found to be 
induced by TNF-a and bacteria (Harder, 2001). Human p-defensin-3 has antimicrobial 
activity against two antibiotic-resistant bacteria, and ultrastructural analysis revealed cell 
wall perforation of one of these bacteria (Harder, 2001). The gene for this AMP is found 13 
kb upstream from the HBD-2 gene on chromosome 8p22-p23 (Jia, 2001b). 
Sheep P-defensin-1 and -2 are the only two P-defensin genes discovered in sheep to date 
(Huttner, 1998a), in contrast to the 15 P-defensin genes discovered in cattle (Diamond, 1991; 
Selsted. 1993; Schonwetter, 1995); however, the majority of the genes discovered in cattle 
are specific to neutrophils, whereas only two (TAP and LAP) are produced by epithelial 
cells. Sheep p-defensin-1 and -2 are both produced by epithelial cells (Huttner, 1998b). 
Also, defensin genes localize to chromosome 26 in sheep and 27 in cattle, which are 
considered homologous to each other (Huttner, 1998a; Gallagher, 1995). These 
chromosomes are considered homologous to chromosome 8 in humans and chromosome 8 in 
mice, the chromosomes upon which the human and mouse P-defensin genes are localized 
(Ouellette, 1989; Chowdhary, 1996; Huttner. 1998a). Thus, the chromosomal location of the 
defensin family genes is conserved in these species (Huttner, 1998a). 
In RT-PCR and Northern blot hybridization analysis of SBD-1 and-2 within the 
gastrointestinal system in sheep ranging from gestation through adult, SBD-1 is 
predominantly expressed, although there is significant developmental and inter-animal 
variation in expression of both defensins (Huttner, 1998b). Although sheep p-defensin 
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expression has been noted in adult ovine trachea and lung (Huttner, 1998b), inducibility of 
SBD-1, the defensin suspected to be expressed predominantly in the ovine respiratory tract, 
has not been determined. 
Cathelicidins 
Another family of AMP prominent to several different mammalian species is the 
cathelicidins. Cathelicidins are bactericidal in micromolar concentrations against gram-
positive and -negative bacteria (Nissen-Meyer, 1997). This family of AMP is so named due 
to the similarity of the prosequence of these peptides, which resemble a protein isolated from 
pig leukocytes called cathelin (Ritonja, 1989). Family members contain a conserved 
proregion of 100 amino acids, with different C-terminal antimicrobial domains, which 
prevents inclusion of these AMP family members into one structural group. Procathelicidins 
are processed and activated by neutrophil elastase (Scocchi, 1992). The presence of 
cathelicidins in many different species is interesting from an evolutionary point of view, 
particularly considering the highly conserved nature of the proregion. In fact, it has been 
suggested that due to the highly conserved nature of the proregion, it may have an important 
biological function (Zanetti. 1995). Dermaseptins, from the skin of frogs, also contain a 
highly conserved proregion with variable C-termini, and a similar explanation has been 
offered for their proregion (Amiche, 1999). Based on the sequences of the promoter regions 
for cathelicidins, it appears that they will respond to cytokine-induced expression 
(Gudmundsson, 1995; Zhao, 1995a; Zhao, 1995b; Gudmundsson, 1996). 
Cathelicidin family members include peptides rich in proline, such as PR-39, prophenin 
and the bactenecins (Bac-5 and Bac-7). PR-39 and prophenin are found in the intestine and 
leukocytes of pigs (Agerberth, 1991; Harwig, 1995), whereas the bactenecins are found in 
neutrophilic large cytoplasmic granules of cattle, goats and sheep (Zanetti. 1990). PR-39 
has been shown to not only have antimicrobial activity, but to be chemotactic for neutrophils 
(Huang, 1997) and inhibit neutrophil oxidase (Shi, 1996). Also, it has been shown to induce 
the heparansulfate extracellular proteins, syndecan 1 and 4 (Gallo, 1994) and bind multiple 
SH3-containing cytoplasmic proteins, including pl30Cas, a signal transduction molecule 
important in integrin-mediated signaling pathways (Chan. 1998), playing a role in keeping 
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wounds sterile and promoting healing, as well as influencing cell motility and metastatic 
potential (Fujimoto, 1998). 
Other family members are rich in tryptophan, such as indolicidin and tritrpticin. 
Indolicidin is found in the granules of bovine neutrophils (Nissen-Meyer, 1997). Tritrpticin 
is a 13-residue synthesized peptide with antimicrobial activity that would presumably result 
from cleavage of prophenin-1 (Lawyer, 1996). It is unknown whether this small peptide 
exists in nature. 
A third group of cathelicidin family members are those that contain intermolecular 
disulfide bonds. These include cyclic dodecapeptide, found in bovine neutrophil granules 
and the protegrins found in porcine leukocytes (Nissen-Meyer. 1997). Protegrins have a 
resemblance to both defensins and the tachyplesins (found in the cytoplasmic granules of 
horseshoe crab haemocytes) (Kokryakov, 1993: Iwanaga, 1994; Nissen-Meyer, 1997). 
A final group of cathelicidin family members include those that form a-helical peptides. 
These include CI 8 (from the C-terminal region of CAP 18 from rabbit heterophils (Tossi, 
1994)), PMAP-36 and -37 (porcine myeloid antibacterial peptides from pig myeloid cells 
(Storici, 1994; Tossi, 1995)), SC5 from sheep bone marrow cells (Mahoney, 1995), CRAMP 
from mouse myeloid cells (Gallo, 1997), eCATH-2 and eCATH-3 from horse neutrophils 
(Scocchi, 1999) and LL37 from human neutrophils, macrophages and epithelial cells 
(Gudmundsson, 1996). BMAP-27 and -28. two more family members which are found in 
bovine neutrophils (Skerlavaj, 1996). have been found to be cytotoxic to human myeloid and 
lymphoid tumor cells and normal proliferating lymphocytes, and are suspected to induce 
apoptosis in these cells, as well as activated human lymphocytes (Risso, 1998). 
There are multiple cathelicidin genes in cattle, pigs, sheep, horses and rabbits, but only 
one discovered so far in mice. There is also only one in humans, LL37, which is induced in 
keratinocytes during inflammation (Zanetti, 1995: Frohm, 1997; Epand, 1999). However, 
LL37 appears to be constitutivelv produced in the human airway, where it is found in the 
alveolar surface fluid, bronchoalveolar lavage fluid, bronchial epithelial cells, bronchial 
epithelial glands and alveolar macrophages (Bals, 1998a; Agerberth, 1999). It is also 
expressed in the epithelial cells of the small and large intestine (Hecht, 1999) and testis 
(Agerberth, 1995). LL37 has been shown to not only have broad-spectrum antimicrobial 
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activity, but to also be chemotactic for T cells and neutrophils (Gudmundsson, 1999). This 
AMP has bactericidal synergy with lactoferrin, but not lysozyme (Bals, 1998a). 
Anionic peptide 
In addition to the defensins and cathelicidins important in the respiratory tract of 
ruminants, there is an AMP present in ruminant lung that cannot be included in either of 
these families. This AMP is called anionic peptide (AP). Anionic peptide is smaller than 
most AMP, and its anionic properties differ from most AMP, which are cationic (Brogden, 
1996). It is composed of consecutive aspartates and requires zinc as a cofactor (Brogden, 
1996). Anionic peptide initially was isolated from ovine surfactant (Brogden, 1996). It also 
is evident in human lung tissue and is detectable in high amounts in BALF collected from 
humans and sheep (Brogden, 1996; Brogden, 1999). Its presence and antimicrobial activity 
in the BALF of adult and neonatal cattle has not been assessed. In contrast to AP, bovine 
epithelial P-defensins, such as TAP and LAP, usually are not found in mucus and serous 
respiratory secretions. Instead, those compounds are found within epithelial cells and are 
locally secreted following their induction (Schonwetter. 1995; Diamond, 1993; Diamond, 
1996). The mode-of -action of AP is unknown, but the peptide is thought to complex with 
Zn* and other cations (Brogden, 1996). 
Anionic peptide is bactericidal against M. haemolyticci as well as other bacteria at a 
minimum inhibitory concentration comparable to that of other AMP, such as a- and P-
defensins (Brogden, 1996). Anionic peptide is believed to be a cleaved fragment secondary 
to a larger proprotein produced in the lungs (Brogden, 1996). In fact, a similar scenario is 
seen with some bacterial AMP, which have leader proteins that are anionic and form 
amphiphilic helices (Nissen-Meyer. 1997). The primary known function of these leader 
proteins is to prevent premature activation of the bacterial AMP, and/or promote interaction 
with modification enzymes (Nissen-Meyer. 1997). 
It is not known if the theoretical protein that AP is cleaved from has its own antimicrobial 
activity. Regardless, cleavage of proteins with no antimicrobial activity sometimes results in 
a peptide with antimicrobial activity. Such is the case with cleavage of the milk protein 
lactoferrin to lactoferricin in cattle and humans (Bellamy, 1992), in which case the change in 
secondary structure of this peptide from an a-helix to a p-sheet may be related to this activity 
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(Hwang, 1998). Interestingly, much of the potency of this peptide resides in just 18 amino 
acids (Tomita, 1994), which makes it attractive for use in the synthesis of analogs for 
commercial testing. Other examples of proteins from which cleavage products have 
antimicrobial activity include hen egg white lysozyme (Ibrahim, 1998), viral T4 lysozyme 
(During, 1999), ribosomal LI protein from Helicobacter pylori (Putsep, 1999), and histone 
H%A from the nucleosome (Kim, 1996; Park, 1998). Of note, these last two AMP give 
credence to the theory that in the ancient evolution of AMP, they originally evolved from 
proteins that had a strong positive charge, such as deoxyribonucleic acid (DNA)- or 
ribonucleic acid (RNA)-binding proteins, in order to better interact with highly negative 
bacterial proteins (Boman, 2000). 
Prokaryote and viral antimicrobial peptides 
As indicated above, antimicrobial peptide production is not limited to eukaryotes. 
Although somewhat dissimilar to the classic AMP, prokaryotes produce their own 
ribosomally synthesized substances which can be considered the bacterial equivalent of 
AMP, and which are generally referred to as bacteriocins. There are several different general 
types, and in addition to membrane permeabilizing effects, some bacterial AMP have other 
modes of bacterial killing, such as interfering with metabolic processing or DNA replication 
(Nissen-Meyer, 1997). Nisin is one bacterially produced AMP. It has an elongated, 
amphiphilic, screw-shaped structure, and forms voltage-dependent pores in the membranes of 
susceptible cells (Moll, 1996). Some bacteriocins are used as food preservatives. 
In addition to the AMP produced by bacteria, two positively charged, highly amphipathic 
helices within the cytoplasmic tail of the envelope protein of HIV-1 have been identified 
through protein modeling (Eisenberg, 1990). These, and other transmembrane proteins from 
lentiviruses, have been shown to have antimicrobial and cytolytic activities and contain a 
high proportion of arginines (Tencza, 1997). 
Mode-of-action of antimicrobial peptides 
Antimicrobial peptides very quickly kill bacteria, making it difficult to assess their mode 
of action. One common theme in microbial killing by AMP is interaction with the 
organism's membrane. Both the linear a-helical AMP and the defensins have been shown to 
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form channels in artificial membranes, and to lyse liposomes (Nakajima, 1987; Kagan, 1990; 
Cociancich, 1993). Liposomes that contain cholesterol show reduced propensity to be lysed 
by AMP (Nakajima, 1987). Cholesterol is a membrane component of higher eukaryotic cells 
and not prokaryotes, possibly explaining why AMP kill prokaryotic cells but spare the host. 
In addition, bacterial cells usually have a high membrane potential with many negatively 
charged phospholipids oriented toward the exterior of the cell and a lack of cationic lipids, 
possibly explaining the preferential association between these cells and cationic AMP, as 
most anionic peptides in mammalian cells are sequestered to the cytoplasmic side (Hancock, 
1997). In addition, in experiments studying the interaction of cationic AMP with 
membranes, a preferential sequestering of the anionic lipids was observed on the membranes, 
leading to less regular distribution between the lipids and the rest of the membrane (Polozov, 
1997a). However, it is unsure what effect this has on the antibacterial activity of the AMP. 
Also, membranes with intrinsic negative curvature tend to be lysed more readily by AMP 
that promote additional negative curvature (Polozov, 1997b). Similarly, the membrane itself 
may affect the structure of an AMP interacting with it, thereby affecting the potency of that 
AMP. For instance, there are two different states of insertion of protegrin in a membrane 
based on concentration of the peptide, nature of the lipid bilayer and extent of hydration 
(Heller, 1998). 
a-helical AMP have been synthesized from entirely D-amino acids, and shown the same 
level of activity as the naturally occurring L-enantiomers, indicting that a protein receptor at 
the level of the target organism's membrane is not functioning in cell lysis (Wade. 1990). 
But to complicate matters, there are some insect AMP that become inactive when synthesized 
from D-amino acids (Casteels, 1994), and some AMP, including magainin, have varying 
activity against different species of bacteria based on their ratio of L/D-enantiomer peptides 
(however, in the case of magainin, the partial D-enantiomer substitution resulted in a change 
in structure) (Chen. 1988). For instance, PR-39 activity was highly L-enantiomer dependent 
against P. aeruginosa and S. aureus, but its activity was not affected by the ration of L- to 
D-enantiomers when used against Escherichia coli or Bacillus subtilis (Vunnam. 1997) - and 
in fact PR-39 has been shown to bind cells in a receptor-dependent manner (Chan, 1998). 
Porcine cecropin P behaves similarly (Vunnam, 1997). 
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To further complicate matters, there is not always an association between the ability of 
AMP to permeabilize a membrane and their antimicrobial activities. Perhaps, in these cases, 
the membrane effects of AMP are not related to their cytotoxic effect, but instead are a 
mechanism to enter the cell to reach an alternative target (Wu, 1999). Some AMP are 
suspected to inhibit bacterial DNA synthesis, such as PR-39 and lactoferricin (Boman. 1993: 
He, 1995; Kanyshkova, 1999). In fact, although PR-39 is membrane active, it does not 
permeabilize membranes (Cabiaux, 1994). Also, magainins have been shown to have a role 
in uncoupling the respiratory chain on the mitochondrial membrane, disrupting membrane 
potential and killing bacteria (Westerhoff, 1989). Based on this evidence, the mechanism of 
action for certain AMP may involve non-receptor based entrance into the cell, but receptor-
based interactions inside the cell. 
The mechanism of action of the various structural groups of AMP is varied and requires 
further study. However, there are certain generalities that can be made. Antimicrobial 
peptides require a metabolically active cell to exert their effect (Martin, 1995). Many, if not 
most. AMP do interact with a bacterial membrane to cause its permeabilization. and appear 
to do so by disrupting the order of the phospholipid bilayer causing destruction of the energy 
gradient across the membrane and lysis. There are two main mechanisms theorized for 
bacterial membrane permeabilization. One is proposed for the a-defensins, and called the 
"barrel-stave mechanism' (White. 1995). It involves bundles of peptides forming 
transmembrane pores. Another theoretic mechanism is proposed for a-helical peptides and is 
called the 'carpet-like mechanism', in which AMP bind parallel to the membrane surface to 
cause cooperative permeabilization of the membrane (the 'carpet effect')) (Shai. 1995). In 
one study with magainins. at small concentrations these AMP were found to associate with 
the lipid bilayer heads to decrease the membrane thickness (Ludtke, 1996). At high 
concentrations, the magainins orient perpendicularly to the membrane to form holes (Ludtke. 
1996). 
These modes of action could explain lysis of gram-positive (one cell membrane) bacteria, 
yet presumably the AMP must transverse the outer membrane of gram-negative (two cell 
membranes) bacteria in order to effect killing at the internal membrane. One model 
hypothesized to explain AMP killing of gram-negative bacteria is called "self-promoted 
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uptake" (Hancock. 1997). In this model, the positively charged AMP interact with 
negatively charged bacterial outer cell membrane sites (LPS). The affinity of the LPS for the 
AMP is greater than it is for the native cations (such as Ca^ and Mg^); therefore, these ions 
are displaced. But, the AMP is much bulkier than the displaced ions, so it disrupts the 
bacterial cell membrane and creates transient membrane destabilization, allowing movement 
of hydrophobic compounds, small proteins, and the AMP itself. Then, if the AMP is one that 
causes lysis, to kill the cell the AMP then forms channels in the inner membrane. Its positive 
residues react with the negative residues of the cell membrane, and the AMP changes from 
an unstructured to a structured form. The hydrophobic faces direct towards the membrane's 
interior, whilst the hydrophilic faces point inwards to form a channel. The bacterial cell dies 
due to lack of membrane integrity. To date, direct evidence of this is lacking, although 
bacterial membrane blebbing had been noted with lactoferricin via election microscopy 
(Yamauchi, 1993). 
This "self-promoted uptake" model could allow not only the AMP itself through a 
microbe's membrane, but also further substances, such as additional AMP, antibiotics and 
other substances toxic to the microbe. Hence, it could explain the synergistic relationship 
often noted between AMP and these other substances in microbial killing. In addition, this 
could be the mechanism by which AMP that do not cause membrane lysis gain entrance into 
the microbial cell to interact with intracellular targets. As the above scheme does allow the 
internalization of AMP. alternate means of killing within the cell are enabled, such as effects 
on DNA or protein synthesis. Also, this may explain the mechanism by which AMP are able 
to effect other actions besides, or in addition to. killing, such as their effects on wound 
healing, acquired immunity, etc. For instance. AMP may stimulate cell proliferation 
(Murphy, 1993) and enhance the production of extracellular matrix proteins (Gallo, 1994), 
potentially aiding in wound healing. Also, AMP have been implicated in the inhibition of 
ACTH-stimulated production of steroids (Singh, 1988) and the inhibition of protein kinase C 
(Charp, 1988). In addition, as mentioned earlier, cultured intestinal epithelial cells upon 
exposure to cryptdin had been shown to stimulate secretion of CI", although this is likely due 
to the formation of membrane pores, similar to the bacterial killing mechanism (Lencer. 
1997). 
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Lipopolysaccharide interaction with AMP is integral to the "self-promoted uptake" 
model, and several AMP have been shown to interact with LPS (Macias, 1990; Rana. 1990; 
Matsuzaki, 1999). Although not an AMP, the antibiotic polymyxin had been shown to also 
interact with LPS (Thomas, 1999), and increased resistance to polymyxin had been shown to 
correlate with extensive modification of LPS in Salmonella typhimurium mutants, which 
resulted in a reduced negative charge (Vaara, 1981; Helander, 1994; Helander, 1997). This is 
concerning as it reflects the potential for development of microbial resistance to AMP. 
However, LPS probably does not play the same role for all AMP. In fact, mutant 
enterobacteria that had defective outer membranes were resistant to polymyxin, but retained 
sensitivity to cecropin, belaying a potential non-outer membrane target for cecropin (Vaara. 
1994). 
The above are possible mechanisms of cell entrance and/or cell killing for the 
amphipathic AMP, yet some AMP do not form amphipathic helices (i.e., bombinin H) 
(Barra, 1995); and less is known about the mechanism of action of these AMP. Of course, 
different structural groups of AMP may have different cytotoxic mechanisms. For instance, 
as mentioned earlier, magainin, a representative of the amphipathic and hydrophobic a-helix 
structural group, can form lytic pores in cell membranes (Epand. 1999). When the helix 
conformation was lost by replacement of several amino acids with D-isomers. antimicrobial 
activity was lost (Chen, 1988). However, when another AMP from this structural group, 
pardaxin, was treated similarly, it converted to a ^-structure and retained antimicrobial 
activity, although it lost hemolytic activity (Oren, 1999). Hence, although amphipathic forms 
were optimal for incorporation into the membrane, membrane incorporation does not always 
correlate with antimicrobial activity. 
Melittin and cecropin have been shown to inhibit replication of animal viruses. Melittin 
has been reported to inhibit replication of murine retroviruses, tobacco mosaic virus (Marcos, 
1995) and herpes simplex virus (Baghian, 1997). Direct lysis of viral membranes has been 
demonstrated for the murine retroviruses (Esser 1979), and is suspected for the other viruses. 
However, much lower, non-virolytic concentrations of melittin have shown anti-viral activity 
for T-cells chronically infected with HIV-1 (Wachinger, 1992). Both melittin and cecropin 
suppress HIV-1 replication in acutely infected T-cells, and are suspected to do so by 
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interfering with host cell-directed viral gene expression (Wachinger, 1992; Wachinger, 
1998). 
Tight control is important to prevent AMP host toxicity. Antimicrobial peptides are often 
cytotoxic to host cells, but at concentrations elevated above those needed to be antimicrobial 
(Gudmundsson, 1999). Also, AMP are generally synthesized as inactive proproteins 
awaiting enzymatic activation (Gudmundsson. 1999). In addition, scavenger molecules are 
present in the serum to neutralize the cytotoxic effects of certain AMP. For instance, a-
defensins are neutralized by a2-macroglobulin and activated CI complement (Panyutich, 
1991; Panyutich. 1994), and LL37 is neutralized by apolipoprotein A-1 (Wang, 1998; 
Sorensen, 1999). Conversely, as PR-39 is not lytic to microbial or host cells, there is no 
inhibitory effect of porcine plasma (Johansson, 1998). 
Antimicrobial peptides as therapeutic agents 
Therapeutic potential 
As AMP become characterized, their potential as therapeutic agents is becoming more 
enticing. However, positive results using AMP as therapeutic agents have been mediocre to 
date. There are several possible reasons for this. Likely, in vivo, AMP work in synergy with 
both other AMP. and with other immune defense molecules and cofactors, to be activated, to 
exert their antimicrobial effects, and to intertwine the innate and acquired defense systems. 
Lysozyme and various AMP have been shown to work effectively in concert against a range 
of gram-negative bacteria (Hancock, 2000). In fish challenged with bacteria, both lysozyme 
and AMP are rapidly induced (Hancock. 2000). Also, the frog peptides, magainins and 
PGLa (Matsuzaki. 1998). have been shown to act cooperatively, as have the mammalian 
AMP, protegrin 1 and indolicidin (Hancock. 2000). It makes it difficult to derive the correct 
methods of using AMP as therapeutic agents when other substances that would work 
cooperatively with the AMP in vivo are unappreciated or not present. 
Another problem for development of AMP as therapeutic agents is the difficulty in 
interlaboratory comparison of the antimicrobial activities of AMP due to the lack of a 
consistent method for their measurement. There are various different lab techniques used, 
including inhibition zone assays, diffusion assays, and MIC assays. The company 
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Intrabiotics has offered a detailed protocol 
(http://wvvw.interchange.ubc.ca/bobh/methods.htm) for universal adoption. Even detecting 
AMP is difficult, so that very sensitive lab methods like PCR are required. In addition, the 
medium an AMP is assessed in often has a direct effect on its activity. For example, 
defensins are more active in low ionic strength media (Lehrer, 1993), anions have effects on 
the folding and activity of LL37 (Johansson, 1998), and zinc is required for anionic peptide 
activity (Brogden. 1996). Requirements for other AMP are unknown, making testing of their 
activity difficult in vitro and conclusions about this activity in vivo potentially erroneous. 
However, researchers are still excited about the potential of using these peptides in 
medicine in varied ways. In a time when many medical researchers and clinicians see a rise 
in resistant strains of pathogens to entire classes of antibiotics, the biggest hope for AMP is 
in their use in patient antimicrobial therapy. In 1994, the World Health Organization stated 
that bacterial resistance to antibiotics is already a serious threat in both developed and 
undeveloped countries, and this threat will likely continue to rise at the same or even greater 
rate as antibiotics lose their effectiveness. The problem is in the rapidity with which bacterial 
strains can develop resistance to entire classes of antibiotics, and the lack of development of 
a new class of antibiotic in 30 years. Researchers hope that the very fact that plants, 
vertebrates and invertebrates have employed AMP for millions of years without large-scale 
development of resistance will allow their use therapeutically without creating resistant 
microbial strains. 
Microbial resistance 
Some bacteria appear to be naturally resistant to AMP. Burkholderia cepacia, Serratia 
marcescens and Proteus sp. are three such resistant strains, possibly due to their non-
interactive outer membrane and production of specific proteases, respectively (Hancock, 
2000). In fact, patients with chronic granulomatous disease, who lack a phagocytic oxidative 
killing response but retain phagocytic AMP, are substantially more susceptible to B. cepacia 
infection (Scott, 1999). Also, Bacillus thuringensis and Brucella sp. may be resistant to 
AMP (Boman, 1987; Martinez de Tejada, 1995). But, for most bacteria, resistance has not 
seemed to be a problem, even after dozens of repeated passages through microbial culture 
levels close to the MIC (Hancock, 1997). Part of the reason there is believed to be a lack of 
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resistance in most microorganisms to AMP is theorized to be due to the speed with which 
AMP kill the target cell. Microorganisms are simply killed before resistance can be 
developed. The only known organism that has developed resistance characteristics due to 
virulence regulators is S. typhimurium (Rana, 1991; Guo, 1997). Resistant strains of this 
bacteria have the ability to activate transcription of genes responsible for structural 
modifications (acylation) of the lipid A component of LPS through activation of PhoP/PhoQ 
virulence regulators in the outer membrane when in the macrophage phagosome, making 
them resistant to a spectrum of AMP found there (Gunn, 1996; Guo, 1998). However, even 
in this case, the MIC are only increased 2 to 4-fold (Hancock. 2000). Regardless, other 
gram-negative bacteria have been shown to have the capacity to modify lipid A (Guo, 1998), 
and proof of the existence of virulence regulators capable of inducing these modifications 
leads to fear that these virulence regulators could become shared among bacteria and cause 
widespread resistance to AMP. Modifying natural AMP so as to reduce the speed or efficacy 
with which they kill microorganisms, and causing resistance in microorganisms against this 
ancient sector of the innate immune system shared among so many varied plants and animals, 
could be catastrophic. However, drugs that block the acylation of lipid A could have utility 
as antibiotics not just to aid the function of AMP, but the function of other antibiotics as well 
by allowing AMP to increase the overall permeability of the bacterial surface (Guo, 1998). 
Enhancement of conventional therapeutic agents 
AMP have the added advantage of not only having the potential to be effective 
therapeutic antimicrobial substances in their own right, but they can also enhance the action 
of other antibiotics. This is due to their membrane disrupting mode-of-action. which allows 
the entrance of antibiotics into resistant strains of bacteria. Thus, AMP can serve as anti-
resistance compounds. In addition, many AMP bind LPS. and so have antiendotoxic activity 
and potential use in treating sepsis, in contrast to many other antibiotics that enhance LPS 
release and endotoxemia (Hancock. 1997). Also, AMP are equally effective against strains 
of pathogens both resistant and non-resistant to conventional antibiotics, and have a broad-
spectrum of activity against gram-negative, -positive, and fungal organisms. (They are 
effective against viruses in vitro, but this activity is less likely in vivo, as the AMP may not 
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efficiently pass through the eukaryotic cell membrane.) Unfortunately, researchers are only 
in the beginning stages, in most cases, of delving into possible therapeutic uses of AMP. 
Radiolabeled antimicrobial peptides 
One potential medical use of AMP being examined that is peripheral to the antimicrobial 
therapeutic potential of these substances, but which does make use of their antimicrobial 
ability, is their application in disease diagnosis. Nibbering, et al. (Nibbering, 1998) have 
recommended the use of radiolabeled AMP in the imaging of infections in patients in cases 
where tools like bloodwork, culture of body fluids, and physical exam do not satisfactorily 
locate the site of infection. In the past, technicians have used radiolabeled leukocytes, 
polyclonal IgG against specific bacteria, antibodies against cytokines, and other agents in an 
attempt to find a radiolabeled pharmaceutical that would sensitively and specifically identify 
infections. These tools often did not discern between inflammation and infection, as many of 
the potential radiolabeled pharmaceuticals were upregulated in both. Or, the radiolabeled 
pharmaceutical was only diagnostic for a specific bacterial infection, as is the case with 
polyclonal IgG against a bacterium. 
AMP may be a desirable radiolabeled pharmaceutical for the imaging of systemic 
infection and as a tool for measuring killing of bacteria in response to therapy. The reasons 
are multiple (Nibbering, 1998). Many AMP react preferentially with a broad spectrum of 
fungi and bacteria, rather than with the patient's cells, allowing a specific labeling of 
infectious organisms of many kinds with no toxicity to the patient. They are small and can 
leave the circulation rapidly to enter sites of infection (within 5-15 minutes), which allows 
timely imaging and reduces the radiation burden to the patient. In fact, there is some 
evidence that certain AMP can cross the blood-brain barrier (Schluesener, 1995). Also. AMP 
are very rapidly metabolized and excreted, although this can, in fact, be a drawback. In some 
cases, AMP bind and kill the bacteria so quickly that the target is neutralized before imaging 
can be used to identify it within the body. The researchers have suggested engineering 
synthetic AMP, which lack the killing ability of natural AMP. but retain the microorganism 
binding specificity. There is the fear, though, that tampering with the killing ability of AMP 
may cause the development of resistant strains of microbes. 
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Topical therapeutics 
As many AMP are of epithelial origin, most researchers looking into possible therapeutic 
applications have attempted to use them topically. MSI-78 (Locilex; Magainin 
Pharmaceuticals, Inc., Plymouth Meeting, PA), a magainin variant peptide, has been taken 
into Phase III clinical trials by Magainin Pharmaceuticals in the treatment of 926 patients 
with polymicrobic diabetic ulcers (Hancock, 1999). Apparently, MSI-78 showed efficacy 
similar to orally administered ofloxacin, but with less side effects. However, orally 
administered ofloxacin works poorly against such infections due to poor perfusion, and so 
MSI-78 was recently rejected by a Food And Drug Administration panel (Hancock. 1999). 
Unfortunately, the same compound (called Cytolex then) was abandoned in Phase III clinical 
trials in use against impetigo, as it was found that 75% of control patients showed clinical 
improvement merely as a result of proper hygiene (Hancock. 1999). 
Antimicrobial peptides have been shown to be effective topically in the treatment of P. 
aeruginosa corneal ulcers in rabbits (Nos-Barbera, 1997). P. aeruginosa is one of the most 
common agents of bacterial keratitis in humans, and is particularly virulent due to the release 
of proteases, which can degrade the stroma of the cornea (Kreger, 1974; Kessler, 1977; 
Alonso, 1986; Ormerod. 1986; Ormerod, 1987). Aggressive treatment with topical 
aminoglycoside antibiotics (i.e. gentamicin) is the treatment of choice. Unfortunately, 
aminoglycoside resistance has increased in this, as well as other ophthalmic diseases. Nos-
Barbera, et al. (Nos-Barbera. 1997) compared varying sizes of cecropin A-melittin (both 
naturally occurring insect AMP) synthetic peptides to gentamicin in topical treatment of 
experimentally induced P. aeruginosa keratitis in New Zealand rabbits (Oryctolagus 
cuniculus). Melittin alone has been shown to have some toxicity to eukaryotic cells; so, the 
authors synthesized various lengths of cecropin A-melittin hybrids to find a peptide that 
retained the amphipathic a-helical structure necessary for its effective antimicrobial ability 
without eukaryotic toxicity. The most successful peptide was only twelve residues long and 
showed comparable anti-inflammatory/antimicrobial activity to gentamicin. 
Other areas of topical therapy research and development include the successful 
completion of Phase I (safety) clinical trials by the protegrin-like IB367 (Intrabiotics, 
Mountain View, CA) in the treatment of mouth ulcerations (oral mucositis) in cancer patients 
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(Hancock, 1999), which was based on its local protection against the same in hamsters 
(Loury, 1999). Another peptide, MBI-226 (Micrologix Biotech, Mountain View, CA), is 
being investigated for sterilizing catheter sites (Hancock, 2000). Results from clinical trials 
so far indicate efficacy, and MBI-226 has been given fast-track status by the Federal Drug 
Administration (Hancock. 2000). Yet another peptide. D4B. has provided protection against 
lethal P. aeruginosa infection of bum-wound sites in mice (Gamelli, 1998). Future 
possibilities for AMP in topical therapy include formulating AMP into an aerosol for the 
treatment of lung infections, such as those in cystic fibrosis patients (Hancock, 1997). and 
possible uses in dental therapy (Bamett. 1997). 
A final potential topical use for AMP might be as contraceptives. One study has shown 
that both HBD-2 and magainin are cytotoxic for mouse oocytes and pre-implantation 
embryos (Sawicki, 1999). The authors speculate that buildup of AMP in tissues during 
infection may be responsible for some idiopathic infertilities - evidence that in addition to 
adaptive immunity, innate immunity may be involved in damage to oocytes and pre-
implantation embryos (Sawicki. 1999). The advantage to using AMP as contraceptives 
would be that AMP would provide a dual role as both antimicrobial agents and prophylactics. 
Systemic therapeutics 
The use of AMP in systemic therapy proves to be an obstacle. It is difficult to find the 
correct formulation of an AMP for in vivo activity, and it is necessary to look for subtle, 
unpredictable AMP-induced toxicities. Also, AMP are potentially vulnerable to proteases in 
the body, another reason why topical treatment is attractive, as proteases are less active on 
the skin. Possible techniques to prevent protease-deactivation of orally or intravenously 
administered AMP include co-administration of a protease-inhibitor, and liposomal 
incorporation or chemical modification to alter protease recognition (Hancock, 1998). 
In the fight against antibiotic-resistant microorganisms, systemic therapy is where the 
greatest need for AMP lies. Hancock, et al. (Hancock, 1997) have used a-helical peptides of 
the MBI-20 series (Micrologix Biotech, Mountain View, CA) in the treatment of gram-
negative infections and as an enhancer of conventional antibiotics. These include the 
successful use of MB 1-27 and MBI-28 to protect against P. aeruginosa peritoneal infections 
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and lethal endotoxemia in mice. This may be due, at least in part, to the binding of AMP to 
LPS, preventing LPS induction of TNF in macrophages. 
In another study, Intrabiotics (Mountain View, CA) has reported up to 100% systemic 
protection against intraperitoneal infection with P. aeruginosa, S. aureus and methicillin-
resistant S. aureus with a single intravenous dose of the porcine P-sheet cathelicidin, 
protegrin (PG-1) (Kung, 1996). Another cathelicidin, indolicidin, has shown activity against 
Aspergillus infections (Schroder, 1999). 
Bactericidal/permeability-increasing protein (BPI) is a 55 kDa protein with antibacterial 
activity present in azurophil granules of neutrophils (Calafat, 2000). Injected rBPI-21 
(Neuprex; Xoma Corp., Berkley, CA), a recombinant BPI fragment, has shown neither 
toxicity nor immunogenicity in clinical trials in humans and effective suppression of LPS-
induced cytokine, PMN and coagulant responses (von der Mohlen, 1995). Ongoing clinical 
trials for Neuprex include for treatment of endotoxemia in meningococcal infections (Phase 
III) (Millier, 1999). Given intravenously with supportive therapies, there was a dramatic 
decrease in deaths (Hancock. 1999). Neuprex is also being examined as therapy for liver 
resection and hemorrhagic trauma (Phase III) and lung infections in cystic fibrosis patients 
(Phase I) (Millier, 1999). Another BPI-derived fragment (Mycoprex; Xoma Corp., Berkley, 
CA) is under preclinical investigation for treatment of systemic Candida infections (Mill 1er, 
1999). 
Nisin (a bacterial origin AMP produced by AMBI. Purchase. NY) provides systemic 
protection against Streptococcus pneumoniae infection in mice (Goldstein, 1998). Nisin has 
undergone Phase I (safety) clinical trials successfully under consideration for stomach ulcers 
due to H. pylori (Hancock, 1999). Another substance, the fish peptide pleurocidin, protects 
Coho salmon against lethal vibriosis {Aeromonas salmonicida infection) when administered 
continuously (Hancock, 2000). 
But the above are only the reports of AMP that have been successful systemically. Many 
of the unsuccessful AMP do not ever become known outside the realms of the 
pharmaceutical company that attempts to develop them. But it is certain that there are many. 
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Cystic fibrosis 
Cystic fibrosis is a disease that attracts a lot of attention as potentially treatable with 
AMP, due to the importance that AMP have in immunity in the respiratory tract, and the lung 
pathology that this disease is characterized by. It has been shown that HBD-1 antibacterial 
activity is reduced in salt (Goldman. 1997). Human P-defensin-2 activity is reduced not just 
in salt, but also in various different ions (Tomita. 2000). As normally these AMP would be 
able to kill many cystic fibrosis-related pathogens, this defect in activity may play a role in 
the sensitivity of cystic fibrosis patients to chronic lung infection. However, others have 
asserted that the defect responsible for the pathogenesis of cystic fibrosis lies not in the 
abnormal ion composition, but in the absorption of airway surface fluid leading to 
abnormally thickened mucus and the failure of mucociliary clearance, with persistence of 
bacteria (Matsui. 1998). Nonetheless, strategies to use AMP against bacteria in cystic 
fibrosis patients, including multidrug-resistant isolates of P. aeruginosa, are being attempted. 
These include designing new salt-insensitive AMP (Schwab, 1999), stimulating endogenous 
AMP or administering exogenous AMP (Travis, 1999). and altering the salt concentration of 
the airway surface fluid in these patients (Beringer. 1999). As previously mentioned. Phase I 
clinical trials are presently ongoing in cystic fibrosis patients with rBPhi (Neuprex, Xoma 
Corp.. Berkley. CA), which, when used in in vitro studies, has shown a 4-fold reduction in 
the MIC of commonly used antibiotics against P. aeruginosa (Ripoll, 1996). Presumably, 
this is due to not only its bactericidal activity, but also its LPS-binding ability allowing a 
general reduction in inflammation. One study showed that overexpression of exogenous 
LL37 by gene transfer in epithelial cells from cystic fibrosis patients grown in a xenograft 
model could restore bactericidal activity (Bals, 1999b). Also, there is some evidence that 
lowering the airway surface liquid salt concentration through the administration of an 
osmolyte may enhance the activity of AMP in the lung, thus this compound may be of value 
in cystic fibrosis patients (Zabner. 2000). 
Neoplasia 
There is also interest in the use of AMP as antineoplastic agents. Magainins have been 
shown to kill various cancer cells at concentrations tenfold lower than that required to kill 
normal cells, and exhibit activity against malignant melanoma and ovarian cancer cells in 
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mouse models (Jacob, 1994). Lactoferricin induces apoptosis of human monocytic tumor 
cells, and this activity involves intracellular reactive oxygen species and Ca2+ and Mg2+ -
dependent endonucleases (Yoo, 1997). And, as mentioned earlier, BMAP-27 and -28, 
cathelicidins from bovine neutrophils, have been found to be cytotoxic to human myeloid and 
lymphoid tumor cells and are suspected to induce apoptosis in these cells (Risso. 1998). 
Commercial production 
Production of AMP in amounts large enough for commercial, therapeutic use has been 
difficult. During the initial experiments with AMP from frog skin, skins were sun-dried and 
AMP was methanol- or acid-extracted (Barra, 1995). Sometimes, 1000 frogs were killed to 
provide sufficient quantity of AMP for identification - this is a concern with the growing 
endangerment of amphibian species worldwide. Alternatively, frogs were given a small 
electric shock and glandular secretions were then collected at the rate of every two to four 
weeks; however, this is a time-consuming and inefficient means of collection (Barra, 1995). 
This led to chemical synthesis as a means of production of AMP. a-helical AMP can be 
made through solid-phase chemical synthesis; but this method is impractical for the 
defensins. Defensins synthesized in this manner are far less active than those obtained from 
natural sources, presumably due to incorrect disulfide bridging between cysteines, resulting 
in incorrect folding of the peptide (Schroder. 1999). Also, the cost is prohibitive for the 
synthesis of amounts large enough for in vivo studies, or medical use. One advantage to 
chemical synthesis of non-defensins is that non-natural amino acids (i.e., D-enantiomers) can 
be introduced to generate diversity (Hancock, 1997). Again, though, caution must be 
involved in attempting to generate unnatural AMP that may be less efficacious than natural 
AMP, and have the potential to cause microbial resistance to these substances. 
Recombinant synthesis is less expensive than chemical synthesis, but it also provides 
some obstacles. Common expression systems like bacteria and yeast will be killed by the 
very peptide they are engineered to produce, unless the peptide is constructed into a fusion 
protein vector. One researcher has used fusion proteins to produce cationic peptides in £. 
coli at up to 2% of the bacteria's biomass (Hancock, 1997). Also, AMP tend to form 
inclusion bodies that are difficult to resolubilize (Hancock, 1997). There has been limited 
success with cecropin A in a baculovirus system in an insect cell line (Andersons, 1991; 
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Hellers, 1991). Fungal expression systems and tobacco-mosaic-virus vector infection of 
tobacco have also been attempted with mixed results (Alves, 1994; Schroder, 1999). 
Transgenic systems 
Transgenic systems for AMP synthesis have been attempted. An early method involved 
synthesis of AMP in the erythrocytes of transgenic mice (Sharma, 1994). The AMP was 
fused to human a-globulin, from which it was cleaved after recovery. In addition, mice have 
been engineered by Yarns, et al. to produce TAP in milk for harvest (Yarns, 1996). Lingual 
antimicrobial peptide is believed to be secreted in milk (Yarns, 1996), so the researchers 
predicted that TAP could be secreted, also, without harm to the gland. In addition, this 
would provide a cheap means to acquire large amounts of TAP that has already been 
posttranslationally modified. In this experiment, the TAP was engineered into an expression 
vector driven by a murine whey acidic protein gene. Transgenic mice were engineered with 
this vector, and the enriched whey fraction from their milk was found to contain TAP at MIC 
necessary for E. coli, Klebsiella pneumonia and C. albicans. In addition, nursing pups as 
well as their transgenic mothers showed no ill effects. The researchers predicted that this 
technique is possible in livestock, and could be used for the harvesting of sufficient quantities 
of TAP for use clinically as an antibiotic. In addition, this technique could be used 
experimentally to see the in vivo effects on pups nursing TAP of challenge with a bacterial 
pathogen. 
Success with transgenic techniques could provide a means of enhancing the growth of 
livestock, fish and plants without the use of classical antibiotics (and the concurrent 
continued development of antibiotic resistance in bacterial strains). Promising results were 
found in a study where mice were engineered to produce a cecropin B analog and then 
challenged with Brucella abortus (Haguis, 1996). Transgenic plants expressing new AMP 
have been shown to have enhanced resistance to fungi (Jach, 1995). Similarly, fruit flies 
unable to make the insect defensin, drosomycin, were found to be more susceptible to fungal 
infection (Lemaitre, 1996). Finally, mice treated with an adenovirus vector containing DNA 
for the human cathelicidin. LL37, showed an increase in serum and lung LL37, fewer 
bacteria, a lower inflammatory response to sublethal challenge and an increase in resistance 
to endotoxin and E. coli challenge (Bals, 1999b). 
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John Conte, Jr. has used AMP in a transgenic approach to reduce the numbers of the 
Chagas' disease-causing agent, Trypanosoma cruzi, in the hindgut of its vector, the reduviid 
bug (Rhodnius prolixus) (Conte, 1997). To do this, he took complementary DNA (cDNA) 
encoding the insect AMP. cecropin A, and cloned it into a plasmid vector. He then 
transformed a bacterial symbiont, Rhodococcus rhodnii. of the hindgut of the reduviid bug 
with this vector to make the transgenic bacteria express cecropin. He allowed sterile reduviid 
bug nymphs to feed on rabbit blood infected with the transgenic bacteria. Then, these 
nymphs fed on human blood containing T. cruzi. He found that the numbers of T. cruzi in 
the hindguts of these nymphs were reduced or eliminated. Although it has not been tested 
yet, this should impact the reduviid bugs ability to spread Chagas' disease to humans. Also, 
reduviid bugs are coprophagic, so the transgenic bacteria should be easily spread within the 
population of reduviid bugs. 
The advantage to such a system is that the vitality of the reduviid bug is not affected: 
therefore, they retain their ability to reproduce, feed and live normally. This is in contrast to 
insecticides, which have the disadvantage of not only environmental toxicity and 
development of resistant insects, but also serve to remove an insect from an ecologically 
important niche, potentially impacting other species adversely. The author wonders if the 
same technology could be used to create transgenic intestinal, nasal and vaginal bacterial 
symbionts in humans to protect against disease-causing agents such as Salmonella sp., 
rhinovirus and HIV-1. respectively, as well as others (Conte,1997). 
Conclusion 
In a time when many conventional antibiotics are made as by-products of fungi, and we 
suffer from the development of resistant microbial strains, AMP as an antimicrobial 
substance with a completely different origin and mode-of-action may provide hope as an 
alternative therapy to conventional antibiotics. The use of conventional antibiotics as growth 
promoters in food animals currently holds a large portion of the blame for microbial 
resistance to these compounds (Falkow, 2001). Infectious organisms, such as M 
haemolytica and associated pathogens in the ruminant respiratory disease complex, decrease 
the overall health of an individual animal as well as lowering herd economic worth. Thus, 
AMP as an alternative to conventional antibiotics would be very important not only to 
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ruminant health and food animal production economics, but could function to prevent some 
of the microbial resistance to conventional antibiotics, and allow these conventional 
antibiotics to be reserved for treating human and companion animal diseases. In addition, the 
finding that many of these AMP are inducible provides hope for development of regulators of 
AMP production that may in the future be used to help an organism protect itself against 
environmental microbial pathogens, a kind of "vaccine promoting innate immunity". 
Reverse Transcriptase-Polymerase Chain Reaction 
Reverse transcriptase - polymerase chain reaction is an ideal tool for examination of the 
gene expression of AMP. This tool allows the identification and amplification of specific 
mRNA sequences that correspond to a gene of interest, in order to not only deduce whether 
the substance is present, but also, when quantitative methods are used, to explore the level of 
expression of the gene. As there is a scarcity of in vivo studies with AMP, RT-PCR becomes 
a very powerful tool for examining the role these substances play in in vivo inflammatory and 
infectious diseases. In other words, deducing whether an AMP is induced or produced 
constitutively during such diseases, and if it is induced, to what degree. 
Real-time RT-PCR (with TaqMan technology) allows relative quantitation of the gene 
expression of a substance of interest (PE Biosystems, 1999). Using this method, a single-
stranded probe that has a reporter dye and a quencher dye is used in the reaction, in addition 
to a sense and antisense primer. Disruption of the reporter dye by extension in the 5' to 3' 
direction from the sense primer leads to release of the reporter dye, which, when not in close 
proximity to the quencher, fluoresces. The fluorescence is analyzed by optic cables, and is 
only analyzed during the geometric phase of template amplification, when the reaction is 
proceeding at optimum efficiency so that no confounders caused by competition for scarce 
reagents is entered into the quantitation. 
Real-time RT-PCR is a powerful tool for examination and comparison of mRNA 
expression of not only a single substance between individuals, but, if RNA from the same 
individual is used universally as a calibrator, multiple substances can also be compared 
between individuals. In real-time relative quantitative RT-PCR, pre-amplification cDNA 
levels for each substance from each individual are calculated, normalized to a housekeeping 
gene, and then expressed as a quantity in relation to the amount of cDNA calculated for the 
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calibrator. As the first step of RT-PCR involves cDNA production by reverse transcription 
of RNA present in the tissue sample, the resultant data represents the relative mRNA 
expression of each substance for each individual. 
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Abstract 
Objectives—To determine the extent to which inhibition of neutrophil adherence with 
selectin inhibitor TBC1269 would affect neutrophil infiltration and neutrophil-associated 
injury during pneumonia induced by Mannheimia haemolytica and the concentration of 
antimicrobial anionic peptide (AAP) in bronchoalveolar lavage fluid (BALF), as well as the 
antimicrobial activity of BALF containing AAP, from healthy (control) neonatal calves, 
neonatal calves with M haemolytica-'mduczd pneumonia, neonatal calves with prior treatment 
with TBC1269, and adult cattle. 
Animals—Eighteen. 1- to 3-day-old. colostrum-deprived calves and 9 adult cattle. 
Procedure—Calves were inoculated with M haemolytica or pyrogen-free saline (0.14M 
NaCl) solution into the right cranial lung lobe, and BALF was collected 2 or 6 hours after 
inoculation. 30 minutes prior to and 2 hours after inoculation, 4 calves received TBC 1269. 
The BALF collected from 9 adult cattle was used for comparison of BALF AAP 
concentration and antimicrobial activity. 
Neutrophil differential percentage and degeneration in BALF were determined, using a 
score assigned to BALF from each calf by multiplying the percentage of neutrophils in the 
BALF by their grade for degeneration. The Bradford method was used to determine BALF 
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protein concentration. An ELISA and killing assay were used to determine BALF AAP 
concentration and antimicrobial activity, respectively. 
Results—Total protein concentration was significantly decreased in BALF from calves 
receiving TBC 1269. Similar concentrations of AAP were detected in BALF from all calves, 
which were three-fold higher than those found in BALF from adult cattle. However, BALF 
from neonates had little or no anti-A/ haemolytica activity, compared with BALF from adult 
cattle. 
Conclusions and Clinical Relevance—These results suggest that TBC 1269 decreases 
pulmonary tissue injury in the lungs of neonatal calves infected with M haemolytica. 
Although AAP is detectable in neonatal BALF at 3 times the concentration detected in adult 
BALF, neonatal BALF lacks antimicrobial activity for M haemolytica, whereas adult BALF 
has significant anti-A/ haemolytica activity. 
Introduction 
Mannheimia haemolytica is an important respiratory pathogen of ruminants that colonizes 
the tonsils and pharyngeal portion of the respiratory tract of cattle.1'2 During transport or 
other stresses, bacteria increase in number3-4 and induce an acute inflammatory response in 
the lungs characterized by dense infiltrates of neutrophils into alveolar spaces and tissue 
damage.5"7 Release of substances such as elastase, myeloperoxidase and oxidative free 
radicals from neutrophils has been associated with tissue damage8*10 and plays a role in the 
pathogenesis of pneumonia attributable to A/ haemolytica.ua Additional evidence of the 
importance of neutrophils in A/ haemolytica-induced pneumonia was indicated in the 
reduction of tissue damage and vascular leakage of protein by depletion of neutrophils.13"16 
Neutrophil-mediated damage to the respiratory tract removes the protective barrier provided 
by endothelial cells and the mucosal epithelium,11"1416 allowing access of bacteria and 
inflammatory mediators to the exposed capillaries and reducing gaseous exchange. Such 
damage may also impair the innate host defense mechanisms, including mucociliary 
clearance and production of antimicrobial peptides (AMP). 
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In response to an infectious agent within alveolar, bronchiolar, or bronchial spaces, 
neutrophils infiltrate into these areas by moving from the bloodstream, through the 
endothelium, through the perivascular tissue and pulmonary parenchyma, until reaching the 
pulmonary spaces. Adhesion molecules expressed by neutrophils and endothelial cells 
mediate neutrophil extravasation. Selectin adhesion molecules mediate the initial relatively 
unstable tethering step of neutrophil adherence to the vasculature by binding sialyl Lewis* 
and related oligosaccharide receptors. There are 3 types of selectins: L-selectin, which is 
detectable on neutrophils and other leukocytes and binds ligands on endothelial cells,17 and 
E- and P-selectin, which are expressed primarily by endothelial cells and bind ligands on 
neutrophils.18"20 This initial selectin-ligand binding initiates expression of p,-integrins on the 
surface of neutrophils,21 which mediate a more stable adherence to an endothelial 
intracellular adhesion molecule (ICAM) in preparation for movement through the 
endothelium and into tissues. Inhibition of the initial selectin-mediated tethering of 
neutrophils to endothelium may play a role in reduction of neutrophil infiltration into the 
lungs during acute M haemolytica-induced pneumonia. 
Investigators have used TBC 1269. a nonoligosaccharide selectin antagonist, to 
competitively inhibit binding of sialyl Lewis* to selectins in vitro.22"25 This mimetic has been 
used in vivo in clinical studies for use in the treatment of humans with allergic asthma. It has 
been effective in preventing neutrophil-mediated reperfusion injury in rat liver23 and in 
reducing the initial cellular response to pulmonary antigen in a sheep model of allergic 
bronchoconstriction.2' Inhibition of selectin-mediated neutrophil infiltration may reduce 
neutrophil-mediated pulmonary damage, thereby maintaining the epithelial barrier and it's 
associated defenses. 
Antimicrobial peptides are substances that have antibacterial, antifungal, and antiviral 
properties in vitro and in vivo.26'27 Several families of AMP are produced in the lungs of 
cattle28"30 and are believed to have an important role in the innate immune system for 
protection of the lungs from bacterial invaders. One AMP in cattle is antimicrobial anionic 
peptide (AAP). This peptide is smaller than most AMP, and its anionic properties differ 
from most AMP. which are cationic.31 It is composed of consecutive aspartates and requires 
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zinc as a cofactor.31 Antimicrobial anionic peptide initially was isolated from ovine 
surfactant. It also is evident in human lung tissue and is detectable in high amounts in 
bronchoalveolar lavage fluid (BALF) collected from humans and sheep.31-32 Antimicrobial 
anionic peptide is bactericidal against M haemolytica as well as other bacteria at a minimum 
inhibitory concentration comparable to that of other AMP such as a- and P-defensins.31 
Antimicrobial anionic peptide is believed to be a cleaved fragment secondary to a larger 
proprotein produced in the lungs.31 In contrast to AAP, some bovine epithelial P-defensins, 
such as tracheal antimicrobial peptide and lingual antimicrobial peptide, usually are not found 
in mucus and serous respiratory secretions. Instead, those compounds are found within 
epithelial cells and are locally secreted following their induction.30 33- 34 The concentration of 
AAP in BALF of neonatal calves has not been previously assessed. 
The objectives of the study reported here were to test the extent to which inhibition of 
neutrophil adherence with TBC 1269 would affect neutrophil infiltration into the BALF of 
neonatal calves inoculated with M haemolytica as well as neutrophil-associated lung injury 
and to discern whether AAP is detectable in BALF of neonatal calves. 
Materials and Methods 
Animals—Eighteen colostrum-deprived, male, neonatal ( 1 to 3 days old) Holstein calves 
were purchased from a university dairy farm and transported to laboratory animal facilities at 
our institution. They were maintained in accordance with guidelines approved by an 
institutional animal care and use committee. Calves were monitored daily for general health 
(appetite, attitude, respiratory effort and sounds, and nasal discharge). Calves were excluded 
from the study if they were febrile, coughed excessively, had abnormal hematologic and 
serologic values, or had other signs of illness. 
Procedure—One to 3 days after arrival, blood was collected from a jugular vein, and 
calves were assigned to groups. Calves were anesthetized, and 12 were inoculated with M 
haemolytica (1 X 10* colony forming units [CFU]/ml in a 5-ml injection, as described 
previously7-35-36), whereas 6 were inoculated with 5 ml of pyrogen-free saline (0.14MNaCI) 
solution. Inoculations were performed into the bronchus of the right cranial lung lobe, using 
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fiberoptic bronchoscopy. One group of calves inoculated with M haemolytica received 
TBC 1269 (25 mg/kg of body weight, IV, 30 minutes before and 2 hours after bacterial 
inoculation). 
Calves were euthanatized 2 or 6 hours after inoculation. Calves were euthanized by IV 
injection of an overdose of sodium pentobarbital immediately prior to necropsy and 
collection of BALF. To avoid hyperstatic congestion and potential vascular leakage in 
postmortem specimens, BALF was collected from each calf within 5 to 15 minutes after it 
was euthanatized. Each group was comprised as follows: saline-inoculated (control) calves 
euthanatized 2 (n = 3) and 6 (3) hours after inoculation; M haemolytica-inoculated calves 
euthanatized 2 (4) and 6 (4) hours after inoculation; and M haemolytica-inoculated, 
TBC1269-treated calves (4) euthanatized 6 hours after inoculation. 
Mannheimia haemolytica inoculum—Mannheimia haemolytica L101 were grown 
overnight on blood agar, transferred to tryptose broth, and incubated for 1 to 3 hours at 37 C 
on a magnetic stirrer to achieve a culture containing approximately I X 10s CFU/ml. The 
organisms were pelleted, using centrifugation (5.900 X g for 5 minutes at 4 C). and 
resuspended in 5 ml of pyrogen-free saline solution. An aliquot of saline solution was 
adjusted to a transmittance value of 78% at a setting of 600 nm in a spectrophotometer3 by 
aseptically adding the bacterial suspension. One milliliter of the inoculum was removed from 
the adjusted suspension and serially diluted (1- to 10-fold) in saline solution. Then, 0.1 ml of 
each dilution was spread onto agar plates containing trypticase soy agar with 5% defibrinated 
sheep blood. Plates were incubated overnight, and colonies then were counted. The original 
solution routinely contained 1.3 to 2.5 X 108 CFU/ml. 
Production of sialyl Lewis" nonoligosaccharide mimetic (TBC 1269)—The compound 
TBC 1269, a synthetic sialyl Lewis" nonoligosaccharide mimetic antagonist (l,6-Bis[3-(3-
carboxymethylphenyl)-4-(2-a-D-mannopyranosyloxy)phenyl]hexane) was produced and 
provided in a powder form.22 b TBC 1269 inhibits binding (by 50%) of human L-, E- and P-
selectins at concentrations of 87, 105, and 17 |iM, respectively.25 This compound does not 
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have cytotoxic effects on neutrophils as documented by safety and efficacy studies in rats and 
dogs.23 The required dose was prepared in sterile pyrogen-free saline solution (pH 7.4). 
Collection of samples—Blood samples were collected from each calf before inoculation 
and at time of euthanasia for CBC and fibrinogen determination. Because calves were 
colostrum-deprived and, therefore, acutely susceptible to infections, blood values obtained 
before inoculation were assessed for indications of systemic disease. Only calves with 
baseline results of CBC that were within reference ranges were used for the study. 
Hematologic variables were compared between samples obtained before and after inoculation 
for all calves used in the study. 
In all calves, BALF was collected from the right cranial lung lobe during necropsy. This 
lobe was dissected from the remainder of the lungs, and 50 ml of pyrogen-free saline solution 
was delivered into the main bronchus via a nozzle-tipped syringe. This fluid immediately was 
gently aspirated back into the syringe, and the volume of fluid was measured. For all samples 
obtained from neonates, a portion of BALF was reserved for cytologic assessment, and a 
portion was centrifuged to remove cellular debris. Supernatant was retained and frozen (-70 
C) until assessed, using Bradford analysis to determine protein concentration, an ELISA to 
determine concentration of AAP, and a killing assay to determine antimicrobial activity. 
In addition, BALF was collected from 9 healthy, adult (> 1 year old) cattle that did not 
have a previous history or clinical signs of respiratory disease. In these cattle, BALF was 
collected from the right tracheal bronchus during an anesthetic episode, similar to the 
procedure previously described in sheep.37 For all samples obtained from adult cattle. BALF 
was centrifuged to remove cellular debris. Supernatant was retained and frozen (-70 C) until 
assessed, using an ELISA to determine concentration of AAP and a killing assay to determine 
antimicrobial activity. 
Cytologic assessment of BALF—Bronchoalveolar lavage fluid from each neonatal calf 
was assessed to determine amount collected, degree of transparency, and color. A nucleated 
cell count was performed, using an automated hematology analyzer/ and the value was 
rounded to the nearest tenth. Fluid protein content was estimated, using a refractometer,d and 
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pH was determined. A differential cell count and cytologic examination were performed on 
each sample (direct smear and centrifuge preparations) after use of Wright's stain, and 
neutrophil degeneration was classified and graded (0, nondegenerate; 1, slightly degenerate; 
2, moderately degenerate; 3, degenerate; 4, severely degenerate). Neutrophil morphology was 
classified with a pre-determined scoring system: 0, nondegenerate neutrophils that contained 
clumped basophilic chromatin and appeared similar to neutrophils in other blood samples 
with only a slight allowance for nuclear swelling attributable to washing; 1, slightly 
degenerate neutrophils that had intact but mildly dispersed chromatin with mild nuclear 
swelling that altered the tinctorial property from dark basophilic to dark eosinophilic; 2, 
moderately degenerate neutrophils that contained nuclei with a dispersed eosinophilic 
chromatin pattern, and nuclei were swollen to twice normal width but still retained a 
lobulated pattern; 3. degenerate neutrophils that had a minimal chromatin pattern with a 
smooth nuclear content, light eosinophilic staining, and a nucleus swollen to fill three fourths 
of the cell with loss of a lobulated pattern; 4. severely degenerate neutrophils that often had a 
ruptured cell membrane and a smooth, light eosinophilic nucleus that was rounded with loss 
of the lobular pattern and lack of chromatin structure. Slides were randomly batched and read 
by the same individual (CBA). Unlike absolute number of neutrophils in blood samples, 
absolute number of neutrophils in BALF is deceptive, because the technique yields a crude 
estimate, and many cells can be lysed in animals with severe inflammation. Because lysed 
cells would yield a low absolute cell count even in the face of severe inflammation, it was 
elected to use percentages for differential neutrophil counts. To numerically describe 
neutrophil percentages and degeneration in BALF samples, a score was assigned to BALF 
obtained from each calf by multiplying the percentage of neutrophils in the BALF by their 
grade for degeneration. Increasing neutrophil scores indicated increasing neutrophil 
percentages or increasing degeneration of neutrophils, or both, in BALF. 
Bradford analysis of BALF—Bronchoalveolar lavage fluid from each neonatal calf was 
analyzed for protein content, using the Bradford method. Briefly, we prepared 8 dilutions of 
bovine serum albumin,6 each of which was mixed with a constant amount of Bradford 
reagent dyef (2 ml of a 20% concentration) to provide solutions with final concentrations 
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ranging from 0.1 to 1.0 mg/ml in a volume of 2.04 ml. These solutions were analyzed to 
create a standard curve, using a spectrophotometer8 set at 595 nm. For determination of 
protein concentration, 40 |il of each BALF sample was added to 2 ml of 20% Bradford 
reagent dye, analyzed, and the resultant concentration compared with values for the standard 
curve. 
Detection of AAP in BALF—Concentration of AAP was determined in BALF obtained 
from each neonatal calf and adult cow by use of an ELISA, as described elsewhere.32"'8 
Briefly, microliter plate wellsh were incubated overnight at 26 C with 100 pi (1 mg/ml) of 
ELISA-negative surfactant (negative-control sample) and ELISA-negative surfactant 
containing dilutions of synthesized AAP (positive-control sample) as well as 100 pi of BALF 
from each animal. Potential open reactive sites in the wells were filled by incubating with 
blocking buffer (2 incubations for 30 minutes at 26 C). Wells were incubated with mouse 
anti-AAP antibody, 1G9-1C2, at 1.0 pg/|il for 1 hour at 26 C. Wells then were washed twice 
with blocking buffer and incubated for 1 hour at 26 C with secondary antibody (goat anti-
mouse IgG conjugated to peroxidase1), washed 3 times with blocking buffer, and incubated 
with developing reagent1 for 5 minutes. Plates were read via a spectrophotometer1 set at 450 
nm. 
Antimicrobial activity of BALF supernatant—Antimicrobial activity for M 
haemolytica serotype A1 was determined for BALF obtained from each animal, using 
methods described elsewhere.31'38 "39 Briefly. M haemolytica serotype A1 was grown in 
tryptose broth at 37 C for 3 hours, pelleted by centri(ligation (5,900 X g for 15 minutes at 4 
C), and resuspended in saline solution. The suspension was adjusted, using a 
spectrophotometer1 set at 600 nm, to 78% transmittance; this suspension contained 1 X 108 
CFU/ml and was diluted with saline solution to achieve a concentration of 103 CFU/ml. A 
dilution susceptibility test was used to obtain the percentage of killed bacteria in BALF, 
compared with that in the saline control solution. Percentage of killed bacteria was 
determined by the following equation: (1 -[CFU in BALF/CFU in saline control mixture]) X 
100. 
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Statistical analysis—An ANOVAk was used initially to determine significant differences 
among the 5 neonatal groups for band neutrophils in blood samples, BALF neutrophil scores 
and BALF protein concentrations. As overall differences were detected among groups, 
pairwise comparisons of groups were performed. An ANOVAk also was used initially to 
determine significant differences among the 5 neonatal groups for BALF AAP concentrations 
and BALF antimicrobial activities. As overall differences were not detected, t-tests were used 
for comparisons of the means for all neonatal calves to those for adult cattle. A value of P < 
0.05 was considered significant. 
Results 
Neonatal calves—In all neonatal calves, WBC, differential counts, and fibrinogen 
concentrations differed between samples collected before and after inoculation. Changes 
were particularly evident in values for calves from the M haemolytica-inoculaled groups and 
included decreased total leukocyte counts (including neutrophils and lymphocytes: data not 
shown). The number of band neutrophils was significantly higher in TBC 1269-untreated 
calves 6 hours after inoculation with M haemolytica, compared with values for calves from 
both control groups (2 and 6 hours after inoculation with saline solution) and for calves 2 
hours after inoculation with M haemolytica (Table 1). The number of band neutrophils in 
TBC 1269-treated calves 6 hours after inoculation with M haemolytica were similar to the 
values for calves from both control groups as well as for TBC 1269-untreated calves 6 hours 
after inoculation with M haemolytica, and values were significantly (P = 0.03) higher, 
compared with values for calves 2 hours after inoculation with M haemolytica. We did not 
detect other notable alterations in blood values between TBC 1269-treated and -untreated 
calves. 
BALF neutrophil scores—Increased neutrophil scores indicated an increase in BALF 
neutrophil percentages or an increase in degeneration of neutrophils, or both. For all calves, 
the factor that had the most effect on neutrophil score was the degree of degeneration, rather 
than neutrophil percentage (Table 2). Neutrophil percentages were similar among calves 
from all groups. Bronchoalveolar lavage fluid from calves from both control groups as well 
76 
as calves 2 hours after inoculation with M haemolytica had significantly lower neutrophil 
scores, compared with scores for TBC 1269-treated and -untreated calves 6 hours after 
inoculation with M haemolytica (Fig 1). Neutrophil scores for calves 2 hours after 
inoculation with M haemolytica were higher, but not significantly, than neutrophil scores for 
both control groups. Neutrophil scores for calves 6 hours after inoculation with M 
haemolytica that were treated with TBC 1269 were lower, but not significantly (P = 0.11), 
than values for calves 6 hours after inoculation with M haemolytica that were not treated with 
TBC 1269. 
BALF protein concentration—Protein concentration in BALF from calves of both 
control groups and calves 2 hours after inoculation with M haemolytica were significantly 
lower, compared with concentrations for TBC 1269-untreated calves 6 hours after inoculation 
with M haemolytica (Fig 2). In addition, protein concentrations for TBC 1269-treated calves 6 
hours after inoculation with M haemolytica were significantly lower than for TBC 1269-
untreated calves. 
Concentration of AAP in BALF—Antimicrobial anionic peptide was detected in BALF 
from all neonatal calves (mean ± SE. 0.32 ± 0.05 mM) and adult cattle (0.11 ± 0.05 mM; 
Table 3). Values for neonates were significantly (P = 0.02) higher than for adults; however, 
we did not detect significant differences in AAP concentrations among neonatal groups. 
Antimicrobial activity of BALF supernatant—With the exception of 2 calves (1 in 
each of 2 groups), BALF from neonatal calves lacked detectable antimicrobial activity, 
whereas BALF from adult cattle had substantial antimicrobial activity (Table 3). Percentage 
killing of M haemolytica achieved by use of BALF from adult cattle ranged from 32 to 84% 
(mean ± SE, 62.7 ± 5.8%). In contrast, percentage killing achieved by use of BALF from 
neonates ranged from 0 to 29% (mean ± SE. 2.0 ± 1.6%). The percentage killing achieved by 
use of BALF from adult cattle was significantly (P = 0.01) higher than for neonates, even 
though neonatal BALF contained more AAP. 
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Discussion 
Values for blood samples from all groups of neonatal calves had changes after inoculation 
in a manner that would be expected in animals undergoing stress or tissue demand for WBC. 
These changes included decreased total leukocyte counts, including neutrophils and 
lymphocytes, and an increased number of band neutrophils. Many of these changes were not 
significantly different until 6 hours after inoculation with M haemolytica, which was 
attributed to the time lag between initial pulmonary inoculation with M haemolytica and the 
leukocyte response in the circulation. Band neutrophil counts in blood samples of calves 
obtained 2 hours after inoculation with M haemolytica were decreased, compared with counts 
before inoculation. This decrease did not differ significantly from changes found in either 
group of control calves (2 or 6 hour after inoculation with saline solution), but did differ 
significantly from the changes in the TBC 1269-treated group. This reflects the lack of a 
leukocyte response in the circulation by 2 hours after inoculation with M haemolytica as well 
as the variability in leukocyte counts of neonates. We did not detect any other significant 
differences in the blood leukocyte counts assessed between the TBC 1269-treated group and 
any other group; therefore, differences in BALF neutrophil counts between calves 6 hours 
after inoculation with M haemolytica that were treated or not treated with TBC 1269 probably 
were attributable to alterations in neutrophil activity in the pulmonary vasculature, rather than 
the drug's ability to inhibit leukocyte production or to sequestration of leukocytes. 
A high neutrophil score reflects a high neutrophil percentage in the BALF, a high degree 
of neutrophilic cellular degeneration and lysis, or both. All animals had similar total 
percentages of neutrophils as a result of the inflammatory response elicited by deposition of a 
fluid substance (saline solution or M haemolytica) within the bronchus. Absolute neutrophil 
counts in BALF could not be accurately assessed, but. in the findings of one of the 
investigators (ZAR), morphometric assessment demonstrated that neutrophilic infiltration 
into pulmonary spaces was significantly reduced in the lungs of calves 6 hours after 
inoculation with M haemolytica that were treated with TBC 1269, when compared with 
results for samples obtained from calves that were not treated with TBC 1269. Similar 
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decreases in neutrophil infiltration have been documented with the use of TBC 1269 in BALF 
obtained from sheep as well as rat liver.23'23 
Despite the reduction in neutrophil infiltration, differences in neutrophil scores among 
groups were attributable largely to differences in degree of neutrophil degeneration. 
Bronchoalveolar lavage fluid that contains an increased number of degenerate neutrophils is 
indicative of a more severe pulmonary inflammatory response. Furthermore, this indicates a 
greater number of lysed neutrophils that release neutrophilic enzymes, resulting in damage to 
pulmonary tissue. In support of another study that documented substantial inflammation in 
the lungs by 4 hours after inoculation with M haemolytica,16 neutrophil scores in BALF were 
significantly (P = 0.01) higher in samples obtained from calves 6 hours after inoculation with 
M haemolytica that were not treated with TBC 1269. compared with samples obtained 2 hours 
after inoculation. Neutrophil scores for calves 2 hours after inoculation with M haemolytica 
were not significantly different than values for either group of control calves, again 
supporting the lack of substantial inflammation by 2 hours after inoculation with M 
haemolytica. Lower scores were seen in BALF obtained from calves 6 hours after 
inoculation with M haemolytica that were treated with TBC 1269. but they were not 
significantly (f = 0.11) different, compared with scores of calves that were not treated with 
TBC 1269. This was largely attributable to decreased degeneration of neutrophils in calves 
given TBC 1269. 
Neutrophil migration into the lungs during M haemolytica-induced pneumonia may be 
beneficial and deleterious. During pneumonia attributable to M haemolytica, neutrophils are 
needed to reduce bacterial viability, yet the release of cellular lysosomal enzymes, free 
radicals, and other factors contribute to tissue damage.8"10 Protein leakage from vessels as a 
result of pulmonary parenchymal and vascular compromise (damage to the alveolar-capillary 
barrier) is a measure of tissue damage.40-41 In the previously mentioned study,16 a significant 
number of neutrophils migrated into the lungs by 4 hours after inoculation with M 
haemolytica, coincident with a significant increase in protein concentrations in the BALF. In 
support of this study, BALF protein concentrations were significantly (P = 0.003) higher 6 
hours after inoculation with M haemolytica from TBC 1269-untreated calves, compared with 
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values 2 hours after inoculation. Protein concentrations from calves 2 hours after inoculation 
with M haemolytica did not differ significantly from values for either group of control calves, 
which further supports a lack of substantial inflammation 2 hours after inoculation with M 
haemolytica. Bronchoalveolar lavage fluid from calves 6 hours after inoculation with M 
haemolytica that were treated with TBC 1269 had significantly (P = 0.02) lower 
concentrations of protein, compared with concentrations in BALF obtained from calves not 
treated with TBC 1269. This result supports studies in which there was a decrease in tissue 
damage and vascular leakage of protein following neutrophil depletion.13"16 
These findings for protein concentration in BALF reflect changes seen in neutrophil 
scores. Neutrophils that are more degenerate are indicative of a more severe inflammatory 
process, and this results in a release of additional neutrophilic enzymes, causing additional 
pulmonary tissue damage with breakdown of the alveolar capillary barrier and protein 
leakage. Use of TBC 1269 caused significantly (P = 0.02) lower protein concentrations in 
BALF, compared with concentrations in BALF from calves not treated with TBC 1269, 
indicating less pulmonary tissue injury in TBC 1269-treated calves. This indicates a lower 
degree of inflammatory response in these calves that may be attributable to several 
mechanisms. First, TBC 1269 inhibits selectin-mediated adherence between neutrophils and 
endothelium,18 and this may reduce the number of neutrophils that pass through pulmonary 
vessels and enter pulmonary spaces. Because we could not assess BALF absolute cell counts, 
decreased infiltration of neutrophils into pulmonary spaces could not be assessed, but it was 
seen during morphometric assessment of these tissues (ZAR) and has been reported with the 
use of TBC 12689 in BALF obtained from sheep25 as well as rat liver.23 Second, TBC 1269 
may alter or reduce neutrophil activation through inhibition of selectin-ligand binding. 
During neutrophil infiltration into the lungs, selectin-ligand binding activates neutrophils to 
express p,-integrins that bind intracellular adhesion molecules (ICAM). mediating vascular 
extravasation and tissue migration.21 Lack of activation may prevent optimal Printegrin 
expression, thus further interfering with neutrophilic infiltration into pulmonary spaces. 
Third, neutrophil activation is followed by metalloproteinase cleavage of the L-selectin 
molecule at the point where the external domain joins the transmembrane domain.42 The 
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internal cytoplasmic tail of L-selectin interacts with cytoskeletal elements, including a-
actinin.42 It is possible that decreased selectin-ligand binding maintains the integrity of the 
selectin molecule and its connection to cytoskeletal elements. This may explain the lower 
amount of neutrophilic degeneration in treated calves. Fourth, M haemolytica leukotoxin may 
promote neutrophil apoptosis by binding to pi-integrin.43 Prevention of selectin-ligand-
mediated activation of pz-integrin expression may prevent leukotoxin binding, providing an 
indirect means for prevention of neutrophil apoptosis. Last, the kinetics of TBC 1269 have not 
been fully explored in cattle, which is attributable to the fact that it is an experimental 
compound. However, in one study, TBC 1269 administered once (3 mg/kg, IV) caused 
reduced neutrophil infiltration in sheep.23 Although the dosage used in the study reported 
here was considered extremely high and the dosing time was considered repetitious, there is 
the possibility that the compound is not effective by 6 hours after administration. In that case, 
the low number of mildly degenerate cells in BALF from TBC 1269-treated calves may have 
migrated from the vasculature into the airways only a short time before BALF was harvested 
and would, at a later time point, resemble those in the untreated calves. Thus, barring 
erroneous interpretation due to inadequate dosing ofTBC1269, selectin inhibition of 
neutrophils appears to prevent a portion of the neutrophil-mediated damage to pulmonary 
tissues, thereby maintaining the protective pulmonary epithelial barrier and preserving 
epithelial defense mechanisms, such as AMP production, in addition to sustaining gas 
exchange. 
Experimental depletion of neutrophils during M haemolytica-induced pneumonia results 
in a reduction in tissue damage and vascular leakage of protein.13"16 However. M haemolytica 
can induce pulmonary tissue damage independent of neutrophils. Mannheimia haemolytica 
endotoxin (lipopolysaccharide) can have cytotoxic effects on endothelial cells and can 
produce pulmonary lesions.5'44'45 Also, M haemolytica has additional products capable of 
producing tissue damage, such as leukotoxin and capsular polysaccharide.3'37'45'46 Thus, 
complete neutrophil depletion is not a viable therapeutic alternative for calves with 
pneumonia attributable to M haemolytica in terms of practicality or in effectiveness at 
clearing the infection and preventing related tissue damage. Selectin inhibition may provide a 
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means to decrease, but not completely block, neutrophil infiltration from the vasculature into 
the pulmonary spaces in response to infection with M haemolytica. Some degree of 
neutrophil infiltration into pulmonary spaces through thin alveolar walls probably is retained 
following TBC 1269 administration. 
Large amounts of AAP are detectable in BALF from humans and sheep31-32; however, to 
our knowledge, this is the first report of the detection of AAP in BALF from neonatal and 
adult cattle. Antimicrobial anionic peptide was evident at similar concentrations in the BALF 
from calves from all groups. Significant differences were not detected in concentrations from 
control calves, calves that had been inoculated with M haemolytica, or calves that had been 
inoculated with M haemolytica and treated with TBC 1269. Mean AAP concentration in 
BALF obtained from all neonatal calves was approximately three-fold higher than the mean 
AAP concentration in BALF obtained from adult cattle. 
Even though mean AAP concentration in BALF from adult cattle was approximately a 
third of the mean concentration in BALF from neonates, BALF from neonates containing this 
peptide had significantly less antimicrobial activity for M haemolytica, compared with the 
activity of BALF from adults. Antimicrobial activity was discernible in BALF from only 2 
calves. Values for these 2 calves may have represented sample error, or there may have been 
antimicrobial activity attributable to AAP or an alternative antimicrobial substance in these 
young animals. It is believed that AAP is a propeptide that is cleaved from a larger peptide.31 
Thus, it is possible that the larger peptide is not being effectively produced or metabolized in 
neonatal calves, and. therefore, neonatal calves lack antimicrobial activity. Also, 
antimicrobial peptides work in concert with other compounds and substances in vivo to kill 
microbes effectively.47 It is possible that unknown cofactors or copeptides necessary for full 
AAP antimicrobial activity may not exist or may not be effective in neonatal animals. 
Although AAP is microcidal alone or in concert with surfactant,31 surfactant proteins and 
other molecules in BALF also are microcidal48 and may result in the antimicrobial activity of 
BALF from adult and neonatal cattle. Thus, although it is possible that the differences in 
antimicrobial activity between adults and neonates seen in this study were related to the 
function of AAP or its regulators, the effectiveness of AAP alone in bovine BALF cannot be 
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assessed in our study. Additional investigations are needed to directly assess bovine BALF 
AAP antimicrobial activity. 
In neonates, M haemolytica-induced pneumonia does not appear to reduce the 
concentration of AAP in BALF. Perhaps AAP simply was not being consumed in fighting the 
infection, because it was not antimicrobially active at that time. This could also explain the 
lower basal concentrations of BALF AAP in adult cattle, compared with values for neonates. 
Antimicrobial peptides function in response to a microbial infection, but they also prevent 
initial colonization.49 Antimicrobial anionic peptide may be continually consumed in adult 
animals in a prophylactic manner, whereas BALF concentrations in neonates remain high 
because the peptide lacks function. This lack of AAP activity may help explain the sensitivity 
of neonates to pulmonary colonization with infectious organisms such as M haemolytica. 
Selectin inhibition resulted in decreased neutrophil-mediated damage to pulmonary 
tissues, as evidenced by decreased vascular leakage of protein into BALF in TBC 1269-
treated calves 6 hours after inoculation with M haemolytica. Thus. TBC 1269 may be an 
effective therapeutic tool for pulmonary infections such as M haemolytica-induced 
pneumonia, because neutrophils retain their ability to infiltrate pulmonary spaces, although 
fewer infiltrate. Neutrophils are necessary to combat infection, so a drug that only partially 
blocks neutrophilic infiltration into pulmonary spaces may be effective in allowing some 
neutrophils into these areas while concurrently limiting their number to prevent excessive 
neutrophil-mediated tissue damage. Additional studies could include evaluation of the use of 
TBC 1269 in conjunction with an antibiotic in the treatment of calves with acute pneumonia 
attributable to M haemolytica to determine whether a beneficial synergistic effect exists 
between the compound and the antibiotic. In addition, TBC 1269 is effective in preventing 
neutrophil-mediated reperfusion injury in rat liver23 and in reducing the initial cellular 
response to pulmonary antigen in a sheep model of allergic bronchoconstriction.25 Thus, 
TBC 1269 may be effective in the treatment of multiple species of animals with several types 
of inflammatory disorders. 
Neonatal calves appear to lack a mature, effective antimicrobial peptide response, as 
evidenced by the decreased bactericidal activity of neonatal BALF (compared with activity of 
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BALF obtained from adult cattle), despite the concentration of AAP in neonatal BALF at 3 
times the concentration found in BALF of adult cattle. We believe that this may be a reason 
for the susceptibly of neonatal calves to pulmonary infections. The potential role of AAP in 
the prevention and treatment of naturally acquired disease requires additional investigation. 
Footnotes 
'Coleman model 35, Bacharach Instrument Co, Pittsburgh, Pa. 
bTBC1269, Texas Biotechnology Corporation, Houston. Tex. 
tell Dyne, Abbot, Santa Clara, Calif. 
"Veterinary Refractometer, Reichert Scientific Instruments. Buffalo, NY. 
'Albumin, Bovine, Sigma Chemical Co, St. Louis, Mo. 
fBio-Rad Protein Assay Kit #1, Bio-Rad Labs, Hercules. Calif. 
sMilton Roy Spectronic 3000 Array. Spectronic Instruments, Inc. Callaway, Ohio. 
hImmuIon IB plates, Dynex Technologies Inc, Chantilly, Va. 
'Peroxidase Labeled Affinity Purified Antibody to Mouse IgG (H + L), Kirkegaard & Perry, 
Gaithersburg, Md. 
JTMB Microwell peroxidase substrate. Kirkegaard & Perry. Gaithersburg, Md. 
kSAS, version 6.12, SAS Institute, Cary, NC. 
References 
1. Shoo MK, Wiseman A. Allan EM, et al. Distribution of Pasteurella haemolytica in the 
respiratory tracts of carrier calves and those subsequently infected experimentally with 
Dictyocaulus viviparus. Res Vet Sci 1990;48:383-385. 
2. Frank GH, Briggs RE. Colonization of the tonsils of calves with Pasteurella haemolytica. 
Am J Vet Res 1992;53:481-484. 
3. Frank GH, Smith PC. Prevalence of Pasteurella haemolytica in transported calves. Am J 
Vet Res 1983;44:981-985. 
4. Frank GH, Briggs RE, Loan RW, et al. Respiratory tract disease and mucosal 
colonization by Pasteurella haemolytica in transported cattle. Am J Vet Res 
1996;57:1317-1320. 
5. Whiteley LO, Maheswaran SK. Weiss DJ. et al. Immunohistochemical localization of 
Pasteurella haemolytica AI-derived endotoxin, leukotoxin, and capsular polysaccharide 
in experimental bovine pasteurella pneumonia. Vet Pathol 1990;27:150-161. 
6. Whiteley LO. Maheswaran SK, Weiss DJ, et al. Alterations in pulmonary morphology 
and peripheral coagulation profiles caused by intratracheal inoculation of live and 
ultraviolet light-killed Pasteurella haemolytica A1 in calves. Vet Pathol 1991 ;28:275-
285. 
84 
7. Ackermann MR, Kehrli, Jr, ME, Brogden KA. Passage of CD 18- and CD 18+ bovine 
neutrophils into pulmonary alveoli during acute Pasteurella haemolytica pneumonia. Vet 
Pathol 1996;33:639-646. 
8. Harlan JM. Neutrophil-mediated vascular injury. Acta MedScand Suppl 1987:715:123-
129. 
9. Henson PM, Johnston RB. Tissue injury and inflammation. J Clin Invest 1987;79:669-
674. 
10. Varani J, Ward PA. Mechanisms of neutrophi 1-dependent and neutrophil-independent 
endothelial cell injury. Biol Signals 1994;3:1-14. 
11. Breider MA, Kumar S, Corstvet RE. Interaction of bovine neutrophils in Pasteurella 
haemolytica mediated damage to pulmonary endothelial cells. Vet Immunol 
Immunopathol 1991;27:337-350. 
12. Maheswaran SK, Kannan MS, Weiss DJ. et al. Enhancement of neutrophil-mediated 
injury to bovine pulmonary endothelial cells by Pasteurella haemolytica leukotoxin. 
Infect Immun 1993;61:2618-2625. 
13. Slocombe RF, Malark J, Ingersoll R, et al. Importance of neutrophils in the pathogenesis 
of acute pneumonic pasteurellosis in calves. Am J Vet Res 1985;46:2253-2258. 
14. Breider MA, Walker RD, Hopkins FM. et al. Pulmonary lesions induced by Pasteurella 
haemolytica in neutrophil sufficient and neutrophil deficient calves. Can J Vet Res 
1988;52:205-209. 
15. Abe Y, Sekiya S, Yamasita T, et al. Vascular hyperpermeability induced by tumor 
necrosis factor and its augmentation by IL-1 and IFN-gamma is inhibited by selective 
depletion of neutrophils with a monoclonal antibody. J Immunol 1990;145:2902-2907. 
16. Weiss DJ. Bauer MC, Whiteley LO, et al. Changes in blood and bronchoalveolar lavage 
fluid components in calves with experimentally induced pneumonic pasteurellosis. Am J 
Vet Res 1991;52:337-344. 
17. Spertini O, Luscinskas FW. Kansas OS. et al. Leukocyte adhesion molecule-1 (LAM-1, 
L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte 
adhesion. J Immunol 1991;147:2565-2573. 
18. Pilewski JM, Albelda SM. Adhesion molecules in the lung. Am Rev Respir Dis 
1993;148:S31-S37. 
19. Bevilacqua MP. Nelson RM. Mannori G. et al. Endothelial-leukocyte adhesion molecules 
in human disease. Annu Rev Med 1994;45:361-378. 
20. Frenette PS, Wagner DD. Adhesion molecules—Part II: blood vessels and blood cells. N 
Engl J Med 1996;334:43-45. 
21. Simon SI, Burns AR, Taylor AD, et al. L-selectin (CD62L) cross-linking signals 
neutrophil adhesive functions via the mac-1 (CD1 lb/CD 18) p2-integrin. J Immunol 
1995;155:1502-1514. 
85 
22. Kogan TP, Dupre B. Scott IL, et al. Di- and trivalent small molecule selectin inhibitors. 
WO patent 9701335; 1997. 
23. Palma-Vargas JM, Toledo-Pereyra L, Dean RE, et al. Small-molecule selectin inhibitor 
protects against liver inflammatory response after ischemia and reperfusion. J Am Coll 
Surg 1997;185:365-372. 
24. Kogan TP, Dupré B, Bui H, et al. Novel synthetic inhibitors of selectin-mediated cell 
adhesion: synthesis of 1, 6-bis[3-(3-carboxymethylphenyl)-4-(2-a-o-
mannopyranosy loxy)phenyl] hexane (TBC 1269). J Med Chem 1998;41:1099-1111. 
25. Abraham WM, Ahmed A, Sabater JR, et al. Selectin blockade prevents antigen-induced 
late bronchial responses and airway hyperresponsiveness in allergic sheep. Am J Respir 
Crit Care Med 1999; 159:1205-1214. 
26. Daher KA, Selsted ME. Lehrer RI. Direct inactivation of viruses by human granulocyte 
defensins. J Virol 1986;60:1068-1074. 
27. Hancock REW. Peptide antibiotics. Lancet 1997;349:418-422. 
28. Diamond G, Zasloff M, Eck H, et al. Tracheal antimicrobial peptide, a cysteine-rich 
peptide from mammalian tracheal mucosa: peptide isolation and cloning of a cDNA. Proc 
Natl Acad Sci USA 1991;88:3952-3956. 
29. Selsted ME, Tang Y-Q, Morris WL. et al. Purification, primary structures, and 
antibacterial activities of p-defensins. a new family of antimicrobial peptides from bovine 
neutrophils. J Biol Chem 1993;268:6641-6648. 
30. Schonwetter BS, Stolzenberg ED, Zasloff MA. Epithelial antibiotics induced at sites of 
inflammation. Science 1995;267:1645-1648. 
31. Brogden KA, De Lucca AJ, Bland J, et al. Isolation of an ovine pulmonary surfactant-
associated anionic peptide bactericidal for Pasteurella haemolytica. Proc Natl Acad Sci U 
SA 1996;93:412-416. 
32. Brogden KA, Ackermann MR, McCray, Jr. PB, et al. Differences in the concentrations of 
small, anionic, antimicrobial peptides in bronchoalveolar lavage fluid and in respiratory 
epithelia of patients with and without cystic fibrosis. Infect Immun 1999;67:4256-4259. 
33. Diamond G, Jones DE, Bevins CL. Airway epithelial cells are the site of expression of a 
mammalian antimicrobial peptide gene. Proc Natl Acad Sci U 5.4 1993;90:4596-4600. 
34. Diamond G, Russell JP, Bevins CL. Inducible expression of an antimicrobial peptide 
g e n e  i n  1  i p o p o  l y s a c c h a r i d e - c h a l  l e n g e d  t r a c h e a l  e p i t h e l i a l  c e l l s .  P r o c  N a t l  A c a d  S c i  U S A  
1996;93:5156-5160. 
35. Brogden KA, Ackermann MR, DeBey BM. Pasteurella haemolytica lipopolysaccharide-
associated protein induces pulmonary inflammation after bronchoscopic deposition in 
calves and sheep. Infect Immun 1995;63:3595-3599. 
86 
36. Ackermann MR, Brogden KA, Florance AF, et al. Induction of CD18-mediated passage 
of neutrophils by Pasteurella haemolytica into pulmonary bronchi and bronchioles. Infect 
Immun 1999;67:659-663. 
37. Brogden KA, Adlam C, Lehmkuhl HD, et al. Effect of Pasteurella haemolytica (Al) 
capsular polysaccharide on sheep lung in vivo and on pulmonary surfactant in vitro. Am J 
Vet Res 1989;50:555-559. 
38. Brogden KA, Ackermann MR, Huttner KM. Detection of anionic antimicrobial peptides 
in ovine bronchoalveolar lavage fluid and respiratory epithelium. Infect Immun 
1998;66:5948-5954. 
39. Brogden KA, Ackermann M, Huttner KM. Small, anionic and charge-neutralizing 
propeptide fragments of zymogens are antimicrobial. Antimicrob Agents Chemother 
1997;41:1615-1617. 
40. Henderson RF, Benson JM, Harku FF, et al. New approaches for the evaluation of 
pulmonary toxicity: bronchoalveolar lavage fluid analysis. Fundam Appl Toxicol 
1985;5:451-458. 
41. Henderson FR. Use of bronchoalveolar lavage to detect lung damage. Environ Health 
Perspect 1984;56:115-129. 
42. Brown E. Neutrophil adhesion and the therapy of inflammation. Semin Hematol 
1997;34:319-326. 
43. Wang JF. Kieba IR. Korostoff J. et al. Molecular and biochemical mechanisms of 
Pasteurella haemolytica leukotoxin-induced cell death. Microb Pathogen 1998:25:317-
331. 
44. Brogden KA, Cutlip RC, Lehmkuhl HD. Response of sheep after localized deposition of 
lipopolysaccharide in the lung. Exp Lung Res 1984;7:123-132. 
45. Whiteley LO, Maheswaran SK, Weiss DJ, et al. Morphological and morphometrical 
analysis of the acute response of the bovine alveolar wall to Pasteurella haemolytica Al-
derived endotoxin and leukotoxin. J Comp Pathol 1991:104:23-32. 
46. Adlam C, Knights JM, Mugridge A, et al. Purification, characterization and 
immunological properties of the serotype-specific capsular polysaccharide of Pasteurella 
haemolytica (serotype Al) organisms. J Gen Microbiol 1984;130:2415-2426. 
47. Gudmundsson GH, Agerberth B. Neutrophil antibacterial peptides, multifunctional 
effector molecules in the mammalian immune system .J Immunol Methods 1999;232:45-
54. 
48. Haagsman HP. Interactions of surfactant protein A with pathogens. Biochim Biophys Acta 
1998;1408:264-177. 
49. Diamond G, Legarda D, Ryan LK. The innate response of the respiratory epithelium. 
Immunol Rev 2000;173:27-38. 
87 
Figure legends 
Figure 1—Mean + SE neutrophil scores in bronchoalveolar lavage fluid (BALF) obtained 
from neonatal calves. Calves were treated as follows: inoculated with 5 ml of 
pyrogen-free saline (0.14A/NaCl) solution (gray), inoculated with 5 ml of solution 
that contained I X 10* colony forming units (CFU) of Mannheimia 
haemolytica!ml (black), or treated with a selectin inhibitor (TBC 1269; 25 mg/kg 
of body weight, IV) 30 minutes before and 2 hours after being inoculated with 5 
ml of solution that contained 1 X 10* CFU of M haemolytica/ml (striped). a,b = 
Values with different letters differ significantly (P < 0.05). 
Figure 2—Mean + SE protein concentrations in BALF obtained from neonatal calves. See 
Figure 1 for key. 
Tables 
Table 1—Mean ± SE number of band neutrophils in blood samples obtained from neonatal 
calves before and after inoculation 
2 hours after inoculation 6 hour after inoculation 
(X 103 cells/ul) (X I03 cells/ul) 
Treatment Before After Change Before After Change 
Saline 0.09 ± 0.09 0.14 + 0.11 0.04 ±0.17* 0.03 ± 0.03 0.11 ±0.11 0.07 ±0.13* 
Mannheimia 
haemolytica 
0.06 ± 0.02 0.02 ± 0.02 -0.03 ± 0.04*t 0.33 ±0.33 1.14 ± 0.51 0.81 ±0.43 
Mannheimia 
haemolytica + 
TBC 1269 
ND ND ND 0.22 ±0.15 0.75 ± 0.22 0.53 ± 0.20 
*Value is significantly (P < 0.05) less than the value for 6 hours after inoculation with M 
haemolytica in calves that were not treated with TBC 1269. tValue is significantly (P < 0.05) 
less than the value for 6 hours after inoculation with M haemolytica in calves that were 
treated with TBC 1269. Saline = Inoculated with 5 ml of pyrogen-free saline (0. l4A/NaCl) 
solution; n = 3 at 2 hours and 3 at 6 hours. Mannheimia haemolytica = Inoculated with 5 ml 
of solution that contained 1 X 10* colony forming units (CFU) of M haemolytica/ml; n = 4 at 
2 hours and 4 at 6 hours. Mannheimia haemolytica + TBC 1269 = Treated with a selectin 
inhibitor (TBC 1269; 25 mg/kg of body weight, IV) 30 minutes before and 2 hours after being 
inoculated with 5 ml of solution that contained 1X10* CFU of M haemolytica/ml; n = 4. ND 
= Not determined. 
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Table 2—Percentage of neutrophils, grade for neutrophil degeneration, and neutrophil scores 
for bronchoalveolar lavage fluid (BALF) obtained from neonatal ca ves 
Treatment Percentage of 
neutroohils 
Grade for neutroohil 
degeneration* 
Scoret 
Saline 
2 hours after inoculation 20 to 81 0 to 3 0 to 0.03 
6 hours after inoculation 80 to 95 0 to I 0 to 0.2 
Mannheimia haemolytica 
2 hours after inoculation 65 to 90 0.5 to 4 0.33 to 1.1 
6 hours after inoculation 60 to 100 1.5 to 4 1.35 to 4 
Mannheimia haemolytica + TBC 1269; 
6 hours after inoculation 60 to 99 0 to 4 1.3 to 2.7 
Values represent ranges for all ca ves in each group. * Scale of 0 (nondegenerate) to 4 
(severely degenerate), tScore was calculated by multiplying percentage of neutrophils by 
grade for neutrophil degeneration. See Table 1 for remainder of key. 
Table 3—Antimicrobial anionic peptide (AAP) concentrations in BALF and percentage of 
AAP ( m M )  Percentae e killing (%) 
Treatment 
2 hours after 
inoculation 
6  hours after 
inoculation 
2 hours after 
inoculation 
6 hours after 
inoculation 
Calves (n = 18) 
Saline 0.32 ±0.17 0.37 ±0.26 9.7 ± 9.7 0 ± 0  
Mannheimia 
haemolvtica 
0.36 ±0.05 0.35 ±0.1 1.8 ± 1.8 0 ± 0  
Mannheimia 
haemolytica 
+ TBC 1269 
ND 0.20 ± 0.06 ND 0 ± 0  
All calves 0.32 ± 0.05' 2.0 ± 1.6' 
Cows (n = 9) 0.11 ±0.05" 62.7 ± 5.8b 
Values reported are mean ± SE. a,b = For each variable, values differ significantly (P < 0.05) 
between BALF obtained from adult and neonatal cattle. See Table 1 for remainder of kev. 
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CHAPTER 4. INCREASED EXPRESSION OF TRACHEAL 
ANTIMICROBIAL PEPTIDE (TAP) MRNA IN THE LUNGS OF 
NEONATAL CALVES AND CALVES WITH ACUTE BACTERIAL 
PNEUMONIA 
A paper to be submitted to the American Journal of Respiratory and Critical Care Medicine 
Jessica M. Caverly. VMD; Gill Diamond, PhD; Kim A. Brogden, PhD; Richard A. F. Dixon, 
PhD; Mark R. Ackermann. DVM. PhD 
Abstract 
Innate immunity of the respiratory mucosa is particularly vital shortly after birth. We 
determined whether an inducible P-defensin, tracheal antimicrobial peptide (TAP), is 
expressed in neonatal calves, and the extent to which expression changes during acute 
bacterial pneumonia. Eighteen 1- to 3-day-old, colostrum-deprived calves were inoculated 
with either Mannheimia haemolytica or pyrogen-free saline by fiberoptic bronchoscopy into 
the left cranial lung lobe bronchus, and necropsied 2 or 6 hours after inoculation. In order to 
assess the effects of leukocyte infiltration on TAP expression, four received the leukocyte 
adhesion molecule (selectin) inhibitor TBC1269 (25 mg/kg) by intravenous injection prior to 
and two hours after the bacterial inoculation and were necropsied 6 hours after inoculation. 
Expression of TAP messenger ribonucleic acid (mRNA), as well as two molecules vital to 
leukocyte infiltration, interleukin (IL)-8 and intercellular adhesion molecule (ICAM)-l, were 
quantified by real-time relative quantitative reverse transcriptase - polymerase chain reaction 
(TaqMan). Basal levels of TAP mRNA were established in control (saline) animals. A 25-
fold and a 3-fold increase in mRNA levels of TAP (f = 0.1) and ICAM-1 (P = 0.01), 
respectively, were discovered in calves that received M haemolytica. Tracheal antimicrobial 
peptide mRNA expression was variable among individuals, and expression in animals treated 
with TBC1269 was not significantly altered. Individual relative mRNA levels between TAP 
and IL-8 had a positive correlation (r2 = 0.89, P < 0.0001). These results indicate that in 
neonates: (i) expression of TAP mRNA is present at a basal level, (ii) expression of TAP and 
ICAM-1 is rapidly upregulated during acute pneumonia; however, variation in TAP 
expression between individual animals could result in suboptimal innate immunity, (iii) 
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inhibition of leukocyte infiltration does not significantly alter TAP expression in this model, 
and (iv) within individuals, correlation between TAP and IL-8 expression suggests common 
pro-inflammatory stimuli for upregulation 
Introduction 
Innate immunity is especially important for preventing microbial infections of the 
respiratory tract shortly after birth. Antimicrobial peptides are increasingly being recognized 
as an evolutionary ancient, yet important, component of innate host defense in the lung. 
Tracheal antimicrobial peptide (TAP), was the first epithelial-derived antimicrobial peptide 
found in mammals.1 Tracheal antimicrobial peptide was initially isolated from bovine 
tracheal mucosa and belongs to the p-defensin family of antimicrobial peptides.1 TAP 
messenger ribonucleic acid (mRNA) has been subsequently detected in the columnar 
epithelial cells of the trachea and bronchi in adult cattle; however, TAP expression is not 
present in fetal cattle.2 In cultured epithelial cells from adult cattle, heat-killed Pseudomonas 
aeruginosa and its lipopolysaccharide (LPS) induce TAP mRNA expression through binding 
of the LPS to CD-14 and likely activation of Toll-like receptors on the cells.3-4 Several other 
infectious and inflammatory agents also upregulate the expression of TAP, including 
interferon-^,4 phorbol 12-myristate 13-acetate. tumor necrosis factor (TNF)-a,3 interleukin 
(IL)-lp, muramyl dipeptide and lipoteichoic acid.6 Although TAP. and inducible P-defensins 
in general, may have an important role in protecting the respiratory mucosa against microbial 
colonization shortly after birth, expression of TAP in neonatal lung has not been determined. 
Mannheimia haemolytica is an important respiratory pathogen of ruminants and a known 
inducer of the bovine P-defensin. lingual antimicrobial peptide (LAP), in cattle older than 
three weeks of age.7 Mannheimia haemolytica incites a severe inflammatory response in the 
lungs of ruminants characterized by dense infiltrates of neutrophils.8'10 Neutrophil-mediated 
damage in both spontaneous and experimental forms of this disease can be severe and 
therefore destroy the protective barrier and innate immunity provided by the respiratory 
mucosa.11-15 Such lesions allow access of bacteria and are, by nature, composed of 
inflammatory mediators that affect the vasculature, and reduce gaseous exchange. Inhibition 
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of neutrophil infiltration reduces the severity of lesions in this disease16 and may also 
preserve activity of the innate immune system. 
One of the most potent inflammatory mediators of M haemolytica pneumonia in 
ruminants is the chemokine IL-8.17 Interleukin-8 is produced by endothelial cells, epithelial 
cells, activated macrophages and neutrophils, and causes activation and chemotaxis of 
neutrophils into sites of secretion.17 Interleukin-8 production is induced by other cytokines, 
IL-1 and TNF being two of the most potent.18 Neutrophils not only produce IL-8 and other 
neutrophil chemoattractants such as leukotriene B4,19 but they also release elastase, which 
induces IL-8 synthesis in human bronchial epithelial cells in vitro}021 Also, a-defensins 
released by activated neutrophils have been shown to stimulate IL-8 synthesis by human 
airway epithelial cells.22 
Adhesion molecules, including selectins (L-, E- and P-selectin) and intercellular adhesion 
molecule (ICAM)-l, are also integral to the inflammatory response during M haemolytica 
pneumonia. The selectins mediate a transient, tethering-like adherence of neutrophils to 
vascular endothelial cells, whereas a more stable type of adherence is mediated by ICAM-
I/P2 integrin interaction.23-29 Neutrophil infiltration into alveoli and bronchioles can be 
inhibited in the lungs of neonatal calves during M. haemolytica pneumonia with the selectin 
inhibitor, TBC1269, resulting in decreased neutrophil-mediated pulmonary damage;l6J0,31 
however, ICAM-1 expression is not altered.31 TBC1269 is a nonoligosaccharide selectin 
antagonist which provides competitive inhibition of sialyl Lewis* binding, in vitro, to 
selectins.32-33 This mimetic has also been used in vivo in an ovine model of asthma34 and in 
clinical studies for use in the treatment of human allergic asthma. 
The purpose of this study is to determine whether mRNA expression of an inducible p-
defensin, TAP, occurs in a neonatal model (calves), and if it does, to define the temporal 
expression of TAP during experimental acute infectious pneumonia caused by M 
haemolytica, a known inducer of the bovine P-defensin, LAP.7 In addition, the expression of 
two other molecules important in the inflammatory response of this disease, IL-8 and ICAM-
1, will be determined. As the pathogeneses of this disease is largely dependent on 
neutrophils, the effect of inhibition of pulmonary neutrophil infiltration and neutrophil-
93 
mediated damage via the selectin-inhibitor, TBC1269, on TAP expression as well as the 
expression of molecules vital to this process (IL-8 and ICAM-1) will be assessed. 
Materials and Methods 
Animals—Eighteen colostrum-deprived, male, neonatal ( 1 to 3 days old) Holstein calves 
were purchased from a university dairy farm and transported to laboratory animal facilities at 
our institution. They were maintained in accordance with guidelines approved by an 
institutional animal care and use committee. Calves were monitored daily for general health 
(appetite, attitude, respiratory effort and sounds, nasal discharge and body temperature) and 
blood was collected for cytological and chemical assessment. Calves were excluded from the 
study if they were febrile, coughed excessively, had abnormal hematologic and serologic 
values, or had other signs of illness. 
Procedure—One to 3 days after arrival, blood was collected from a jugular vein, and 
calves were assigned to groups. Calves were anesthetized, and 12 were inoculated with M 
haemolytica (I X 108 colony forming (CFU)/ml in a 5-ml injection, as described 
previously10'29'33), whereas 6 were inoculated with 5 ml of pyrogen-free saline3 (0.l4A/NaCl) 
solution. Inoculations were performed into the bronchus of the left cranial lung lobe, using 
fiberoptic bronchoscopy. One group of calves inoculated with M haemolytica received 
TBC1269b (25 mg/kg of body weight, IV, 30 minutes before and 2 hours after bacterial 
inoculation). 
Calves were euthanatized 2 or 6 hours after inoculation. Calves were euthanatized by 
intravenous injection of an overdose of sodium pentobarbital immediately prior to necropsy 
and collection of lung tissue. To avoid ribonucleic acid (RNA) degradation, as well as 
hyperstatic congestion and potential vascular leakage in postmortem specimens, lung tissue 
was collected from each calf within 5 to 15 minutes after it was euthanatized. Each group 
was comprised as follows: saline-inoculated (control) calves euthanatized 2 (n = 3) and 6 (3) 
hours after inoculation; M hasmolytica-inoculated calves euthanatized 2 (4) and 6 (4) hours 
after inoculation; and M haemolytica-moc\x\zXsd, TBC1269-treated calves (4) euthanatized 6 
hours after inoculation. 
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Mannheimia haemolytica inoculum—Mannheimia haemolytica L101 were grown 
overnight on blood agar, transferred to tryptose broth, and incubated for 1 to 3 hours at 37 C 
on a magnetic stirrer to achieve a culture containing approximately 1 X 108 CFU/ml. The 
organisms were pelleted, using centrifugation (5,900 X g for 5 minutes at 4 C), and 
resuspended in 5 ml of pyrogen-free saline solution." An aliquot of saline solution was 
adjusted to a transmittance value of 78% at a setting of 600 nm in a spectrophotometer0 by 
aseptically adding the bacterial suspension. One milliliter of the inoculum was removed 
from the adjusted suspension and serially diluted (1- to 10-fold) in saline solution. Then. 0.1 
ml of each dilution was spread onto agar plates containing trypticase soy agar with 5% 
defibrinated sheep blood. Plates were incubated overnight, and colonies then were counted. 
The original solution routinely contained 1.3 to 2.5 X 108 CFU/ml. 
Production of sialyl Lewis* nonoligosaccharide mimetic (TBC1269)—The compound 
TBC1269,32 a synthetic sialyl Lewis" nonoligosaccharide mimetic antagonist (1.6-Bis[3-(3-
carboxymethylphenyl)-4-(2-a-D-mannopyranosyloxy)phenyl]hexane) was provided by the 
manufacturer11 in powder form. TBC1269 inhibits binding (by 50%) of human L-. E- and P-
selectins at concentrations of 87. 105, and 17 (xM, respectively.34 This compound does not 
have cytotoxic effects on neutrophils as documented by safety and efficacy studies in rats and 
dogs.36 The required dose was prepared in sterile pyrogen-free saline solution (pH 7.4). 
Collection of samples—Blood samples were collected from each calf before inoculation 
and at time of euthanasia for complete blood count (CBC) and fibrinogen determination. 
Because calves were colostrum-deprived and, therefore, acutely susceptible to infections, 
blood values obtained before inoculation were assessed for indications of systemic disease. 
Only calves with baseline results of CBC that were within reference ranges were used for the 
study. 
In all calves, tissue was collected from the left cranial lung lobe at necropsy. This lobe 
was divided into 3 equal sections from anterior to posterior, denoted as sections 1,2 and 3. 
Section 2 included the left cranial lung lobe bronchus, so it coincided with the initial focus of 
inoculation within the lobe. Tissue samples from section 2 were collected into cryovia!sd and 
immediately placed in liquid nitrogen (-196 C). These vials were then stored at -80 C until 
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analysis, when a random vial from each calf was used for RNA isolation for that calf. All 
complementary deoxyribonucleic acid (cDNA) production and subsequent reverse 
transcriptase (RT) - polymerase chain reaction (PCR) analysis for each substance from each 
calf was done with the RNA made from this tube. 
Ribonucleic acid isolation— Ribonucleic acid isolation from each calf, with the 
exception of Calf #7, was performed with a phenol and guanidine isothiocyanate solution,6 
following manufacturer's directions. Briefly, for each calf, 1 gram of frozen lung tissue was 
placed in 10 ml of solution and homogenized with an electric homogenizer.' Following 5 
minutes of incubation at room temperature, 2 ml of chloroform® were added to each tube, the 
tubes were shaken by hand, and then the samples were again incubated at room temperature 
for an additional 2 to 3 minutes. The samples were then spun in a centrifuge11 at no more than 
12,000 X g for 15 minutes at 2 to 8 C. and the resultant aqueous phase from each sample was 
transferred to a fresh tube. Following addition of 5 ml of isopropyl alcohol1 to each aqueous 
phase, the samples were incubated at room temperature for 10 minutes and then centrifuged 
at no more than 12,000 X g for 10 minutes at 2 to 8 C. The supernatant from each tube was 
removed and discarded, and each resultant RNA pellet was washed with 10 ml of 75% 
ethanol,J vortexed to mix. and then centrifuged at no more then 7,500 X g for 5 minutes at 2 
to 8 C. The tubes were propped upside down to allow the RNA pellets to air dry for 5 to 10 
minutes, and then 100 |il of diethyl pyrocarbonate (DEPC)-treated water was added to each 
pellet. The samples were mixed by passing the solutions through a pipette tip a few times, 
and then incubated for 10 minutes at 55 to 60 C. The RNA samples were transferred to 
microcentrifuge tubesk for storage at -80 C. Ribonucleic acid from each calf was measured 
within a spectrophotometer1 for quantity and purity ratio. Ribonucleic acid from each calf 
was assessed for integrity by ultraviolet visualization of ribosomal RNA bands following 
denaturing gel electrophoresis and ethidium bromide staining. 
The RNA from one calf (Calf #7) was isolated via an alternative method, column 
purification of RNA, following the directions of the manufacturer of a commercially 
available kit.m Briefly, approximately 0.5 grams of frozen lung tissue were mixed with 
approximately 12 volumes of lysis/binding solution per mass amount of tissue, and then 
homogenized with the electric homogenizer. Homogenized tissue in solution was spun for 5 
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minutes at 8,000 - 9,000 X g in the centrifuge. The lysate was then mixed with an equal 
volume of 64% ethanol. This mixture was pushed through a filter at 3 - 5 drops per second. 
Two separate wash solutions were then pushed through the filter a total of three times. 
Finally, 0.5 ml of elution solution were pushed through the filter and collected three times for 
a total of 1.5 ml, which was aliquoted into microcentrifuge tubes for storage at -80 C. 
Ribonucleic acid quantity, purity and integrity were assessed by spectrometry and ultraviolet 
visualization as described for the other RNA samples. 
Complementary deoxyribonucleic acid production— Complementary 
deoxyribonucleic acid was produced by RT of RNA isolated from lung tissue from each calf. 
Sufficient RNA was used from each calf to provide for two to three replicates at a final RNA 
concentration per replicate of 2 pg in 100 pi of RT reaction volume. In addition, positive and 
negative RNA controls (human control RNA" and DEPC-treated water, respectively) were 
prepared and submitted to identical and concurrent procedures as were the RNA samples 
(positive control RNA was diluted to 0.001 pg/100 pi of RT reaction volume, as per 
manufacturer's directions). Tubes containing RNA from all individuals in an experimental 
group, as well as from one positive and one negative control per experimental group, were 
run as a batch. Deoxyribonuclease (DNase) treatment was performed to remove potential 
genomic deoxyribonucleic acid (DNA) contamination with a commercially available DNase0 
following manufacturer's directions. Then, RT was performed with a commercially 
available kitp following manufacturer's directions. Briefly, 2 pg of DNase-treated RNA from 
each sample and control were added to a reaction mixture which contained final 
concentrations of IX TaqMan RT buffer, 5.5 mM MgCb, 2 mM deoxyribonucleoside 
triphosphate (dNTP) mixture (500 pM each dNTP), 2.5 pM random hexamers, 1.25 U/pl 
murine leukemia virus (MuLV) RT, 0.4 U/pl ribonuclease (RNase) inhibitor and DEPC-
treated water. The following thermocyclerq conditions were then used: 10 minutes @ 25 C, 
30 minutes @ 48 C and 5 minutes @ 95 C. Resulting cDNA was stored in microcentrifuge 
tubesk at -20 C in a non-defrosting freezer. 
Primer and Probe Design—Sequence-specific oligonucleotide primers and fluorescent 
probes for detection and relative quantification of TAP, IL-8 and ICAM-1 cDNA were 
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designed with software' according to the software manufacturer's suggestions, and were 
engineered to be within the coding sequence of each respective mRNA and to span an intron 
of the respective genomic DNA, whenever possible. Resultant potential primer and probe 
sequences were compared to all available sequence databases via the search tool BLAST5 for 
similarity, and only unique sequences were used for primer and probe design. See Table 1 
for sequences. 
Sequence-specific oligonucleotide primers and fluorescent probe for detection of cDNA 
corresponding to the endogenous reference gene, 18S Ribosomal RNA. to which TAP, IL-8 
and ICAM-1 cDNA levels would be normalized, were purchased commercially." 
Polymerase Chain Reaction Optimization and Validation—The sequence detection 
system used1 allowed dual amplification and analysis of cDNA corresponding to both a target 
gene of interest and an endogenous reference gene within the same tube concurrently. 
Optimization and validation tests necessary to enable this were performed as directed by a 
Perkin Elmer technical representative. Complementary deoxyribonucleic acid from a control 
calf (Calf #1) was used for all optimization and validation experiments. 
Optimization experiments were performed to find the correct concentrations of target 
primers and probes, as well as cDNA concentrations, for each target gene of interest (TAP, 
IL-8 and ICAM-1 ) which would allow the PCR to proceed at optimum efficiency without 
competition between target and reference primers and probes for available cDNA. There 
were three different tests. First, various concentrations of cDNA were tested (one well 
contained full strength cDNA, four wells contained progressive dilutions of cDNA at 1:10 
each, and a final control well contained RNA from Calf #1 as a negative control for RT). In 
these wells, constant concentrations of target primers and probe were used (target 
primer:primer:probe concentrations were 300nM:300nM:200nM in a 50 pi solution in each 
well), and no endogenous reference primers and probe were included. Second, the same 
conditions as first tested were used, but with endogenous reference primers and probe added 
(reference primer:primer:probe concentrations were 50nM;50nM:200nM in a 50 pi solution 
in each well). And third, the same concentrations of cDNA were tested with the same 
concentrations of endogenous reference primers and probe as tested second, but with 
different concentrations of target primers and probe than used in the first test (target 
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primer.primer.probe concentrations were 900nM:900nM:200nM in a 50 pi solution in each 
well). Each well also contained 25 pi of a commercial master mix" and DEPC-treated water. 
For each target gene of interest, a plate containing all of these wells was run in the sequence 
detection system' with the following conditions: HOLD 2 minutes % 50 C, HOLD 10 
minutes @ 95 C and then 40 cycles of 15 seconds @ 95 C followed by 1 minute @ 60 C. 
Software* * was used to analyze the resultant data. For each target gene of interest, standard 
curves were created from the amplification plots of the target and endogenous reference over 
the various cDNA concentrations, plotting Cr (see Table 2 for definitions) against log 
concentration of input cDNA. These standard curves were compared across the different 
primer and probe concentrations, and assessed for slope and correlation. A slope of-3.23 
was equal to 100% reaction efficiency and a correlation close to 1 implied an equal 
efficiency for the amplification reactions over various cDNA concentrations. For each target 
gene of interest, this analysis allowed identification of appropriate cDNA concentrations to 
use for relative quantitative RT-PCR, the appropriate target primer and probe concentrations 
to use, as well as examination of the efficiency of the cDNA amplification reactions of both 
target and endogenous reference and identification of any inference either amplification 
reaction had on the other. 
Finally, as validation that the target and endogenous reference cDNA amplification 
reactions did not interfere with each other, for each cDNA concentration, the CJ of the 
endogenous reference was subtracted from the C-r of the target, and this value (ACr) was 
plotted against the log concentration of input cDNA. A resultant line with a slope of < ± 0.1 
was considered to represent cDNA amplification reactions of target and endogenous 
reference with equal efficiencies across the various cDNA concentrations tested. In this case, 
the CT method was chosen for data analysis of all future amplification reactions for this target 
gene of interest. If the slope was not <±0.1, the standard curve method was chosen for data 
analysis of future amplification reactions of this target gene of interest. 
Polymerase Chain Reaction—Based on the optimization and validation experiments, 
the standard curve method was chosen for data analysis for both TAP and IL-8. For each of 
these substances, a single separate microwell plate" was designed to enable PCR of cDNA 
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from all calves simultaneously, with three replicates run for each calf, as well as three 
replicates run of a negative control (DEPC-treated water). In addition, on each plate were 
three replicates each of seven progressive 1:2 dilutions of cDNA from a control calf (Calf #1) 
that served in the generation of a standard curve. The assay compositions was as follows: the 
50 pi PCR mixtures contained 25 gl of a commercially available master mix;" 5 |il of a 1:10 
dilution of cDNA (or DEPC-treated water for the negative control); target primers and probe 
concentrations of 900nM and 200nM, respectively, for TAP or 300 nM and 200 nM. 
respectively, for IL-8; and DEPC-treated water. Microwell plates were then submitted to the 
same thermocycler conditions as used for the optimization and validation plates. Using 
software,vw the resultant data was analyzed as per the directions of the Applied Biosystems 
literature^ as follows. A standard curve was constructed for both the target and the 
endogenous reference from the progressive cDNA dilutions by plotting each gene's 
respective C%s for all calves and all replicates versus the log concentrations of input cDNA 
corresponding to those Cjs. From each respective curve, the equation describing the 
resultant line was used to extrapolate the log input amount of cDNA for each replicate from 
each calf for that gene by evaluating the equation: (CT - b)/m. Then, the input amount of 
cDNA was calculated. Next, the target was normalized to the reference by dividing the 
target input amount of cDNA by the reference input amount of cDNA for each replicate, 
followed by calculation of the average and standard deviation input amount of cDNA for all 
replicates. Finally, the normalized target level relative to the calibrator was calculated. For 
this, the arbitrarily chosen calibrator, Calf #1, the calf with the lowest message level common 
to all three substances being assessed, was referred to as 1. This value for all other calves 
was calculated by dividing the average value for the target normalized to the reference for 
that calf by the average value for the target normalized to the reference for the calibrator. 
The standard deviation was calculated for this value by dividing the target normalized to the 
reference standard deviation by its average. 
Based on the optimization and validation experiments, the Ct method was chosen for 
data analysis for ICAM-1. Please see literature- for derivation of the equations involved in 
the Ct method. A single microwell plate was designed to enable PCR of cDNA from all 
calves simultaneously, with three replicates run for each calf, as well as three replicates of a 
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negative control (DEPC-treated water). The assay composition was as follows: the 50 pi 
PCR mixtures contained 25 pi of the commercially available master mix; 5 pi of a 1:10 
dilution of cDNA (or DEPC-treated water for the negative control); target primers and probe 
concentrations of 900nM and 200nM, respectively; and DEPC-treated water. The microwell 
plate was then submitted to the same thermocycler conditions as used for the optimization 
and validation plates. Using software/'" the resultant data was analyzed as per the directions 
of the Applied Biosystems literature/ The ACT (target CT minus reference CT) was 
calculated for each replicate from each calf, followed by calculation of the average and 
standard deviation ACT for all replicates from that calf. Next, the AACT (average ACT for the 
calf minus the average ACt for the arbitrarily chosen calibrator, Calf #1) was calculated for 
each calf, as well as its standard deviation. Finally, the target was normalized to the 
endogenous reference, relative to the calibrator, by evaluating the equation: 2'xxcr. with a 
range calculated by evaluating the expression: 2'"ViCT with AACR + s and AACR - s where s = 
the standard deviation of the AACT value. The range was also calculated for the calibrator. 
The calibrator was considered equal to 1. 
Statistical Analysis—For each substance, statistical analysis was performed using the 
means of the three replicate tubes for each calf of either the target normalized to the reference 
(TAP and IL-8) or the AACT (ICAM-1). 
To see if there were significant treatment or time effects, a 2-factor ANOVA' was used 
on those calves that did not receive TBC1269 (the first four treatment groups). Then, to see 
if the selectin inhibitor had a significant effect, a t-test was performed on the calves 6 hours 
after inoculation with M haemolytica who did and did not receive TBC1269 (the last two 
treatment groups). A P-value of < 0.1 was considered significant. 
To compare all five groups to each other, a one-way ANOVAz including calves from all 
five groups was used initially to determine significant differences among the five neonatal 
groups. As overall differences were detected among all groups only for ICAM-1, pairwise 
comparisons of this group were performed. A f-value of < 0.1 was considered significant. 
A correlation procedure2 was used to compare individual relative cDNA levels of TAP. 
IL-8 and ICAM-1 each to the others. A f-value of < 0.1 was considered significant. 
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Results 
Tracheal Antimicrobial Peptide—See Figure 1 for values of TAP mRNA normalized 
to the endogenous reference gene, Ribosomal 18S RNA, and relative to the calibrator sample. 
Calf #1. These values represent the initial relative amounts of TAP cDNA prior to PCR 
amplification in lung tissue from each calf, which in turn represent the relative amounts of 
TAP mRNA present in the lung tissue from each calf. Calf #1 was chosen as the calibrator 
sample to allow comparison to IL-8 and ICAM-1, which are also calibrated relative to Calf 
#1. 
See Table 3 for the raw data and group means. Tracheal antimicrobial peptide cDNA 
levels were higher in calves inoculated with M. haemolytica versus those inoculated with 
saline (control calves) (P = 0.1). Based on group means, peak TAP cDNA levels within the 
time span examined in this study occurred at 6 hours after inoculation with M. haemolytica. 
In addition, levels in calves 6 hours after inoculation with A/, haemolytica and treated with 
TBC1269 are in between, but more similar, to calves 2 hours after inoculation with M. 
haemolytica versus calves 6 hours after inoculation with M haemolytica and not treated with 
TBC1269. However, variability is too high to make these comparisons statistically accurate. 
Interleukin-8—See Figure 2 for values of IL-8 mRNA normalized to the endogenous 
reference gene. Ribosomal 18S RNA, and relative to the calibrator sample. Calf #1. These 
values represent the initial relative amounts of IL-8 cDNA prior to PCR amplification in lung 
tissue from each calf, which in turn represent the relative amounts of 11-8 mRNA present in 
the lung tissue from each calf. Calf #1 was chosen as the calibrator sample due to it having 
the lowest relative IL-8 cDNA levels. 
See Table 4 for the raw data and group means. Although IL-8 cDNA levels were 
generally higher in calves inoculated with M. haemolytica versus those inoculated with saline 
(control calves), these differences were not significant {P = 0.25). Similarly to TAP, based 
on group means, peak IL-8 cDNA levels within the time span examined in this study 
occurred at 6 hours after inoculation with M. haemolytica. In addition, levels in calves 6 
hours after inoculation with M. haemolytica and treated with TBC1269 are in between, but 
more similar, to calves 2 hours after inoculation with M. haemolytica versus calves 6 hours 
102 
after inoculation with M. haemolytica and not treated with TBC1269. However, variability is 
too high to make these comparisons statistically accurate. 
Intercellular Adhesion Molecule-1—See Figure 3 for values of ICAM-1 mRNA 
normalized to the endogenous reference gene, Ribosomal I8S RNA, and relative to the 
calibrator sample, Calf # 1. These values represent the initial relative amounts of ICAM-1 
cDNA prior to PCR amplification in lung tissue from each calf, which in turn represent the 
relative amounts of ICAM-1 mRNA present in the lung tissue from each calf. Calf #1 was 
chosen as the calibrator sample due to it having the lowest relative ICAM-1 cDNA levels. 
See Table 5 for the raw data and group means. Intracellular adhesion molecule-1 cDNA 
levels were higher in calves inoculated with M haemolytica versus those inoculated with 
saline (control calves) (P = 0.01). In contrast to TAP and IL-8, ICAM-1 peak cDNA levels 
within the time span examined in this study occurred at 2 hours after inoculation with M 
haemolytica versus all other groups (P <0.1 ), including calves 6 hours after inoculation with 
M. haemolytica and not treated with TBC1269 (P = 0.5). Also, mean ICAM-1 levels in 
calves 6 hours after inoculation with M haemolytica and treated with TBC1269 were similar 
to calves 6 hours after inoculation with M haemolytica and not treated with TBC1269. 
Moreover, ICAM-1 levels were higher at 2 hours after inoculation with M. haemolytica than 
at 6 hours after inoculation in calves treated with TBC1269 (P = 0.10). 
Correlation—Upon comparison of relative mRNA values between TAP. IL-8 and 
ICAM-1, the graphs have similar shapes (Figures 1, 2, 3). The correlation coefficient for all 
relative values between TAP and IL-8 is 0.89 (P < 0.0001). Between IL-8 and ICAM-1 the 
correlation is 0.41 (P = 0.09) and between TAP and ICAM-1 it is 0.27 (P = 0.28), which is 
not statistically significant. 
Discussion 
Real-time reverse transcriptase - polymerase chain reaction allows examination and 
comparison of mRNA expression of not only a single substance between individuals, but, if 
RNA from the same individual is used universally as a calibrator, multiple substances can 
also be compared between individuals. In this study, real-time RT-PCR allowed relative 
quantification of mRNA expression of TAP and two molecules that have a known role in 
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inflammation in M haemolytica pneumonia and other types of bacterial pneumonia. 
Although TAP expression is widely documented in adult animals,1"6 TAP has not been 
previously detected in fetal lung.2 The finding, in this study, of basal levels of TAP mRNA 
expression that are increased during M. haemolytica pneumonia in neonatal calves suggests 
that the lung is capable of induced expression at birth; however, the variation between 
animals indicates that some individuals may have robust TAP expression, whereas others 
may have limited induction. 
The wide variation of responses among calves may be due to one or more factors. First, 
as TAP is not expressed in the fetus,2 its expression in the neonate can be expected to be less 
consistent than in an immunologically mature animal. However, even in mature ruminants, 
P-defensin expression is notoriously variable between individuals.37 Also, the calves used in 
this study were full term and similar ages after birth, but, as in any species, may have had 
subtle differences in their lengths of gestation. Finally, although samples were taken from 
the same areas of the lung, subtle differences in these areas may be present. For example, 
areas may vary in the number of bronchi versus alveoli present, causing overall higher levels 
of TAP mRNA expression since bronchi and bronchioles have higher levels of TAP 
expression than alveolar epithelium.2 In any case, the variability of P-defensin mRNA 
expression between individual neonates noted in this study might explain the enhanced 
susceptibility of one neonate to a pulmonary infection that spares a nearby neonate. In 
addition, we have shown that bronchoalveolar lavage fluid (BALF) from neonatal calves 
infected with M haemolytica that contains the AMP anionic peptide has little or no anti-A/ 
haemolytica activity in vitro, compared to the significant anti-A-/ haemolytica activity of 
BALF containing anionic peptide from adult cattle.16 It is unknown if TAP from neonates 
has full antimicrobial activity compared to TAP from adults. 
Mannheimia haemolytica pneumonia is characterized by severe tissue damage that is 
often distinguished by extensive areas of necrosis."12 As epithelial cells produce TAP, 
overall TAP mRNA expression in the lung may be expected to increase initially upon 
induction, and then decrease as damage progresses beyond the acute stages and large 
numbers of epithelial cells die. The increases above basal levels in TAP mRNA expression 
at 2 and 6 hours after inoculation with M. haemolytica occurred prior to parenchymal 
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necrosis, and it is unknown if TAP expression would have continued to increase, or would 
have decreased at later times. Unfortunately, calves assigned to be sacrificed at 24 hours 
after inoculation did not survive. 
Expression of TAP and other inducible P-defensins may be an important innate defense 
mechanism in neonates. In the face of widespread epithelial cell destruction, increases in 
TAP mRNA expression in remaining viable cells might be sufficient to prevent spread of 
microbial agents. Thus, it might be assumed that treatment with a compound that prevents 
some of the neutrophil-mediated tissue damage inherent in the pathogenesis of M 
haemolytica pneumonia would lead to an increase in TAP mRNA expression in the lung. 
However, TBC 1269 did not increase TAP mRNA expression in the calves 6 hours after 
inoculation with M. haemolytica. Instead, although not statistically significant, calves 6 
hours after inoculation with M haemolytica that had been treated with TBC 1269 had TAP 
mRNA expression levels similar to calves earlier in the progression of the disease (similar to 
levels in the calves 2 hours after inoculation with M. haemolytica). The inability of 
TBC 1269 to significantly alter TAP expression was likely due to the fact that the severity of 
the lesion at 6 hours after inoculation was not sufficient to cause widespread epithelial cell 
necrosis. 
Patterns of change in IL-8 mRNA expression were similar to those seen for TAP, which 
is not surprising because for both substances, expression is stimulated by some of the same 
types of inflammatory cytokines, including IL-1 and TNF.5 618 Intracellular adhesion 
molecule-1 mRNA was expressed at higher levels in neonatal calves inoculated with M. 
haemolytica versus those inoculated with saline, as has been noted in older calves inoculated 
with M. haemolytica.28 As its expression is also stimulated by some of the same 
inflammatory mediators as TAP and IL-8, including TNF and IL-1,3-618,25'38J9 neither is this 
surprising. However, in contrast to TAP and IL-8 mRNA expression, ICAM-1 mRNA 
expression was higher at 2 hours after inoculation with M haemolytica than at 6 hours after 
inoculation, both in calves not treated with TBC 1269 and treated with TBC 1269. Given the 
importance ICAM-1 has in the immediate host response to infection, by purpose of its role in 
mediating the stable adherence between endothelial and epithelial cells and neutrophils in the 
migration of neutrophils from the blood to the tissue site of inflammation, it is likely that 
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upregulation in ICAM-1 mRNA expression would be an almost immediate event. Reflecting 
this, in contrast to TAP and IL-8, mean ICAM-1 expression levels in calves treated with 
TBC 1269 were more similar to calves 6 hours after inoculation with M haemolytica and not 
treated with TBC 1269 then they were to calves 2 hours after inoculation. As. ICAM-l levels 
were already decreased by 6 hours after inoculation with M. haemolytica compared to 2 
hours after inoculation, there was no statistically significant difference between the 
TBC1269-treated and -untreated calves at 6 hours after inoculation. 
Upon comparison of relative mRNA values between TAP, IL-8 and ICAM-1. the graphs 
have similar shapes as the same individuals are in each graph in the same order, and the 
relative values for each substance are positively correlated within an individual. In other 
words, the individual in an experimental group with the largest relative level of mRNA 
expression for TAP generally also had the largest relative level of mRNA expression for IL-8 
and ICAM-l, the individual with the next largest relative level of expression for TAP 
generally had the next largest relative level of expression for IL-8 and ICAM-1, and so forth. 
This positive correlation may be due to a similarity in the scope of response that TAP, IL-8 
and ICAM-1 genes have to the same set of inflammatory cytokines and mediators. 
TAP and IL-8 had a strongly positive correlation coefficient. It is unknown whether 
these substances affect the expression of each other. Although a-defensins released by 
human neutrophils have been shown to simulate IL-8 synthesis by human airway epithelial 
cells,22 further studies will be needed to decide if the P-defensins released by bovine 
neutrophils, or those released by the epithelium (TAP and LAP), have an affect on IL-8 
mRNA expression in the bovine airway. The correlations between TAP and ICAM-1 and 
between IL-8 and ICAM-1 were not positive (and in the case of TAP and ICAM-1, not 
statistically significant) due to ICAM-1 mRNA levels peaking at 2 hours versus 6 hours after 
inoculation for the other substances. 
Based on this in vivo study. TAP mRNA expression is increased during acute M 
haemolytica pneumonia in neonatal colostrum-deprived calves relative to the basal 
expression levels seen in control calves. Intracellular adhesion molecule-1 mRNA 
expression is also increased in these calves inoculated with M haemolytica. Additionally, 
reduction of pulmonary neutrophil infiltration and neutrophil-mediated damage through use 
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of the selectin inhibitor, TBC 1269, resulted in TAP and IL-8 mRNA expression levels that 
seem lower than levels in untreated calves; however, these results were not statistically 
significant due to high interanimal variation in expression of these substances. Also, in the 
calves in this study, individual relative mRNA levels for TAP and IL-8 correlated positively 
with each other. These results suggest: I) TAP mRNA expression occurs in neonates, 2) 
mRNA expression of TAP and ICAM-1 is upregulated during acute infectious pneumonia in 
neonates and this mRNA expression occurs rapidly following infection; however, between 
individual animals there is considerable variation in mRNA expression that could result in an 
individual having suboptimal innate immunity, 3) inhibition of leukocyte infiltration does not 
significantly alter TAP expression in this model; and 4) within an individual, the patterns of 
mRNA expression of TAP and IL-8 correlate positively with each other during acute 
inflammation. suggesting common stimuli for upregulation, some known (IL-1, TNF) and 
some unknown. 
Footnotes 
"pyrogen-free saline, Baxter Healthcare Corp.. Deerfield, III. 
bTBC1269, Texas Biotechnology Corp., Houston, Tex. 
'Coleman model 35, Bacharach Instrument Co. Pittsburgh. Penn. 
dNunc Cryo Tube Vials, Nunc Brand Products. Denmark 
cTRIzol, Life Technologies. Inc., Grand Island, New York 
rOmni TH, Omni International, Inc., Warrenton, Vir. 
'chloroform - molecular biology grade. Fisher Scientific, Fair Lawn, New Jersey 
hHermle Z 360K, Natural Labnet Company, Woodbridge, New Jersey 
'2-propanol - HPLC grade, Fisher Scientific, Fair Lawn, New Jersey 
jethyl alcohol - 200 proof anhydrous 99.5%, Aldrich, Milwaukee, Wis. 
k1.5 ml microtubes - sterile, RNase and DNase free, Daigger, Wheeling, 111. 
'DU 640B. Beckman Coulter, Fullerton, Calif. 
mRNAqueous-Midi. Ambion. Austin. Tex. 
"TaqMan Ribosomal RNA Control Reagents. PE Biosystems. Foster City, Calif. 
°RQ1 RNase-Free DNase, Promega, Madison, Wis. 
pTaqMan Reverse Transcriptase Reagents, PE Biosystems, Foster City, Calif. 
qGeneAmp PCR System 2400, Perkin Elmer, Norwalk, Conn. 
rABI Prism Primer Express, Version 1.5, PE Applied Biosystems, Foster City, Calif. 
'Basic Local Alignment Search Tool, Version 1.4, National Center for Biotechnology 
Information, Bethesda, Md. 
lABI Prism 7700, PE Applied Biosystems, Foster City, Calif. 
"Taqman Universal PCR Master Mix - 2X Concentration, PE Biosystems, Foster City, Calif. 
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vABl Prism Sequence Detection Systems, Version 1.7, Perkin Elmer Corp., Foster City, 
Calif. 
"Microsoft Excel, Microsoft, Version 9.0, Redmond, Wash. 
"MicroAmp Optical 96-well Reaction Plates and Optical Caps. PE Biosystems. Foster City. 
Calif. 
" User Bulletin #2, December 11, 1997, PE Applied Biosystems, Foster City, Calif. 
ZSAS, Version 8.1, SAS Institute, Cary, North Car. 
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Figures legends 
Figure 1—Mean + SD relative values of tracheal antimicrobial peptide messenger 
ribonucleic acid (mRNA) of all replicates from each calf, all groups. Values of 
individual calves are normalized to thelSS ribosomal ribonucleic acid (RNA) 
level of that individual and are relative to the calibrator (Calf #1). Calves were 
treated as follows: inoculated with 5 ml of pyrogen-free saline3 (0.14MNaCl) 
solution (gray), inoculated with 5 ml of solution that contained 1 X 108 colony 
forming units (CPU) of Mannheimia haemolytica/ml (black), or treated with a 
selectin inhibitor (TBC 1269;b 25 mg/kg of body weight, intravenously) 30 
minutes before and 2 hours after being inoculated with 5 ml of solution that 
contained 1 X 10* CPU of M haemolytica/m\ (striped). * Designates the calibrator 
animal. 
Figure 2—Mean + SD relative values of interleukin-8 mRNA of all replicates from each 
calf, all groups. Values of individual calves are normalized to thelSS ribosomal 
RNA level of that individual and are relative to the calibrator (Calf #1). See 
Figure 1 for remainder of key. * Designates the calibrator animal. 
Figure 3—Mean + range relative values of intercellular adhesion molecule-1 mRNA of all 
replicates from each calf, all groups. Values of individual calves are normalized 
to thelSS ribosomal RNA level of that individual and are relative to the calibrator 
(Calf #1). See Figure 1 for remainder of key. * Designates the calibrator animal. 
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Tables 
Table 1—Primer and TaqMan fluorescent probe sequences used in real-time reverse 
transcriptase - polymerase chain reaction (RT-PCR) for relative quantitation of 
bovine tracheal antimicrobial peptide (TAP), interleukin-8 (IL-8) and intracellular 
adhesion molecule-1 (ICAM-1) complementary deoxyribonucleic acid (cDNA). 
5 GGCAGTAAAATGCTGTAGAAAGAAGTAAAJ ' 
5 CTCTGTCAAAGGGCGCAGTTJ ' 
5 '6FAM-ACACAGCCGGGATCAATGCCCAG-TAMRAJ ' 
5TGGGCCACACTGTGAAAATTCi ' 
5 CCTTCTGC ACCC ACTTTTCCT3 ' 
5 '6FAM-TAAGCTTACCAATGGAAACGAGGTCTGCCTAAAC-TAMRAJ ' 
5CGATCGACCCTCACCTTGAGJ ' 
5CCATCCAGCGTGCAATTCAJ ' 
5 '6FAM-CCCGATTGTGGAAGTAGGCTCACGGT-TAMRAJ ' 
G = Guanine. C = Cytosine. A = Adenine. T= Thymine. 6FAM = Fluorescent reporter dye. 
TAMRA = Fluorescent quencher dye. 
TAP: 
IL-8: 
ICAM-l: 
Table 2—Definitions of TaqMan nomenclature used in this study.3" 
R„: normalized reporter 
AR„ = (R„~) - (R„") where: 
R„* = emission intensity of reporter/emission intensity of passive reference = 
PCR with template 
R„" = emission intensity of reporter/emission intensity of passive reference = 
PCR without template or early cycles of a real time reaction 
CT: threshold cycle (statistically significant increase in ARn is first detected) 
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Tabic 3—Mean ± SD pre-amplification TAP cDNA values normalized to ribosomal 18S 
ribonucleic acid (RNA) and relative to the calibrator (Calf #1) of all replicates 
from each calf, all groups. 
Calf Identification TAP* (mean ± SD) TAPN Rel. to Cal. 
(mean ± SD) 
Grown TAP* Rel. to 
Cal. (mean ± SD) 
2 hours Saline 
#1 0.52 ± 0.40 1 ± 0.78 
2.5 ± 2.63 #2 2.87 ± 1.58 5.54 ± 0.55 
#3 0.5 ±0.21 0.96 ± 0.43 
6 hours Saline 
#4 0.16 ±0.28 0.31 ± 1.73 
0.67 ± 0.67 #5 1.50 ±0.35 0.25 ± 0.24 
#6 0.74 ± 0.38 1.44 ±0.51 
2 hours Mannheimia haemolytica 
#7 1.76 ±0.11 3.41 ±0.06 
18.12 ± 16.65 t #8 2.48 ± 0.43 4.79 ±0.17 
#9 14.19 ± 1.95 27.4 ±0.14 
#10 19.1 ±8.93 36.88 ± 0.47 
6 hours Mannheimia haemolytica 
#11 29.68 ± 2.27 57.31 ± 0.08 
62.13 ± 79.28 t #12 91.03 ± 11.39 175.74 ±0.13 
#13 3.18 ±0.9 6.14 ±0.28 
#14 4.83 ±2.13 9.32 = 0.44 
6 hours Mannheimia haemolytica + TBC 1269 
#15 14.79 ± 1.66 28.55 ±0.11 
28.53 ±23.51 #16 31.76 ± 1.87 61.31 ± 0.06 
#17 8.74 ± 1.25 16.86 ±0.14 
#18 3.82 ±2.28 7.38 ± 0.6 
Saline = Calves inoculated with 5 ml of pyrogen-free saline3 (O.MMNaCl) solution and 
necropsied at 2 hours or at 6 hours after inoculation (n = 3/timepoint). Mannheimia 
haemolytica = Calves inoculated with 5 ml of solution that contained I X 10s colony forming 
units (CPU) of M haemolyticalml and necropsied at 2 hours or at 6 hours after inoculation (n 
= 4/timepoint). Mannheimia haemolytica + TBC 1269 = Calves treated with a selectin 
inhibitor (TBC1269;b 25 mg/kg of body weight, intravenously) 30 minutes before and 2 
hours after being inoculated with 5 ml of solution that contained 1 X 108 CPU of M 
haemolyticalml and necropsied at 6 hours after inoculation (n = 4). TAPN = Tracheal 
antimicrobial peptide normalized to ribosomal 18S RNA. Rel. = Relative. Cal. = Calibrator. 
tValues are significantly greater than values for calves inoculated with saline (P = 0.1). 
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Table 4—Mean ± SD pre-amplification IL-8 cDNA values normalized to ribosomal 18S 
RNA and relative to the calibrator (Calf #1) of all replicates from each calf, all 
groups. 
Calf Identification IL-8* (mean ± SD) IL-8* Rel. to Cal. 
(mean±SD) 
GrouD IL-8* Rel. to 
Cal. (mean ±SD) 
2 hours Saline 
#1 0.61 ±0.07 1 ±0.11 
5.38 = 5.75 #2 1.98 ±0.18 3.25 ± 0.09 
#3 7.24 ± 0.3 11.9 ±0.04 
6 hours Saline 
#4 0.15 ±0.04 0.24 ± 0.29 
2.59 ± 3.07 #5 0.9 ± 0.09 1.48 ±0.10 
#6 3.68 ±0.16 6.06 ± 0.04 
2 hours Mannheimia haemolytica 
#7 23.82 ±0.99 39.15 ±0.04 
16.61 = 15.06 #8 4.79 ± 0.42 7.88 ± 0.09 
#9 5.51 ±0.3 9.05 ± 0.06 
#10 6.29 ± 0.53 10.34 = 0.08 
6 hours Mannheimia haemolytica 
#11 30.55 ± 1.87 50.21 ±0.06 
82.96 ± 124.81 #12 162.82 ± 19.07 267.59 ±0.12 
#13 6.83 ±0.41 11.22 ±0.06 
#14 1.71 ±0.25 2.82 ±0.15 
6 hours Mannheimia haemolytica + TBC 1269 
#15 6.73 ± 0.39 11.07 ±0.06 
33.52 = 26.2 #16 12.17 ± 0.19 20 ± 0.02 
#17 19.74 ±3.39 32.44 ±0.17 
#18 42.93 ± 9.85 70.55 ± 0.23 
IL-8N = Interleukin-8 normalized to ribosomal 18S RNA. See Table 3 for remainder of key. 
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Table 5—Mean, SD and range ACT. AACT and pre-amplification ICAM-l cDNA values 
normalized to ribosomal 18S RNA and relative to the calibrator (Calf #1) of all 
replicates from each calf, all groups. 
Calf 
Identification 
ACT (mean ± AACT (mean ± ICAM-1* Rel. to Cal. Group ICAM-l* Rel. to 
SD) SD) (mean (ranee)) Cal. (mean ± SD) 
2 hours Saline 
#1 13.51 ±0.26 0 ± 0.26 1 (0.83, 1.2) 
2.65 ± 1.44 #2 11.65 ±0.09 -1.85 ±0.09 3.61 (3.39.3.85) 
#3 11.76 ±0.3 -1.74 ±0.3 3.35(2.72,4.12) 
6 hours Saline 
#4 12.89 ±0.12 -0.61 ±0.12 1.53 (1.41, 1.66) 
2.5 ± 1.32 #5 12.54 ±0.35 -0.97 ± 0.35 1.96(1.53,2.50) 
#6 11.51 ±0.12 -2 ±0.12 4 (3.68, 4.34) 
2 hours Mannheimia haemolytica 
m 9.04 ±0.15 -4.47 ±0.15 22.16(20.03,24.52) 
11.69 ± 7.14 t* #8 10.9 ±0.04 -2.61 ±0.04 6.09(5.91,6.28) 
#9 10.28 ±0.24 -3.23 ± 0.24 9.36(7.91, 11.08) 
#10 10.31 ±0.2 -3.19 ±0.2 9.15(7.97, 10.5) 
6 hours Mannheimia haemolytica 
#11 11.43 ± 0.18 -2.08 ±0.18 4.23 (3.72, 4.8) 
5.17 = 4.38 + #12 9.97 ±0.1 -3.54 ±0.1 11.6 (10.84, 12.42) 
#13 11.99 ±0.24 -1.52 ±0.24 2.87(2.42,3.4) 
#14 12.51 ±0.32 -0.99 ± 0.32 1.99(1.59, 2.49) 
6 hours Mannheimia haemolytica + TBC 1269 
#15 12.09 ± 0.09 -1.42 ±0.09 2.68 (2.51.2.86) 
5.2 ± 2.44 #16 11.36 ±0.1 -2.15 ±0.1 4.43 (4.14,4.73) 
#17 11.14 ±0.32 -2.37 ± 0.32 5.17(4.15,6.44) 
#18 10.42 ±0.2 -3.09 ± 0.2 8.51 (7.41,9.79) 
ICAM-1N = Intracellular adhesion molecule-1 normalized to ribosomal 18S RNA. ACT = CT 
for ICAM-1 minus CT for ribosomal 18S RNA. AACT = Average ACT for the calf minus the 
average ACT for Calf #1. See Table 2 for definition of CT- See Table 3 for remainder of key. 
tValues are significantly greater than values for calves inoculated with saline (P = 0.01). 
* Value is significantly (P <0.1) greater than the value for all other groups. 
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CHAPTER 5. EVIDENCE THAT SHEEP p-DEFENSIN-1 EXPRESSION 
IS CONSTITUTIVE IN THE LUNG DURING MANNHEIMIA 
HAEMOLYTICA PNEUMONIA 
A paper to be submitted to Infection and Immunity 
Jessica M. Caverly, VMD, Rafael Ramirez-Romero, DVM, PhD, Jack M. Gallup. MS. Kim 
A. Brogden, PhD and Mark R. Ackermann, DVM, PhD 
Abstract 
Antimicrobial peptides (AMP) are an important component of the innate immune system 
of the respiratory tract. In humans, cattle and other mammals, expression of some members 
of one class of AMP, the p-defensins, is upregulated in lung by bacterial infections and other 
pro-inflammatory stimuli. Expression of yet other P-defensins is constitutive. Sheep P-
defensin-1 (SBD-1) is expressed in the lungs of juvenile and adult sheep; however, the 
inductive or constitutive nature of SBD-l expression has not been determined. Twenty 
juvenile sheep were inoculated with either Mannheimici haemolytica, a known inducer of P-
defensin expression in cattle, or pyrogen-free saline into the right cranial lung lobe by 
fiberoptic bronchoscopy, and lung tissues were collected at 1. 15 or 46 days after inoculation. 
Sheep p-defensin-1 messenger ribonucleic acid (mRNA) levels were quantitated by real-time 
relative quantitative reverse transcriptase - polymerase chain reaction (TaqMan). There were 
no differences in SBD-1 mRNA expression between saline and infected animals during the 
acute, subacute and chronic stages of inflammation, nor did expression change in these 
animals over the progression of the infection. These results suggest that SBD-l is produced 
constitutively in the lung, similarly to another p-defensin, human P-defensin-1 (HBD-1), and 
SBD-1 expression is not altered by acute, subacute and chronic inflammation during M 
haemolytica pneumonia. 
Introduction 
Antimicrobial peptides (AMP) are an important component of the innate immune system 
of species of multiple phyla, including animals and plants. P-defensins are one class of AMP 
expressed in mammals, p-defensins range from 29-40 amino acids in length, are 3 to 4 kDa 
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in size, and are cationic, amphipathic peptides that contain six cysteine residues arranged in 
three disulfide bonds (Diamond, 2000a). They exhibit strong microbicidal activity against 
bacteria, fungi, mycobacteria and viruses (Diamond, 2000a). 
P-defensins with inductive properties that are expressed by respiratory epithelia during 
acute infections or with inflammation include human P-defensin-2 and 3 (HBD-2; HBD-3) 
(Harder, 1997; Liu, 1998; Harder 2001; Jia, 2001), tracheal antimicrobial peptide (TAP) and 
lingual antimicrobial peptide (LAP) of cattle (Diamond. 1996; Schonwetter. 1995). and 
mouse P-defensin-2 and -3 (MBD-3; MBD-3) (Bals, 1999; Morrison, 1999). Human P-
defensin-1 (HBD-1) and mouse P-defensin-1 (MBD-1) are also expressed by respiratory 
epithelia, but their expression is constitutive (Liu, 1997; Morrison, 1998). Although changes 
in AMP expression and activity have been detected during chronic pneumonia of patients 
with cystic fibrosis (Goldman, 1997; Brogden, 1999), to our knowledge, the effects of the 
progression through the acute, subacute and chronic stages of infection/inflammation on 
expression of either inducible or constitutively expressed P-defensins has not been 
determined. 
Sheep P-defensin-1 and -2 (SBD-1; SBD-2) are the only P-defensin genes discovered in 
sheep to date (Huttner, 1998a), and both are produced by epithelial cells. Sheep p-defensin-1 
is expressed in the respiratory and gastrointestinal tracts, and SBD-2 is expressed in the 
gastrointestinal tract, but only at very low to negligible levels in the respiratory tract 
(Huttner, 1998b; McLachlan. unpublished). The inductive or constitutive nature of SBD-l 
expression by respiratory epithelia has not been determined, nor has the extent to which 
acute, subacute and chronic pulmonary infection/inflammation may affect expression been 
assessed. 
The purpose of this study is to characterize the messenger ribonucleic acid (mRNA) 
expression of SBD-1 during experimental acute infectious pneumonia caused by Mannheimia 
haemolytica. a known inducer of other ruminant P-defensins. including LAP and TAP 
(Stolzenberg, 1997; Caverly, unpublished). In addition, we will determine if this expression 
is altered during the acute, subacute and chronic stages of the disease. 
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Materials and Methods 
Animals—Twenty sheep, mixed breed and of both sexes, three months old, were 
obtained from Iowa State University. Laboratory Animal Resources. These sheep were 
maintained in isolation rooms in accordance with procedures approved by the American 
Association of Laboratory Animal Care and under a protocol previously approved by the 
Iowa State University Animal Care Review Committee. 
Procedure— After 24 hours, the animals were randomly assigned to two large groups; 
one group received M. haemolytica, while the other received saline. Bacterial-inoculated 
sheep were inoculated with M. haemolytica (1 X 10* colony forming (CFU)/ml in a 5-ml 
injection), whereas controls were inoculated with 5 ml of pyrogen-free saline3 (PFS) (0.14M 
NaCl) solution. Inoculations were performed into the bronchus of the right cranial lung lobe, 
using fiberoptic bronchoscopy, as previously described (Brogden. 1995). 
Subsequently, the larger groups were subdivided in accordance to the time of sacrifice at 
1, 15 and 46 days after inoculation. Sheep were euthanized by intravenous injection of an 
overdose of sodium pentobarbital immediately prior to necropsy and collection of lung 
tissue. To avoid ribonucleic acid (RNA) degradation, as well as hyperstatic congestion and 
potential vascular leakage in postmortem specimens, lung tissue was collected from each 
sheep within 5 to 15 minutes after it was euthanized. Each group was comprised as follows: 
saline-inoculated (control) sheep euthanized 1 (n = 3), 15 (3) and 46 (4) days after 
inoculation and M haemolytica-inocu\aled sheep euthanized I (n = 3), 15 (4) and 46 (3) days 
after inoculation. 
Mannheimia haemolytica inoculum—Mannheimia haemolytica (strain 82-25; originally 
recovered from a natural case of M. haemolytica pneumonia in sheep) were grown overnight 
on blood agar, transferred to tryptose broth, and incubated for 1 to 3 hours at 37 C on a 
magnetic stirrer to achieve a culture containing approximately I X 10* CFU/ml. The 
organisms were pelleted, using centrifugation (5,900 X g for 5 minutes at 4 C), and 
resuspended in 5 ml of PFS solution.1 An aliquot of saline solution was adjusted to a 
transmittance value of 78% at a setting of 600 run in a spectrophotometer^ by aseptically 
adding the bacterial suspension. One milliliter of the inoculum was removed from the 
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adjusted suspension and serially diluted (1- to 10-fold) in saline solution. Then, 0.1 ml of 
each dilution was spread onto agar plates containing trypticase soy agar with 5% defibrinated 
sheep blood. Plates were incubated overnight, and colonies then were counted. The original 
solution routinely contained 1.3 to 2.5 X 108 CFU/ml. 
Collection of samples— In all sheep, tissue was collected from the site of inoculum 
deposition in the right lung at necropsy. Tissue samples were collected into cryovials' and 
immediately placed in liquid nitrogen (-196 C). These vials were then stored at -80 C until 
analysis, when a random vial from each sheep was used for RNA isolation for that sheep. 
All complementary deoxyribonucleic acid (cDNA) production and subsequent reverse 
transcriptase (RT) - polymerase chain reaction (PCR) analysis for each sheep was done with 
the RNA made from this tube. 
Ribonucleic acid isolation— Ribonucleic acid was isolated from each sheep via column 
purification, following the directions of the manufacturer of a commercially available kit/ 
Briefly, approximately 0.5 grams of frozen lung tissue were mixed with approximately 12 
volumes of lysis/binding solution per mass amount of tissue, and then homogenized with an 
electric homogenizer/ Homogenized tissue in solution was centrifuged for 5 minutes at 
8.000 - 9.000 X g.1 The lysate was then mixed with an equal volume of 64% ethanol. This 
mixture was pushed through a filter at 3 - 5 drops per second. Two separate wash solutions 
were then pushed through the filter a total of three times. Finally. 0.5 ml of elution solution 
were pushed through the filter and collected three times for a total of 1.5 ml. which was 
aliquotted into microcentrifuge tubes8 for storage at -80 C. Ribonucleic acid from one tube 
was measured within a spectrophotometer11 for quantity and purity ratio. Ribonucleic acid 
was then assessed for integrity by ultraviolet visualization of ribosomal RNA bands 
following denaturing gel electrophoresis and ethidium bromide staining. 
Complementary deoxyribonucleic acid production— Complementary 
deoxyribonucleic acid was produced by RT of RNA isolated from lung tissue from each 
sheep. Sufficient RNA was used from each sheep to provide for two to three replicates at a 
final RNA concentration per replicate of 2 pg in 100 jil of RT reaction volume. In addition. 
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positive and negative RNA controls (human control RNA' and diethyl pyrocarbonate 
(DEPC)-treated water, respectively) were prepared and submitted to identical and concurrent 
procedures as were the RNA samples (positive control RNA was diluted to 0.001 (a.g/100 pi 
of RT reaction volume, as per manufacturer's directions). Deoxyribonuclease (DNase) 
treatment was performed to remove potential genomic deoxyribonucleic acid (DNA) 
contamination with a commercially available DNase1 following manufacturer's directions. 
Then, RT was performed with a commercially available kitk following manufacturer's 
directions. Briefly, 2 fo.g of DNase-treated RNA from each sample and control were added to 
a reaction mixture which contained final concentrations of IX TaqMan RT buffer. 5.5 mM 
MgCla, 2 mM deoxyribonucieoside triphosphate (dNTP) mixture (500 |iM each dNTP), 2.5 
pM random hexamers, 1.25 U/|il murine leukemia virus (MuLV) RT, 0.4 U/pl ribonuclease 
(RNase) inhibitor and DEPC-treated water. The following thermocycler1 conditions were 
then used: 10 minutes @ 25 C, 30 minutes @ 48 C and 5 minutes @ 95 C. Resulting cDNA 
was stored in microcentrifuge tubes8 at -20 C in a non-defrosting freezer. 
Primer and Probe Design—Sequence-specific oligonucleotide primers and a fluorescent 
probe for detection and relative quantification of cDNA corresponding to the target gene, 
SBD-1. were designed with software"1 according to the software manufacturer's suggestions, 
and were engineered to be within the coding sequence of the mRNA. Resultant potential 
primer and probe sequences were compared to all available DNA sequence databases via the 
search tool BLAST" for similarity, and only unique sequences were used for primer and 
probe design. See Table 1 for sequences. 
Sequence-specific oligonucleotide primers and a fluorescent probe for detection of cDNA 
corresponding to the endogenous reference gene. I8S Ribosomal RNA, to which SBD-1 
cDNA levels would be normalized, were purchased commercially.1 
Polymerase Chain Reaction Optimization and Validation—The sequence detection 
system used0 allowed dual amplification and analysis of cDNA corresponding to both a 
target gene of interest and an endogenous reference gene on the same plate but within 
separate tubes, concurrently. Optimization and validation experiments were performed as 
directed by the manufacturer to find the correct concentrations of SBD-1 primers and probe, 
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as well as cDNA concentrations, which would allow the PCR to proceed at optimum 
efficiency. Complementary deoxyribonucleic acid from a control sheep (Sheep #2) was used 
for all optimization and validation experiments. 
There were two different optimization tests. First, a platep was designed to enable the 
testing of various combinations and concentrations of forward and reverse SBD-1 primers 
ranging from 50 nM to 900 nM. In each well, constant concentrations of SBD-1 probe (200 
nM) and cDNA (1:10 dilution) were used, as well as 25 |il of a commercial master mixq and 
DEPC-treated water. This plate was run in the sequence detection system with the following 
conditions: HOLD 2 minutes @ 50 C, HOLD 10 minutes @ 95 C and then 40 cycles of 15 
seconds @ 95 C followed by 1 minute @ 60 C. Software^ was used to analyze the resultant 
data. The combination, which, upon analysis, provided the highest Rn (see Table 2 for 
definitions) with the lowest primer concentration, was chosen. 
Second, a plate was designed to enable the testing of various concentrations of SBD-1 
probe ranging from 25 nM to 225 nM. In each well, constant concentrations of forward and 
reverse SBD-1 primer (900 nM and 900 nM, respectively) and cDNA (1:10 dilution) were 
used, as well as 25 |il of the commercial master mix and DEPC-treated water. This plate was 
run in the sequence detection system with the same conditions as used in the first 
optimization test. Software was again used to analyze the resultant data. The combination, 
which, upon analysis, provided the lowest Cr with the lowest probe concentration, was 
chosen. 
Finally, as validation that the target and endogenous reference cDNA amplification 
reactions were proceeding at equal efficiency across a spectrum of cDNA concentrations, a 
plate was designed to enable the testing of various concentrations of cDNA ranging from full 
strength cDNA to a 1:15,625 dilution. In each well, constant concentrations of forward and 
reverse SBD-1 primers (900 nM and 900 nM, respectively) and SBD-1 probe (150 nM) were 
used, as well as 25 nl of the commercial master mix and DEPC-treated water. Also, on this 
plate were wells identical to the ones just described; however instead of SBD-1 primers and 
probe, they contained endogenous reference forward and reverse primers and probe1 at 
concentrations of 50nM, 50nM and 200 nM, respectively, as recommended by the 
manufacturer. This plate was run in the sequence detection system with conditions identical 
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to those used in the optimization tests. Software was again used to analyze the resultant data. 
For each cDNA concentration, the Or of the endogenous reference was subtracted from the 
Or of the target, and this value (AOr) was plotted against the log concentration of input 
cDNA. A resultant line with a slope of <±0.1 was considered to represent cDNA 
amplification reactions of target and endogenous reference with equal efficiencies across the 
various cDNA concentrations tested. As the slope was not < ± 0.1, the standard curve 
method was chosen for data analysis of future amplification reactions of SBD-1 (if the slope 
was <±0.1, the Cr method for data analysis would have been chosen). 
Polymerase Chain Reaction—Five separate microwell platesp were designed to enable 
PCR using cDNA from all sheep, with three replicates run for each sheep, as well as three 
replicates run of a negative control (DEPC-treated water), on each plate. In addition, on each 
plate were three replicates each of five progressive 1:5 dilutions of cDNA from a control 
sheep (Sheep #3) that served in the generation of a standard curve, as well as three replicates 
containing cDNA from a sheep (Sheep #2) that served as a calibrator to which all other 
cDNA values would later be compared during analysis. On each plate, target and 
endogenous reference PCR wells were run simultaneously for the sheep represented on that 
plate. The assay composition was as follows: the 50 |a1 PCR mixtures contained 25 |il of the 
commercially available master mix;q 5 ^1 of a 1:5 dilution of cDNA (or DEPC-treated water 
for the negative control); forward and reverse primers and probe concentrations of 300 nM. 
900 nM and 150 nM, respectively, for SBD-1 or 50 nM, 50 nM and 200 nM, respectively, for 
the endogenous control;' and DEPC-treated water. This plate was run in the sequence 
detection system0 with conditions identical to those used in the optimization and validation 
tests. 
Using software/'5 the resultant data was analyzed as follows. The target was normalized 
to the reference by dividing the target input amount of cDNA by the reference input amount 
of cDNA for each replicate, followed by calculation of the average and standard deviation 
input amount of cDNA for all replicates from each sheep, from all plates. Finally. 
normalized SBD-l relative to the calibrator was calculated. For this, the arbitrarily chosen 
calibrator, the 1 day control sheep with the lowest SBD-1 message, Sheep #2, was referred to 
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as 1. This value for all other sheep was calculated by dividing the average value for the 
target normalized to the reference for that sheep by the average value for the target 
normalized to the reference for the calibrator. The standard deviation was calculated for this 
value by dividing the target normalized to the reference standard deviation by its average. 
Statistical Analysis—Statistical analysis was performed using the means of the three 
replicate tubes for each sheep of the target normalized to the reference. This data was 
transformed (the log of the data was used) in order to stabilize the variances. 
To see if there were significant treatment and time effects, a two-factor analysis of 
variance (ANOVA)1 was used on all sheep. As the treatment and time interaction was not 
significant, an additive model was used. Significant treatment and time effects were noted, 
so a one-way ANOVA1 was then performed, followed by a Tukey's multiple comparison 
test.' A f-value of < 0.05 was considered significant. 
Results 
Sheep P-defensin-1—See Figure 1 and Table 3 for input amounts of SBD-1 cDNA 
normalized to the endogenous reference gene, Ribosomal 18S RNA. and relative to the 
calibrator sample. Sheep #2. These values represent the initial relative amounts of cDNA 
prior to PCR amplification in lung tissue from each sheep, which in turn represent the 
relative amounts of SBD-1 mRNA present in the lung tissue from each sheep. Levels of 
pulmonary SBD-1 mRNA expression were similar in sheep from all groups, with the 
exception of two control sheep 15 days after inoculation with saline. Pulmonary SBD-1 
mRNA expression was significantly higher in sheep from this group, as compared to sheep 1 
day after inoculation with M haemolytica {P < 0.05). The other groups were not different 
from each other, nor were the two aforementioned groups different from any other groups. 
Thus, at each timepoint, there were no differences in SBD-1 mRNA expression between M. 
haemolytica-inoculated sheep and controls, nor did these expression levels change within 
infected sheep over time, or within control sheep over time. 
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Discussion 
The finding that SBD-1 is not an inducible P-defensin, but is instead produced 
constitutive!^ in the lung, was unexpected. The pulmonary inflammation induced by M. 
haemolytica pneumonia did not cause upregulation of SBD-1 during the acute, subacute or 
chronic phases of the disease. With the exception of two individuals within the 15 day after 
inoculation with saline group, sheep in all groups had similar relative levels of SBD-1 
mRNA, regardless of inactivity status or time after inoculation. Sheep P-defensin-1 and -2 
expression has been demonstrated to show marked interanimal variation (Huttner, 1998), a 
fact that may be verified by the two in the 15 day saline group. It is unlikely that the 
increased mRNA levels of these two sheep reflect an upregulation of expression in response 
to inflammation, because the lung tissue of these two animals and all the control sheep lacked 
gross and histopathologic lesions. In contrast. M. haemolytica-inoculated animals showed 
classic A/ haemolytica pneumonia lesions, which confirmed the successful experimental 
reproduction of severe inflammation induced by infectious pneumonia. These gross and 
histological lesions included a severe bronchopneumonia with areas of necrosis acutely, 
which progressed to an interstitial pneumonia with variable areas of epitheliazation and 
pyogranulomatis foci subacutely, and finally to fibrotic changes chronically (Ramirez-
Romero. 2001). 
A decrease in SBD-1 mRNA expression levels at 1 day after inoculation with M. 
haemolytica resulted in significantly lower expression of SBD-1 in this group in comparison 
to the control sheep 15 days after inoculation. This is likely due to necrosis of the epithelial 
cells that produce SBD-1 in the M. haemolytica-inoculated sheep. Epithelial cells appear to 
have sufficiently regenerated by 15 days and 46 days after inoculation with M. haemolytica 
to return mRNA expression levels to those of the sheep in the rest of the groups. However, 
this decrease in overall pulmonary expression of SBD-1 during acute infectious pneumonia 
may contribute towards increased susceptibility or worsening of the bacterial infection during 
the first few days following infection. 
Further evidence that the results of this study demonstrate that SBD-1 is expressed 
constitutively in the lung can be found upon comparison of these results to the expression 
patterns in the lung of a known inducible ruminant p-defensin, TAP, during M. haemolytica 
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pneumonia. Tracheal antimicrobial peptide mRNA expression was statistically higher in 
calves infected with M. haemolytica versus control animals (Caverly, unpublished). In fact, 
at 6 hours after inoculation (the end time point of the study), mean relative levels were 62.13 
for the infected calves versus 0.67 for those calves inoculated with saline (Caverly, 
unpublished). 
Increased HBD-2 protein levels have been found in the plasma of patients with bacterial 
pneumonia (Hiratsuka, 1998) and both HBD-1 and HBD-2 have been found in 
bronchoalveolar lavage fluid (BALF) from cystic fibrosis patients and patients with 
inflammatory lung diseases (Singh, 1998). However, HBD-1, but not HBD-2, is found in 
BALF from healthy volunteers, implying that it is important in host defense in the absence of 
inflammation (Singh, 1998). As both TAP and LAP are inducible, neither is a homolog to 
HBD-1, which is produced constitutively in the lung; thus, SBD-l is apparently the ruminant 
P-defensin with properties of expression most similar to pulmonary HBD-1. 
Most species that express pulmonary P-defensins have been found to have at least one 
that is induced by bacteria and inflammatory substances. These species include humans 
(HBD-2; HBD-3) (Harder, 1997; Liu, 1998; Harder 2001; Jia. 2001), cattle (TAP, LAP) 
(Diamond, 1996; Schonwetter, 1995), and mice (MBD-3; MBD-3) (Bals, 1999; Morrison, 
1999). Since SBD-1 expression is constitutive, it is reasonable to suspect that the ovine lung 
expresses a yet undiscovered inducible AMP. To date, few published studies have been done 
to evaluate the role of SBD-2 in the ovine lung. No SBD-2 isoforms were found in sheep 
trachea in one study (Huttner, 1998b) and negligible expression has been noted on 
immunohistochemical assessment of healthy ovine lung tissue (Grubor, unpublished); 
however, low to undetectable expression has been detected in cultured tracheal cells and 
proximal and distal airway and lung parenchyma by RT-PCR with cDNA clones isolated 
from trachea (McLachlan, unpublished). Although preliminary results suggest that SBD-2 is 
also constitutively expressed (McLachlan, unpublished), further studies of SBD-2 expression 
in ovine lung during inflammation will be needed to rule out the possibility of induced 
upregulation of the expression of this P-defensin to levels necessary for antimicrobial 
activity. 
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In conclusion, this work suggests that SBD-1 is a constitutively produced p-defensin in 
ovine lung, similar to HBD-1 of humans, and SBD-1 expression is not altered by acute, 
subacute and chronic inflammation during M haemolytica pneumonia. As most other 
species in which P-defensins have been discovered express at least one P-defensin upon 
induction with bacteria and inflammatory substances, additional studies of the ovine 
respiratory tract may identify either an inducible P-defensin or some other inducible AMP. 
Footnotes 
aPyrogen-free saline, Baxter Healthcare Corp., Deerfield, 111. 
bColeman model 35, Bacharach Instrument Co, Pittsburgh, Penn.. 
eNunc Cryo Tube Vials, Nunc Brand Products, Denmark 
dRNAqueous-Midi, Ambion, Austin, Tex. 
'Omni TH, Omni International, Inc., Warrenton, Virg. 
'Hermle Z 360K, Natural Labnet Company, Woodbridge, New Jersey 
=1.5 ml microtubes - sterile, RNase and DNase free, Daigger, Wheeling, 111. 
hDU 640B, Beckman Coulter, Fullerton, Calif. 
'TaqMan Ribosomal RNA Control Reagents, PE Biosystems. Foster City, Calif. 
JRQ1 RNase-Free DNase, Promega, Madison, Wis. 
kTaqMan Reverse Transcriptase Reagents, PE Biosystems. Foster City, Calif. 
'GeneAmp PCR System 2400, Perkin Elmer, Norwalk. Conn. 
mABI Prism Primer Express. Version 1.5, PE Applied Biosystems, Foster City, Calif. 
"Basic Local Alignment Search Tool. Version 1.4. National Center for Biotechnology 
Information, Bethesda, Md. 
"GeneAmp 5700 Sequence Detection System, Applied Biosystems. Foster City, Calif. 
pMicroAmp Optical 96-well Reaction Plates and Optical Caps, PE Biosystems, Foster City, 
Calif. 
qTaqman Universal PCR Master Mix - 2X Concentration. PE Biosystems, Foster City, Calif. 
rGeneAmp 5700 Sequence Detection Systems. Version 1.3. PE Biosystems. Foster City. 
Calif. 
^Microsoft Excel, Microsoft. Version 9.0, Redmond. Wash. 
'SAS, Version 8.1, SAS Institute, Cary, North Car. 
"Taqman Universal PCR Master Mix-Protocol, PE Applied Biosystems, Foster City, Calif. 
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Figures legends 
Figure 1—Group mean + SD relative levels of sheep P-defensin-1 messenger ribonucleic 
acid (mRNA) of all replicates from each calf, all groups. Values of individual 
calves are normalized to thel8S ribosomal ribonucleic acid (RNA) level of that 
individual and are relative to the calibrator (Sheep #2). Sheep were treated as 
follows: inoculated with 5 ml of pyrogen-free saline (0.14M NaCl) solution (gray) 
or inoculated with 5 ml of solution that contained 1 X 10* colony forming units 
(CFU) of Mannheimia haemolytica/ml (black). Values marked by different letters 
are significantly different from each other. 
131 
Tables 
Table 1—Primer and TaqMan fluorescent probe sequences used in real-time reverse 
transcriptase - polymerase chain reaction for relative quantitation of sheep (3-
defensin-1 (SBD-1) complementary deoxyribonucleic acid (cDNA). 
SBD-l : 5 CCATAGG AATA AAGGCGTCTGTGT3 ' 
5 CGCGACAGGTGCCAATCTJ ' 
5 6FAM-CCGAGCAGGTGCCCTAGACACATGA-TAMRAJ ' 
G = Guanine. C = Cytosine. A = Adenine. T= Thymine. 6FAM = Fluorescent reporter dye. 
TAMRA = Fluorescent quencher dye. 
Table 2—Definitions of TaqMan nomenclature used in this study." 
R„: normalized reporter 
AR„ = (R„')-(R„) where: 
R„* = emission intensity of reporter/emission intensity of passive reference = 
PCR with template 
R„" = emission intensity of reporter/emission intensity of passive reference = 
PCR without template or early cycles of a real time reaction 
Cr: threshold cycle (statistically significant increase in AR„ is first detected) 
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Table 3—Mean ± SD pre-amplification SBD-1 cDNA values normalized to ribosomal 18S 
ribonucleic acid (RNA) and relative to the calibrator (Sheep #2) of all replicates 
from each calf, all groups. 
Sheen Identification SBD-l v (mean ± SD) SBD-1 „ Rel. to Cal. 
(mean ± SD) 
CrouD SBD-l s Rel. to 
Cal. (mean ± SD) 
1 day Saline 
#1 1.96 ±0.35 1.99 ± 0.18 
1.49 ±0.5 #2 0.98 ± 0.09 1.0 ±0.09 
#3 1.46 ±0.09 1.49 ±0.06 
1 day Mannheimia haemolytica 
#5 0.8 ± 0.06 0.81 ±0.07 
0.63 ±0.19 #6 0.43 ± 0.04 0.44 ± 0.1 
#7 0.63 ±0.12 0.64 ±0.18 
15 days Saline 
#8 8.32 ± 0.44 8.46 ± 0.05 
4.62 ± 3.72 * #9 4.29 ± 0.23 4.36 ±0.05 
#10 1.01 ±0.05 1.03 ±0.05 
15 days Mannheimia haemolytica 
#4 1.25 ±0.17 1.27 ±0.14 
1.44 ±0.62 #11 2.26 ± 0.05 2.3 ± 0.02 
#12 1.34 ±0.04 1.37 ±0.03 
#14 0.08 ± 0.08 0.82 ± 0.09 
46 days Saline 
#13 2.26 ± 0.33 2.3 ±0.15 
1.57 ±0.70 #17 2.0 ±0.19 2.03 ± 0.09 
#18 0.85 ± 0.07 0.87 ±0.08 
#19 1.05 ±0.09 1.07 ±0.09 
46 days Mannheimia haemolytica 
#16 1.13 ± 0.14 1.15 ±0.22 
1.21 ±0.08 #20 1.15 ± 0.14 1.17 ± 0.12 
#21 1.28 ±0.05 1.3 ±0.04 
Saline = Sheep inoculated with 5 ml of pyrogen-free saline3 (0.14M NaCl) solution and 
necropsied at 1 day (n = 3), at 15 days (n = 3) and at 46 days (n = 4) after inoculation. 
Mannheimia haemolytica = Sheep inoculated with 5 ml of solution that contained 1 X 10* 
colony forming units (CPU) of M haemolytica! ml and necropsied at 1 day (n = 3). at 15 days 
(n = 4) and at 46 days (n = 3) after inoculation. SBD-lN = Sheep p-defensin-1 normalized to 
ribosomal 18S RNA. Rel. = Relative. Cal. = Calibrator. *Value is significantly different 
than value for sheep 1 day after inoculation with M. haemolytica (P < 0.05). 
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CHAPTER 6. GENERAL CONCLUSIONS 
Antimicrobial peptide (AMP) expression is a dynamic process in the ruminant lung 
during Mannheimia haemolytica pneumonia and can be markedly affected by the degree of 
pulmonary inflammation. The following supports this statement: 
The first study determined the presence of anionic peptide (AP) in the bronchoalveolar 
lavage fluid (BALF) of neonatal calves, both in health and during acute inflammation caused 
by M. haemolytica pneumonia. Anionic peptide was present at a similar concentration in all 
calves, infected and uninfected, which was three times higher than in adult cattle; however, 
BALF from neonates had little or no anti-M haemolytica activity in vitro, compared with 
adult cattle. Thus, neonatal calves appear to lack a mature, effective AMP response. We 
believe that this may be a reason for the susceptibility of neonatal calves to pulmonary 
infections. The potential role of AP in the prevention and treatment of naturally acquired 
disease requires further study. 
In addition, in this study it was found that the selectin inhibitor, TBC1269, decreased the 
amount of pulmonary tissue injury in infected calves (as measured by BALF protein 
concentration); however, it had no effect on BALF AP concentration or antimicrobial 
activity. As neutrophils are needed to combat infection. TBC1269's ability to reduce 
neutrophil-mediated pulmonary damage during M. haemolytica pneumonia, while blocking 
some, but not all, neutrophil infiltration into the site of inflammation, may make it an 
effective therapeutic tool for pulmonary infections. Additional studies could include 
evaluation of the use of TBC1269 in conjunction with an antibiotic in the treatment of calves 
with acute pneumonia attributable to M. haemolytica to determine whether a beneficial 
synergistic effect exists between the compound and the antibiotic. Also, its efficacy in other 
species with several types of inflammatory disorders could be investigated. 
The second study used the same groups of calves as used in the first to determine that 
tracheal antimicrobial peptide (TAP) messenger ribonucleic acid (mRNA) expression occurs 
at a basal level in neonates, and the expression of it and intracellular adhesion molecule 
(ICAM)-l are rapidly upregulated in neonatal calves during acute inflammation caused by M. 
haemolytica pneumonia. However, there was variation in mRNA expression between 
individual animals that could result in suboptimal innate immunity at birth, possibly 
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explaining the susceptibility of an individual neonate to a pulmonary infection that a neonate 
in the same herd or pen may resist. Additionally, reduction of pulmonary neutrophil 
infiltration and neutrophil-mediated damage through use of the selectin inhibitor, TBC1269, 
resulted in TAP and interleukin (IL)-8 mRNA expression levels that were lower than levels 
in untreated calves; however, these results were not statistically significant due to high 
interanimal variation in expression of these substances. Also, within an individual, the 
patterns of mRNA expression of TAP and IL-8 correlated positively with each other during 
acute inflammation, suggesting common stimuli for upregulation, some known (IL-1, tumor 
necrosis factor) and some unknown. Further study into the antimicrobial activity of TAP in 
neonates might be warranted to determine if it. like AP, is lacking shortly after birth. 
In the final study, we sought to follow the level of mRNA expression of an ovine P-
defensin suspected to be inducible by bacterial infections and other pro-inflammatory stimuli, 
sheep P-defensin (SBD)-l, during the progression of M haemolytica pneumonia (acute, 
subacute and chronic inflammation stages) in juvenile sheep. Surprisingly, it was discovered 
that there were no differences in SBD-1 mRNA expression between control and infected 
animals during the acute, subacute and chronic stages of inflammation, nor did expression 
change in these animals over the progression of the stages. However, SBD-1 mRNA 
expression was significantly higher in control sheep 15 days after saline inoculation versus 
infected sheep 1 day after bacterial inoculation, which was attributed both to interanimal 
variation in SBD-1 expression, as well as an overall decrease in pulmonary SBD-1 
expression in infected sheep due to necrosis of epithelial cells. This decrease in overall 
pulmonary expression of SBD-1 during acute infectious M haemolytica pneumonia may 
contribute towards increased susceptibility or worsening of the bacterial infection during the 
first few days following infection. These results suggest that SBD-1 is produced 
constitutively in lung and its expression is not upregulated during inflammation. Studies in 
another laboratory (Gerry McLachlan. Scotland) using in vitro tests reinforce the finding that 
SBD-1 expression is constitutive. This finding makes sheep similar in this way to human P-
defensin-1, which is also produced constitutively in the lung. The only other known SBD, 
SBD-2, is expressed at only low to negligible levels in the respiratory system, and it is 
suspected to be expressed constitutively. Because the respiratory tract of most species, 
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including cattle, humans, and mice, produce at least one inducible P-defensin, we believe that 
an inducible p-defensin, or another inducible AMP, in the ovine lung remains to be 
discovered. 
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